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SUMMARY 
 
 
 
 Inhibiton of histone deacetylases inhibitors (HDACi) hold great promise in cancer 
therapy due to their demonstrated ability to arrest proliferation of nearly all transformed 
cell types.  However, small molecule HDACi, especially the alphatic hydroxamates, 
suffers from low oral bioavailability.  More importantly, these HDACi non-selectively 
inhibits various HDAC isoforms leading to reduction of their in vivo potency and 
production of toxic side effect.  Of the several structurally distinct small molecules 
HDACi reported, macrocyclic depsipeptides have the most complex recognition cap-
group moieties and present an excellent opportunity for the modulation of the selectivity 
and biological activities of HDACi. Unfortunately, the structure–activity relationship 
(SAR) studies for this class of compounds have been impaired largely because most 
macrocyclic HDACi known to date are comprised of complex peptide macrocycles. I 
document in this thesis the discovery of a new class of macrocyclic HDACi based on the 
macrolide antibiotics skeletons. SAR studies revealed that these compounds displayed 
both linker-length and macrolide-type dependent HDAC inhibition activities with IC50 in 
low nanomolar range. In addition, these non-peptide macrocyclic HDACi are more 
selective against HDAC 1 and 2 relative to HDAC 8, another class I HDAC isoform, and 
hence have subclass HDAC isoform selectivity as well as producing selective toxicity to 
cancer cells.  
 Some of the challenges facing conventional therapies, as described above, are 
poor bioavailability and intrinsic toxicity. These have seriously compromised the 
therapeutic efficacy of many otherwise beneficial drugs.  Nanoscopic systems that alter 
xix 
 
the pharmacological and therapeutic properties of molecules are being designed to 
overcome some of these limitations. Research efforts in this area have resulted innovative 
nanostructures, such as gold nanoparticles (AuNPs), that remain relatively nontoxic to 
cells with enhancement in bioavailability.  Additionally, AuNPs possess unique optical 
and electrical properties, making it possible to track its intracellular trafficking and 
localization.  These unique properties make AuNPs especially attractive for biological 
and medical applications.   
 The delivery of AuNPs takes advantage of pathophysiological conditions and 
anatomical changes within diseased tissues, compared to normal tissues, to achieve site-
specific and targeted delivery. However, efficient delivery of AuNPs into a living system 
requires overcoming natural biological barriers such as the cell membrane and the 
reticuloendothelial system (RES). For specific tumor targeting, AuNPs face additional 
challenges from receptor specificity and intra-tumor barriers.  Several investigators have 
grafted different delivery platforms onto AuNPs surface to attempt cellular selectivity, 
internalization, and localization within heterogeneous population of cancer cells in solid 
tumors.  I document in this thesis our efforts of conjugating peptidyl-based delivery 
platforms onto AuNPs that selectively entered and identified the nucleus of HSC oral 
cancer cells under optical microscopy. 
 In continuation of the general theme of molecular targeting, we are investigating 
potential transformation of β-lactam antibiotics, such as penicillins, for facile conjugation 
to assorted cell permeable peptides and peptoids that may potentially enable bacterial 
cell-selectivity.  We synthesized various 6-aryltriazolylpenicillanic acids using a facile, 
high yielding synthetic route. Preliminary biological studies indicated retention of 
xx 
 
antibacterial activity in several of these 6-aryltriazolylpenicillanic acids.   The observed 
antibacterial activity of 6-azidopenicillanates represents an important step toward the 
development of cell permeable peptide-conjugated penicillins. 
 Finally, biomacromolecules, such as peptides and oligonucleotides, undoubtedly 
play important roles in molecular- and cell-targeting.  However, current peptide and 
oligonucleotide synthesis, derived from solid phase method, usually required initial 
loading of lead monomer onto solid support or resin using special coupling protocols that 
can often be difficult and time-consuming.  We have developed a modified solid-
supported azide capable of facile, rapid loading of lead monomer as well as retaining the 
innate synthetic property of the unmodified solid supports.  This led to a milder, flexible 
methodology for synthesizing oligonucleotides and targeting peptides, such as nuclear 
localization signaling (NLS) peptides, investigated in the research herein described.   
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CHAPTER 1 
 
Histone Deacetylase, Gold Nanoparticles, and Cancer Therapy 
 
 
1.1 Histone Deacetylase and Tumorigenesis 
 The proper control of double-stranded DNA supercoil is essential for normal 
functioning of all living cells.1 Three functionally related enzymes that maintain the 
structural integrity of the DNA supercoil are topoisomerase, histone acetyltransferases 
(HATs) and histone deacetylases (HDACs).  In both prokaryotes and eukaryotes, the 
function of topoisomerases is to relieve the supercoiling and torsional stress of DNA 
helix caused by replication, transcription, and chromatin remodeling and recombination.  
In eukaryotes, HATs, and HDACs are two functionally opposing enzymes that tightly 
regulate the chromatin structure and function via sustenance of equilibrium between the 
acetylated- and deacetylated-states of nucleosomal histones.1, 2  HATs acetylate histones, 
thereby gradually loosen the chromatin structure and aid transcription through increasing 
accessibility of gene promoter regions to transcription factors, regulatory complexes and 
the RNA polymerase.2, 3  HDACs deacetylate histones, resulting in positively charged, 
hypoactylated histones, which bind tightly to the phosphate backbone of DNA, thus 
inducing gene-specific repression of transcription.1-3 Aberrations in intracellular histone 
acetylation-deacetylation equilibrium have been linked to the repression of a subset of 
gene resulting in tumorigenesis and are implicated in a number of malignant diseases.2   
The aberrant activity of HDACs has been shown to sustain the abnormal transcriptional 
silencing of tumor-supressor-gene expression leading to the development and 
maintenance of tumor cells.3   
 
1 
 
1.1.1 Classical HDACs Biology 
 The eukaryotic HDACs are categorized as class I (HDAC-1, -2, -3, and -8); class 
II (HDAC-4, -5, -6, -7, -9, and -10); and class IV (HDAC-11) with Zn2+ ion at the base of 
their catalytic core. Class III HDACs are identified as NAD-dependent proteases for their 
deacetylase function.1-4 The aberrant HDAC activity leading to tumorigenesis has been 
linked to HDACs class I and II.5, 6 The specific involvement of each HDAC isoform in 
tumor cells varied from one isoform to another.  For examples, siRNA knockout of 
HDAC-1, and -2 confirmed their involvement in apoptosis and proliferation of 
transformed cells.7, 6b-c However, the exact cellular function of HDACs is still far from 
being completely elucidated.  Nevertheless, inhibiting HDAC activity should lead to 
chromatin decondensation and overall increasing in gene transcription.5, 8   
 
   
  (b) (a) 
Figure 1-1.  Crystal structure of (a) HDLP and (b) HDAC-8 presented in secondary        
structural motif viewed in PYMOL.  Zinc ion is shown as gray ball.3 
 
 Structural information essential for rational design of isoform selective class I and 
II HDACs inhibitors is scarce.  To date, only the crystal structure of histone deacetylase-
2 
 
like protein (HDLP, bacterial homologue to human class I HDAC), HDAC-7, and human 
HDAC-8 are available (Figure 1-1).3 Overall architecture of HDLP and HDAC-8 active 
site is conserved relative to other class I and II HDACs.  In HDLP, the active site is 
composed of a hydrophobic tunnel about 14 Å deep (Figure 1-2).3a, 5 The amino acid 
residues, Pro 22, Phe141, Phe198, Leu265, His180, Gly140, and Tyr297, formed the  
                                                               
  (a)   (b) 
 
Figure 1-2.  Mesh representation of the (a) HDLP and (b) HDAC-8 tunnel-like active site 
viewed in PYMOL.  Zinc ion is shown as red ball. 3 
 
 
 
wall of the tunnel.  The Zn2+ ion at the base of the tunnel is coordinated with adjacent 
amino acid residues (Asp168, His170, and Asp258) and water molecules to hydrolyze the 
acetylated lysine of the N-terminal tail of core histones.3a In HDAC8, the only 
architectural difference is the replacement of leucine with methionine among the amino 
acid residues that constructed the wall of the active site.  In addition, HDAC-8 active site 
adopted a different shape and is only 12 Å deep, which can be used to gain isoform 
selectivity for the design of HDAC inhibitors (Figure 1-2).5   
3 
 
 Proposed mechanism for the hydrolysis of N-acetylated lysine residue required 
that the carbonyl group of the N-acetyl amide bond of the acetylated lysine residue first 
coordinate to the Zn2+ ion.  More importantly, the coordination brings the actylated lysine 
in close proximity with the water molecule at the base of the active site.  The Zn2+ ion 
then pololarized the carbonyl group making the carbonyl carbon a better eletrophile.3 The 
nucleophilicity of the water molecule is increased by both hydrogen bonding to His 131 
as well as coordination to the Zn2+ ion and therefore, leading to the hydrolysis of the 
carbonyl carbon to form a tetrahedron oxyanion intermediate.  The intermediate is 
stabilized by two oxygen-zinc interactions and hydrogen bonding to the Tyr297 hydroxyl 
group.3 Oxyanion reformed the carbonyl group leading to the cleavage the carbon-
nitrogen bond of the intermediate.  The free nitrogen then accepts a proton from His132 
yielding the free lysine residue and the acetate group (Figure 1-3).3 Understanding the  
 
 
Figure 1-3.  The proposed mechanism for the deacetylation of acetylated lysine residue 
in HDLP active site. 
 
4 
 
overall structure and mechanism of the class I and II HDACs active site has led to the 
development of many HDAC inhibitors with few in clinical trials. In fact, HDAC 
inhibition has been clinically validated with approval of suberoylanilide hydroxamic 
acids for the treatment of cutaneous T cell lymphoma.8   
 
1.1.2 Pharmacology of HDAC Inhibitors 
  Because of their demonstrated ability to arrest proliferation of nearly all 
transformed cell types8, HDAC inhibitors (HDACi) hold great promise as agents of 
choice, either as stand alone therapeutics or in combination with others, in the fight 
against the cancer scourge.  More importantly, majority of these HDAC inhibitors 
displayed relative low toxicity profile because a broad variety of transformed cell are 
more sensitive to HDACi-induced apoptosis than normal cells.1 However, they suffer 
from short half-life and low oral bioavailability.  In addition, most of the HDAC 
inhibitors non-selectively inhibit various isoforms of HDACs leading to reduced in vivo 
potency.5, 8 Hence, selective inhibition against specific HDAC isoforms in conjunction 
with improving pharmacokinetic profile are important issues that must be addressed 
toward HDAC inhibitors.  
     
1.2 Gold in Medicine 
 Chrysotherapy, the use of gold in medicine, has been practiced since antiquity. 
Ancient cultures such as those in Egypt, India, and China used gold to treat diseases such 
as smallpox, skin ulcers, syphilis, and measles.9-13 Presently, gold is in use in medical 
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devices including pacemakers and gold plated stents,14, 15 for the management of heart 
disease; middle ear gold implants,16 and gold alloys in dental restoration.17, 18 
Because of their photo-optical distinctiveness, biocompatibility, and enhanced 
permeability and retention (EPR) effect, nanoscopic gold or gold nanoparticles (AuNPs) 
have also proven to be powerful tools in various nanomedicinal and nanomedical 
applications, such as bioimaging and photothermal therapy,  
 Bioimaging is achieved through the generation of colorimetric contrast between 
different cells/sub-cellular organelles by imaging agents.  The use of AuNPs as imaging 
or contrast agents eliminate most of the vulnerabilities (photobleaching, low quantum 
yields, broad emission window, and nonselective localization in extravascular space) of 
the conventional imaging agents (lanthanide chelates and organic fluorophores).19-21 In 
addition, the colorimetric contrast observed within the AuNPs treated cells could be 
controlled by size,22-24 shape25-27 or even surface modification28, 29 of the AuNPs due to a 
phenomenon called surface plasmon resonance (SPR).21 When excited, the SPR of 
AuNPs could scatter and/or absorb light in the visible or the near-infrared (NIR) 
spectrum,30 an extremely useful property for in vivo optical imaging.   
 Photothermal therapy is a less invasive experimental technique that holds great 
promise for the treatment of cancer and related disease conditions.31 It combines two key 
components: (i) light source, specifically lasers with a spectral range of 650-900 nm31 for 
deep tissue penetration, and (ii) optical absorbing AuNPs which transform the optical 
irradiation into heat on a picosecond time scale, thereby inducing photothermal 
ablation.32, 33 Recent developments have shown that the spectral signature of AuNPs 
could be tailored or tuned by altering their shape or size.  El-Sayed and co-workers have 
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demonstrated that gold nanorods have a longitudinal absorption band in the NIR on 
account of their SPR oscillations and are effective as photothermal agents.31 Other gold 
nanostructures such as gold nanoshells,34 gold nanocages,32 and gold nanospheres35 have 
also demonstrated effective photothermal destruction of cancer cells and tissue. However, 
efficient in vivo targeting of AuNPs to heterogeneous population of cancer cells and 
tissue still requires better selectivity and non-cytotoxicity to surrounding normal cells.     
 
 
1.2.1 Selective Delivery of AuNPs 
 Efficient delivery of AuNPs into a living system requires overcoming natural 
biological barriers such as the cell membrane and the reticuloendothelial system (RES). 
For specific tumor targeting, AuNPs face additional challenges from receptor specificity 
and intra-tumor barriers.  Potential approach for optimizing AuNPs delivery is particle 
size reduction (“true nanometer scale”) or acquisition of surface modification.   For 
example, large AuNPs are quickly opsonized by blood and eliminated by the RES in 
mammalian cells.36-39 To bypass RES, antibiofouling agents such as thiol-derivatized 
poly-ethylene glycol (PEG-SH) have been grafted onto AuNPs surface as secondary 
coating.  It has been observed that this secondary coating could delay RES clearance to 
liver from 0.5 hour to 72 hours in a mice model, an approximately 150 folds 
improvement compared to the unmodified CTAB-capped AuNPs.40 Several investigators 
have grafted different delivery platforms onto AuNPs surface to attempt cellular 
selectivity, internalization, and localization within heterogeneous population of cancer 
cells in solid tumors.  These delivery platforms generally consist of macromolecules such 
as proteins and peptides or small molecules such as folic acid and paclitaxel.  Several of 
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these platforms have shown very promising results in delivering AuNPs into solid tumors 
for therapeutic or imaging applications.41-45 
The sustained fascination of the scientific community with AuNPs research have 
been facilitated by significant strides in many fronts including availability of a plethora of 
methods for the production and functionalization of AuNPs of various shapes and sizes. It 
is now possible to control particle sizes at nanometer resolution. Improved understanding 
of molecular targeting in biology has furnished several ligands that have been 
successfully used for specific delivery of AuNPs. With information accruing from 
proteomics studies on various diseases, one expects that many more ligands will be made 
available for AuNPs targeted delivery. 
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CHAPTER 2 
 
TARGETED HISTONE DEACETYLASE INHIBITION 
 
 
 
2.1 Aliphatic Hydroxamates  
 Histone deacetylase inhibitors (HDACi) have become promising anticancer 
agents in recent years. They have shown ability to block angiogenesis and cell cycling, as 
well as initiate differentiation and apoptosis.1, 2 Histone deacetylase (HDAC) inhibition 
has recently been clinically validated as a new therapeutic strategy for cancer treatment 
with the FDA approval of suberoylanilide hydroxamic acid (SAHA) for the treatment of 
cutaneous T cell lymphoma.3 Intense research activities are ongoing in pharmaceutical 
and academic laboratories toward improving the pharmacokinetic and therapeutic indices 
of current HDACi. The classic pharmacophore for HDACi consists of three distinct 
structural motifs: the zinc-binding group (ZBG), a hydrophobic linker, and a recognition 
cap group (Figure 2-1).4 The X-ray structures of a bacterial HDAC homolog, histone 
deacetylase-like protein (HDLP), bound to SAHA or Trichostatin A (TSA) and,  
 
 
Surface recognition
group
Linker group
Zinc binding
group (ZBG)
 
A B 
Figure 2-1. Small molecule HDACi - (a) selected examples of acyclic HDACi; (b) 
pharmacophoric model of HDACi 
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more recently, human HDAC8 and HDAC7, confirmed that the ZBG interacts with a 
Zn2+ ion at the base of a channel-like active site.4-6  The hydrophobic linker efficiently 
presents the ZBG to the active site by filling the channel while the cap-group at the other 
end of the linker makes contacts with amino acid residues at the rim of the channel.   
The common ZBG of HDACi is the hydroxamate moiety.  The structural 
modifications of the hydroxamate ZBG have been modestly successful; yielding isosteres 
such as benzamide, α-ketoesters, electrophilic ketones, mercaptoamide and 
phosphonates.4, 7 Hence, the cap group presents an alternative opportunity to discover 
potent and more selective HDACi.  In this regard, recent work by Schreiber and co-
workers has led to the identification of cap group-modified agents that display differential 
inhibition against specific HDAC sub-types.8, 9     
In a prototypical HDACi, the cap group could be linked to the aliphatic linker 
group through either hydrogen bonding accepting or donating groups such as keto- and 
amide- groups (Figure 2-1). The apparent lack of preference for H-bond donor or 
acceptor in the linking-moiety presents an opportunity to incorporate other more 
synthetically accessible and pharmacokinetically desirable moieties that may help 
simplify the molecular design and synthesis of novel HDACi. We proposed that a 1, 2, 3-
triazole ring could act as a linking-moiety which joins the cap group to the linker group in 
a HDACi. The triazole ring could serve two purposes: (1) it could facilitate stronger cap 
group interactions with the amino acid side chains at the entrance of the HDAC active 
site; (2) it could serve as an isostere to the pharmacokinetically and toxicologically 
disadvantageous groups such as amide and ketone. We report here the synthesis and 
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structure activity relationship for HDACi incorporating 1, 2, 3-triazole as the cap group 
linking moiety.  
 
 2.1.1 Molecular Design of SAHA-like Triazole-Linked HDAC Inhibitors 
The key reaction in the synthesis of the proposed HDACi is the Cu(I)-catalyzed 
Huisgen cycloaddition between azides and terminal alkynes (click chemistry). Click 
chemistry was popularized by elegant works from Sharpless and Medal’s laboratories,10, 
11 and has become a tool for the construction of various complex macromolecules and 
rapid identification of small molecules with interesting biological activities.11 To directly 
assess the effect of triazole ring as a cap group linking moiety in simple linear aliphatic-
hydroxamate HDACi, we first synthesized a series of SAHA-like hydroxamates 4a-d. 
These compounds link the aromatic surface recognition cap group to the aliphatic zinc 
binding hydroxamate moiety via 1, 2, 3-triazole ring.  
 
 
 
Scheme 2-1.  Synthesis of aryltriazolylhydraxamate 4a-d.  Conditions:  (a) CuI, Hunig’s 
base, THF, rt; (b) NH2OH(aq), KCN, 1:1 THF/MeOH, rt.   
 
Cu(I)-catalyzed Huisgen cycloaddition between phenylacetylene 1 and known azido 
esters 2a-d12-14,  followed by treatment of the intermediate esters 3a-d with 50% aqueous 
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hydroxylamine15 furnished the desired hydroxamic acids 4a-d in good to excellent yields 
(Scheme 2-1). Similarly, the synthesis of analogs with other aromatic surface recognition 
cap groups is achieved starting from the corresponding aryl alkynes and azido esters 
(Scheme 2-2).  Aryl alkynes, 5g, 5i, 5j, 5l, 5p, and 5q, that were not commercially 
available were synthesized from the corresponding aldehydes and carboxylic acids 
(through the intermediacy of aldehyde) using the Bestmann-Ohira Reagent.16-18 
 
N
NN
OR1
O
nR2
a
6
6a: n = 3, R1 = Me, R2 = Anil
6b: n = 4, R1 = Me, R2 = Anil
6c: n = 3, R1 = Me, R2 = 3-Py
6d: n = 3, R1 = Me, R2 = 4-Py
6e: n = 3, R1 = Me, R2 = 2-Py
6f: n = 4, R1 = Me, R2 = 2-Py
6g: n = 3, R1 = Me, R2 = 4-Tol
6h: n = 3, R1 = Me, R2 = 3-Tol
6i: n = 3, R1 = Me, R2 = 2-Tol
6j: n = 3, R1 = Me, R2 = 4-Anis
6k: n = 3, R1 = Me, R2 = 3-Anis
6l: n = 3, R1 = Me, R2 = 2-Anis
6m: n = 3, R1 = Me, R2 = 2,6-DMP
6n: n = 3, R1 = Me, R2 = Thp
6o: n = 3, R1 = Me, R2 = 4-bp
6p: n = 3, R1 = Me, R2 = 3-bp
6q: n = 4, R1 = Me, R2 = 3-bp
6r: n = 3, R1 = Me, R2 = 2-bp
6s: n = 3, R1 = Me, R2 = PyP
6t: n = 4, R1 = Me, R2 = PyP
6u: n = 3, R1 = Me, R2 = Nap
6v: n = 4, R1 = Me, R2 = Nap
6w: n = 3, R1 = Me, R2 = 2-Quin
6x: n = 3, R1 = Me, R2 = 7-Quin
6y: n = 2, R1 = Me, R2 = Bz
N
NN
N
H
O
OH
nR2
b
7
7a: n = 3, R2 = Anil
7b: n = 4, R2 = Anil
7c: n = 3, R2 = 3-Py
7d: n = 3, R2 = 4-Py
7e: n = 3, R2 = 2-Py
7f: n = 4, R2 = 2-Py
7g: n = 3, R2 = 4-Tol
7h: n = 3, R2 = 3-Tol
7i: n = 3, R2 = 2-Tol
7j: n = 3, R2 = 4-Anis
7k: n = 3, R2 = 3-Anis
7l: n = 3, R2 = 2-Anis
7m: n = 3, R2 = 2,6-DMP
7n: n = 3, R2 = Thp
7o: n = 3, R2 = 4-bp
7p: n = 3, R2 = 3-bp
7q: n = 4, R2 = 3-bp
7r: n = 3, R2 = 2-bp
7s: n = 3, R2 = PyP
7t: n = 4, R2 = PyP
7u: n = 3, R2 = Nap
7v: n = 4, R2 = Nap
7w: n = 3, R2 = 2-Quin
7x: n = 3, R2 = 7-Quin
7y: n = 2, R2 = Bz
R2
5
5a: R2 = Anil
5b: R2 = 3-Py
5c: R2 = 4-Py
5d: R2 = 2-Py
5e: R2 = Thp
5f: R2 = Nap
5g: R2 = 2-bp
5h: R2 = 4-bp
5i: R2 = 3-bp
5j: R2 = 2,6-DMP
5k: R2 = Bz
5l: R2 = PyP
5m: R2 = 4-Tol
5n: R2 = 3-Tol
5o: R2 = 2-Tol
5p R2 = 2-Quin
5q: R2 = 7-Quin
5r: R2 = 4-Anis
5s: R2 = 3-Anis
5t: R2 = 2-Anis
 
Scheme 2-2.  Synthesis of aryltriazolylhydraxamate 7 for SAR studies.  Conditions:  (a) 
2b-d, CuI, Hunig’s base, THF, rt, (b) NH2OH(aq), KCN, 1:1 THF/MeOH, rt.  
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2.1.2  Structure Activity-Relationship Studies of SAHA-like Triazole-linked HDAC 
Inhibitors 
 
 To establish whether 1, 2, 3-triazole ring is a suitable moiety for connecting the 
surface recognition cap group to the aliphatic zinc binding hydroxamate in a prototypical 
HDACi, we initially synthesized simple SAHA-like linear aliphatic-hydroxamates 4a-d. 
Subsequent in vitro evaluation in Fluor de lys assay19 reveals some interesting features 
about the anti-HDAC activity of these compounds.  Compound 4a, an analog with three 
methylene spacers separating the triazole ring and the hydroxamate moiety, has no 
detectable anti-HDAC activity. Conversely, compounds 4b-d displayed spacer-length 
dependent HDAC inhibitory activities with 4c and 4d, analogs with five- and six-
methylene spacers, being most potent (Table 2-1). This preliminary result shows that the 
anti-HDAC activities of these compounds track with, and thus confirm the early 
observation about the optimal spacer length for TSA- and SAHA-like anti-HDAC 
hydroxamates.4, 20 More importantly, a head-to-head comparison reveals that 
incorporation of triazole ring potentiates HDAC inhibition. For example, compound 4c, 
the closest analog of SAHA, is about 4-fold more active than SAHA. 
 Interestingly, there is no clear trend in activity between the five- or six-methylene 
group spacer groups. For the simple phenyl substituted compounds, the six-methylene 
linked compound 4d is slightly more active than the five-methylene compound 4c (Table 
2-1). However, the introduction of N, N-dimethylamino moiety to the para position of the 
cap group, similar to the substitution pattern on TSA (Fig. 2-1a), led to a five-methylene 
linked compound that is about 25-fold more active than the corresponding six-methylene 
compound in the Fluor de lys assay (Table 2-2, compare 7a and 7b). Because of this cap 
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Table 2-1.  In vitro inhibition data for aryltriazolylhydroxamates 4. TSA and SAHA with 
IC50 values of 5 nM and 65 nM, respectively, were used as controls.   
    
 
Compound n IC50 (nM)a
4a 1 N.D.b
4b 2 110.0 
4c 3 14.2 
4dc 4 9.6 
               a Data represent mean values of at least three independent  
                          experiments in Fluor de Lys assay, performed by William  
                          Guerrant.  
                          b  N.D. = Not Determinable. 
    c Compounds made by Vishal Patil.  These are included to clarify the  
      SAR.  See Chen et al, Bioorg. & Med. Chem., 2008, 16, 4839-4853  
    for detailed synthetic protocol. 
    
 
group dependent potency of the five- and six-methylene spacer group, we prepared a 
series of aromatic and heteroaromatic derivatives consisting of either spacer group in 
order to further explore the SAR of these compounds. This exercise results in compounds 
that display potent HDAC inhibiting activity which trends with both the hydrophobicity 
and the substitution pattern of the aromatic ring. Relative to compounds 4c and 4d, 
nitrogen substitution into the phenyl ring did not improve the potency of the simple 
phenyl substituted compounds (Table 2-2, compounds 7c-f). However, the HDAC 
inhibitory activity of these pyridine derivatives is dependent on the ring location of the 
nitrogen atom with the 2-pyridyl derivative 7e being more active than the corresponding 
3-pyridyl  and 4-pyridyl analogs 7c and 7d respectively. Additionally, homologous 
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analogs 7e and 7f, differing by a methylene group, show a chain length dependency 
similar to that observed with 4c and 4d. Similarly, methyl-substituted compounds 7g-i 
have ring ortho-position substitution preference. However, para-substitution is preferred 
when the substitutent is a methoxy group (Table 2-2, compare compounds 7j-l with 7g-i). 
In fact, the activity of para-methoxylated compound 7j is enhanced compared to the  
 
Table 2-2.  In vitro inhibition data for aryltriazolylhydroxamates 7a. 
 
Compound R- n IC50 
(nM)
Compound R- n IC50 
b (nM)b
7a 7n      
3 4.3 3 31.7 
  
7bc 7o      
4 106.1 3 52.4 
  
c7c 7p     
N
3 287.2 3 1.9   
7dc 7qc    
3 112.5 4 5.4    
c 7r 7e     
3 67.6 3 162.6   
c c7s7f      
4 23.9 3 2.3   
7gc c7t     
3 43.4 4 16.6   
7hc 7u     
3 31.9 3 1.8 
  
c7i 7vc    
3 17.4 4 15.3   
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Table 2-2 (continued) 
c7j 7wc3 2.09 3 2.1 
 
 
7kc 7xc3 13.9 3 151.5 
 
 
c7l
 
3 76.0 7yc d N.D.
2  
 
7m       O
O
SAHA  315.9  65 
3    
In addition to SAHA, TSA with IC50 value of 5 nM was used as control.  aVishal Patil 
and Patience Green also contributed to the synthesis of aryltriazolylhydroxmates 7.   bData 
represent mean values of at least three independent experiments in Fluor de Lys assay, 
performed by William Guerrant.  cCompounds made by Vishal Patil.  These are included 
to clarify the SAR.  See Chen et al, Bioorg. & Med. Chem., 2008, 16, 4839-4853 for 
detailed synthetic protocol. dN.D. = Not Determinable. 
 
 
reference compound 4c. A similar para-substitution preference has been observed with 
methoxy-substituted SAHA-like HDACi in which the surface recognition cap group is 
linked to the aliphatic zinc binding hydroxamate through a ketone moiety.21 The para-
position preference may be due to the increased steric bulk of the methoxy group. To 
further investigate this possibility, we synthesized bisortho methoxy-substituted 
compound 7m. We observed an attenuation of the anti-HDAC activity of compound 7m 
relative to 7l. This observation confirmed the influence of steric constraints at the ortho 
position on the potency of SAHA-like compounds.  
Cap groups consisting of fused six-six ring systems such as naphthalenes and 
quinolines also furnished compounds with potent HDAC inhibitory activities. Parallel to 
the activity of pyridine derivatives 7c-e, the 2-quinoline analog 7w is more active than 
the 7-quinoline analog 7x. The enhanced potency of the five-methylene linked,  6-
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methoxynaphthalene capped compound 7u relative to a corresponding six-methylene 
analog 7v further underscored the preference of  the larger cap groups for a five-
methylene spacer. Furthermore, biphenyl compounds 7o-t display varying anti-HDAC 
activity that is dependent on the relative position of the triazole ring and the ring 
heteroatomic substitution pattern. In general, unsubstituted biphenyl compounds show 
preference for the meta-placement of the triazole ring and a five-methylene spacer (Table 
2-2, compare compounds 7o-r). 
Finally, the location of the triazole ring influences anti-HDAC activity. 
Compounds 4c and 7y are two isomeric compounds with the same number of carbon 
atoms separating the cap group and the hydroxamate moiety. Compound 4c, which has 
the triazole ring directly attached to the phenyl cap group is several orders of magnitude 
more potent than 7y whose triazole ring is separated from the cap group by a methylene 
group. This result is an indirect evidence that the triazole ring is indeed an active 
participant in the interaction of this class of compound with the HDAC active site.  
 
2.1.3 SAHA-like Triazole-linked HDAC Inhibitors Docking Results 
 To obtain information on the structural basis of the observed disparity in the 
HDAC inhibitory activity of these compounds, we performed molecular docking using a 
validated molecular dock program (AutoDock) 22-24 Docking analysis was performed on 
histone deacetylase-like protein (HDLP).5 We chose to use the HDLP structure because it 
shared conserved active site residues with class I HDACs.  Additionally, direct docking 
experiments using this structure or HDAC1 homology model built from the same HDLP 
structure have given docking results that are essentially of the same quality and also  
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Figure 2-2.  Molecular docking of aryltriazolylhydroxamates 7o (orange), 7p (green), 7u 
(magenta), and SAHA (cyan) to HDLP using Autodock 3.0519-21 and viewed in PYMOL.  
Upper picture: surface of HDLP near the active site; lower picture: side view of the 
triazolylhydroxamics 7o, 7p, 7u, and SAHA coordinating to zinc with amino acid 
residues in and near the active sites.19-21    
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agreed with experimentally obtained data.  Either of these approaches has been 
extensively used in the literature to interrogate the binding interaction of HDAC 
inhibitors at the protein active site.22b, c The crystal structures of HDLP alone and bound 
to two known HDACi, SAHA and TSA, are currently available in the public domain.5 
We performed docking studies with AutoDock 3.05 as described by Lu et al.24 
Independent docking of SAHA (IC50 = 65 nM), 4c (IC50 = 14 nM), 7o (IC50 = 52 nM), 7p 
(IC50 = 1.9 nM), and 7u (IC50 = 1.8 nM) into HDLP revealed that these compounds have 
preferences for two different binding pockets at the protein surface (Fig. 2-2). Previous 
investigation have shown that there are four possible binding pockets on the HDLP 
surface whose interactions with the aromatic cap groups could enhance the inhibitor 
binding ability.23 Compounds 7o and 7u bind within the binding pocket designated 
pocket 1 while SAHA, 4c and 7p bind within pocket 2. The 1,4-biphenyl ring of 7o 
adopts a co-planar geometry in order to fit within pocket 1. Presumably the stacking 
interactions in pocket 1 favor a co-planar geometry of the cap group, an inference that 
may be supported by the binding of 7u, an analog with a flat fused six-six ring, within 
pocket 1. To adopt the observed conformation, a sharp kink is introduced into the 
methylene spacer group portion of 7o. The consequence of this kinked structure is a twist 
in the orientation of the critical hydroxamate moiety of 7o, pulling its hydroxamate-group 
farther from the active site Zn2+ ion, compared to that of 7p and SAHA.  This potentially 
nullified any positive effects derived from the cap group interaction with pocket 1 and 
may proffer explanation about the reduced potency of 7o compared to structurally related 
7p. Unlike 7o, the 1,3-biphenyl ring of 7p preferred a non-planar geometry with the 
biphenyl ring protruding deeper into the binding pocket 2 where it hydrophobically  
23 
 
Table 2-3.  Cell Growth Inhibitory data for lead compounds.   
Aryltriazolylhydroxamates 7 IC50 
(nM) 
EC50 
(µM)
EC50 
(µM)a b
   
N
NN
O
N
H
OH
O
   
 
1.8 3.95 2.6 
7u 
 
   
N
NN
O
H
N
O
OH 15.3 7.76 3.99 
 
7vc
   
N
NN
N
H
OH
O
N
   
2.3 4.72 3.07  
c7s   
   
N
H
OH
O
N
N
N
N
   
2.1 2.25 2.46  
7wc
   H
N
O
N
H
O
OH
   
 
65.0 2.12 2.11 
SAHA 
SAHA was used as a control for these experiments.  EC50 values were determined from 
atrypan blue exclusion data and bMTS assay (Progmega), in DU-145 prostate cancer cell 
line, performed by William Guerrant. cCompounds made by Vishal Patil.  These are 
included to clarify the SAR.  See Chen et al, Bioorg. & Med. Chem., 2008, 16, 4839-4853 
for detailed synthetic protocol. 
24 
 
interacted further with the pocket residues. This extra interaction could explain the higher 
potency of 7p compared to 4c and SAHA. 
 
2.1.4 Cell Growth Inhibition Studies of SAHA-like Triazole-linked HDAC Inhibitors  
 To preliminarily screen for the whole cell activity of compounds described in this 
study, we tested the effect of the exposure of selected compounds on the viability of DU- 
145, a human prostate cancer cell line known to respond to HDACi.25 We evaluated 
compounds 7s, 7u, 7v and 7w with SAHA as a reference, using both the MTS test (a 
colorimetric method) and trypan blue exclusion, to qualitatively and quantitatively 
measure the effect of compound exposure to cell viability.26, 27 We obtained an EC50 
value of 2.12 μM for SAHA, a value in close agreement with the reported EC50 in DU 
145 under similar experimental conditions.28 Compounds 7s, 7u, 7v and 7w also inhibit 
the proliferation of DU 145 in a dose-dependent manner, with EC50 values ranging from 
2.2 to 8.0 µM (Table 2-3). These results validate the suitability of the triazole ring as a 
linking moiety in the design of SAHA-like HDACi. 
 
2.2 Nonpeptide Macrocyclic HDAC Inhibitors 
To date, several structurally distinct small molecules HDACi have been reported 
including aryl hydroxamates, benzamides, short-chain fatty acids, electrophilic ketones 
and macrocyclic-peptides (Scheme 3-1).4, 7, 29, 30 All HDACi so far reported fit into the 
class HDAC three-motif pharmacophoric model.4 Of these HDACi, macrocyclic-peptides 
have the most complex recognition cap-group moieties and present an excellent 
opportunity for the modulation of the biological activities of HDACi. Although cyclic-
peptide HDACi possess potent HDAC inhibition activity (nanomolar range), their broad 
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application in cancer therapy currently remains largely unproven.4 One promising 
exception, FK-228 (Figure 2-3), is currently in phase II study for the treatment of 
cutaneous T-Cell lymphoma.31  
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Figure 2-3. Structure of various HDACi and macrolide antibiotics (a) Selected examples 
of acyclic HDACi; (b) Representative examples of Cyclic-peptide HDACi; (c) 
Representative examples of Macrolide Antibiotics.  
 
 
 The dearth of clinically effective cyclic-peptide HDACi may be in part due to 
development problems characteristic of large peptides, most especially poor oral 
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bioavailability. In addition to retaining the pharmacologically disadvantaged peptidyl-
backbone, they offer only limited opportunity for side-chains modifications.32 
Identification of non-peptide macrocyclic HDACi will offer a new class of macrocyclic 
HDACi with potentially more favorable drug-like properties. Furthermore, this will aid 
comprehensive SAR studies and further enhance our understanding of the roles of 
specific interactions between the enzyme outer rim and inhibitor cap-groups in HDACi 
activity and selectivity. Herein we report the discovery of a new class of potent, non-
peptide macrocyclic HDACi derived from the macrolide macrocyclic ring structures. 
 
2.2.1 Molecular Design of Nonpeptide Macrocyclic HDAC Inhibitors 
 Macrolides are glycosylated polyketide antibiotics that have been in use for over 
50 years for the treatment of respiratory tract infections. Additionally, macrolides have 
elicited other non-antibiotic effects, including anti-inflammatory and immunomodulatory 
effects that make them promising candidates for the management of diseases of chronic 
airway inflammation.33, 34 More recently, macrolides derived from 6-O-
methylerythromycin A ring have been reported to serve as nonpeptidic surrogate for the 
peptide backbone of macrocyclic peptide luteinizing hormone-releasing hormone 
(LHRH) receptor antagonists.35 Drawing inspiration from the peptidomimetic property of 
macrolides, we hypothesize that an appropriate substitution of the cyclic peptide moiety 
of a prototypical cyclic-peptide HDACi with macrolide skeletons will generate a new 
class of potent non-peptide macrocyclic HDACi. 
To test our hypothesis, we first sought a SAHA-macrolide conjugate which 
incorporated the 15-membered azalide ring of azithromycin as the macrolide template 
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(Figure 2-3). Azithromycin skeleton is an attractive choice due to its excellent pharmaco-
kinetic (PK) profile and ease of chemical transformation of key moieties on the 
skeleton.36 Our design approach is to attach the HDAC inhibiting group to a macrolide 
moiety that is remote from the macrocyclic ring. We anticipate that this will minimize the 
potential steric clash at the HDAC active site that might result from the introduction of 
the azithromycin skeleton, a macrocyclic ring not optimized to bind HDAC enzyme. 
NMR structure37 and 3D model revealed that the 3’-tertiary amine of the desosamine 
sugar and the 4”-OH of the cladinose sugar met our design requirement. We opted for the 
former group because of the well established facile transformations of the tertiary amine 
moiety.35, 36 Almost all modifications of this moiety have resulted in the attenuation of the 
antibacterial activity of this class of compound.36b Furthermore, coupling of such 
desosamine modifications with cladinose sugar removal will result in compounds devoid 
of antibacterial activity,38 a property of the parent macrolides undesirable to our goals. 
Toward this end, we synthesized compound 15, which incorporates a SAHA-like moiety 
(Scheme 2-3) into the 3’-tertiary amine of azithromycin, as a prototype molecule. 
Compound 15 was synthesized from azithromycin 12 and methyl 8-chloro-8-
oxooctanoate 8 through a five-step synthetic route as shown in Scheme 2-3. To gain some 
preliminary insights into the roles of key macrolide moieties in anti-HDAC activity of 15, 
we synthesized compound 17, an analog of 15 lacking the cladinose sugar. Acid 
promoted removal of cladinose sugar according to published protocol35 quantitatively 
yielded compound 16, which was converted to hydroxamate 17 using the same protocol 
for the synthesis of 15 from 14 (Scheme 2-3). We then tested for the HDAC inhibition 
activity of 15 and 17 using a cell free kit assay (Fluor de Lys),19 and found that both 
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compounds caused a concentration dependent inhibition of HDACs 1 and 2 from HeLa 
cell nuclear extract (Table 2-4). In fact, both compounds have identical anti-HDAC 
activity, with IC50 values in low nanomolar range. Conversely, compound 14, the methyl 
ester precursor of 15, is completely inactive in this assay. This result suggests that the 15-
membered azalide ring of azithromycin macrolide is a suitable non-peptidyl surrogate for 
the macrocyclic peptide moiety of a typical cyclic-peptide HDACi. Additionally, the 
binding orientations of these compounds at the HDAC active site may be such that the 
hydroxamate group is efficiently presented to chelate the active site Zn2+ ion while the 
cladinose moiety is oriented away from the enzyme’s outer rim.  
 
0.25 N
HCl
qunati
tative
 
Scheme 2-3. Synthesis of prototypical nonpeptide macrocyclic HDACi 15 and 17.  
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2.2.2 Preliminary Structure Activity-Relationship Studies of Nonpeptide Macrocyclic 
HDAC Inhibitors 
 
 We then initiated structure activity relationship studies on 15 and 17 to optimize 
the HDAC binding affinity of these compounds. Preliminarily, we focused on the effects  
of the modification of linker-cap group connection moiety, macrolide skeleton, and linker 
length on anti-HDAC activity. We used AutoDock program22 and the crystal structure of 
a histone deacetylase-like protein (HDLP)5 to guide our structural optimization. In 
 
Table 2-4. In vitro HDAC inhibition (IC50) and isoform selectivity of nonpeptide 
macrocyclic HDACi.  
Compound HDAC 1/2 
(nM) 
HDAC 8 
(nM) 
Isoform Selectivitya
c d14 N.D. N.T. - b
15 107.10 6,680 62 
17 109.80 2,320 21 
23a 91.60 4,730 51 
23b 88.80 3,740 42 
23c 13.85 994 72 
23d 10.56 1,020 97 
23e 58.88 7,130 121 
23f 72.44 6,780 94 
23g 145.50 11,050 38 
23h 226.73 N.D. - b
31a 36.98 3,990 108 
31b 44.26 4,750 107 
31c 4.09 1,890 462 
31d 1.87 1,390 743 
31e 55.59 5,880 106 
31f 123.03 4,420 36 
31g 169.80 10,550 56 
31h 223.36 N.Dc - b
SAHA 65.00 1,860 29 
IC50 values were determined from the Fluor de Lys assay, performed by William 
Guerrant.  Each data is obtained from three independent experiments. acalculated by 
dividing  the IC50 of HDAC 8 with the IC50 of HDAC 1/2.  bundeterminable. cN.D. = not 
determinable. dN.T. = not tested 
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section 2.1, we demonstrated the suitability of a 1,2,3-triazole ring as an alternative 
linker-cap group connection moiety in SAHA-like HDACi.39 In addition to serving as an 
alternative connection moiety with a potentially favorable pharmacokinetic properties, 
the triazole ring is a more synthetically tractable group,10 and has been adopted in the 
construction of active-site directed chemical probes for profiling HDAC activities in 
proteomes and live cells.40 Its incorporation into our design could facilitate a facile, high 
yielding synthesis of the triazole-based SAHA-macrolide conjugates and thus provide 
solution to the problems of low yields that currently plagued the synthesis of the amide-
based compounds 15 and 17 (Scheme 2-3). 
 Accordingly, we proceeded to test the compatibility of the triazole ring with the 
anti-HDAC activity of 15 and 17. We prepared compounds 23a and 23b, analogs of 15 
and 17 respectively, having the amide moiety connecting the cap group and the linker 
region substituted with a 1, 2, 3-triazole ring (Scheme 2-4a). The reaction of 4-
ethynylbenzyl mesylate with 18 led to the desired desosamine alkylation product 19 in 
very good yields. Cu(I) catalyzed cycloaddition reaction of alkyne 19 with O-silyl azido-
hydroxamate 2110, 39 gave the desired cycloadduct 22 in good yields. Similarly, the 
reaction of alkynes 19 and 20 with azido ester 25 gave the desired cycloadducts 26a and 
26b respectively. The deprotection of the silyl group of compound 22 is accomplished 
with TBAF treatment, leading to desired hydroxamate 23a in good yields. However, 
difficulties were encountered in separating 23a from the TBAF reagent. In much the 
same manner as in the synthesis of 15 or 17 (Scheme 2-3), the conversion of methyl ester 
26a and 26b to the corresponding hydroxamate is dogged by low yields. Subsequently, 
we found that a direct Cu(I) catalyzed cycloaddition between unprotected azido- 
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Scheme 2-4. SAR studies on nonpeptide macrocyclic HDACi (a) Synthesis of triazole-
linked nonpeptide macrocyclic HDACi based on azithromycin 15-membered ring; (b) 
Synthesis of triazole-linked nonpeptide macrocyclic HDACi based on clarithromycin 14-
membered ring. 
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hydroxamate 24 and alkyne 19 or 20 in anhydrous, degassed THF under exclusion of 
oxygen uneventfully gave the desired hydroxamates (Scheme 2-4a). 
 
2.2.3 Nonpeptide Macrocylic HDAC Inhibitors Docking Results 
HDAC inhibition studies revealed that the triazolyl-compounds 23a and 23b have 
virtually identical anti-HDAC activity as the amide-compounds 15 and 17 (Table 2-4). 
This result is in contrast with our observation on simple aliphatic hydroxamates where 
the introduction of the triazole ring led to an enhancement of anti-HDAC activity.41 To 
gain insights on the molecular interactions between these non-peptide macrocyclic 
HDACi and HDAC active site, we performed molecular docking analysis of 23b on 
HDLP, using AutoDock program, as previously described.22, 39  The obtained docked 
structure indicated interesting molecular surface complementarities between the 
macrolide skeleton of 23b and the HDAC outer rim. Previous investigations have shown 
that there are four possible binding pockets on the HDLP surface whose interactions with 
the HDACi cap groups could enhance the inhibitor binding ability.22b Compound 23b 
adopts a docked structure that placed the macrolide macrocyclic ring in binding pockets 1 
and 3 (Figure 2-4a). In addition, the hydrophobic components of the macrolide ring 
optimally interact with the hydrophobic residues in pockets 1 and 3 while the hydrophilic 
hydroxyl groups are oriented away from the pocket’s hydrophobic residues. Compared to 
the structure of SAHA, the hydroxamate moiety of 23b is farther oriented from the active 
site Zn2+ ion (Figure 2-4b). Based on the preceding observation, we inferred that 
optimization of the linker region could result in compounds with enhanced HDAC 
affinity due to a better presentation of the hydroxamate moiety to the catalytic Zn2+ ion. 
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Subsequent docking analyses with analogs of 23b having varied methylene-linker lengths 
revealed that 23d, a C -linker compound, optimally interacts with the Zn2+7  ion (Figure 2-
4c). Interestingly, compound 31d, an analog of 23d in which the 15-membered 
azithromycin ring has been substituted with the 14-membered clarithromycin ring, has a 
slight preference for the enzyme.  A closer analysis of the docked structures of 23d and 
31d revealed that the C12 - C14 region of the larger 15-membered ring is about 0.5Å  
 
 
(c) (d) 
(a) (b) 
Figure 2-4. Docked structures of SAHA, 14- and 15-membered macrocyclic HDACi in 
the active site of HDLP. (a) Super-position of the low energy conformation of 23b (blue) 
and SAHA (yellow) revealed the pocket binding preferences of inhibitors at the HDLP 
surface. Ball and stick model of the orientation of the hydroxamate group of SAHA and 
23b (b); 23b and 23d (orange) (c) with respect to the active site Zn2+ ion (grey ball). (d) 
Relative orientation of the macrocyclic rings of 23d and 31d (yellow) with respect to Phe 
338 at the HDLP surface. 
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closer to the phenyl ring of Phe338 that defines one of the hydrophobic pockets at the 
enzyme outer rim compared to that of the 14-membered compound (Figure 2-4d). This 
might compromise the binding affinity of the 15-membered compounds relative to the 
14-membered analogs.  
 To experimentally test these in silico observations, we synthesized compounds 
16c-h and 24a-h, 14- and 15-membered non-peptide macrocyclic hydroxamates 
respectively (Fig. 2-4a and 2-4b). Results from the Fluor de Lys assay on these 
compounds revealed HDAC inhibition activities that essentially paralleled the in silico 
prediction (Table 2-4). The compounds displayed both linker-length and macrolide-type 
dependent HDAC inhibition activities. For compounds derived from the same macrolide 
ring, an increase in the linker length from C  to C6 7 conferred a better anti HDAC activity. 
Further linker length increase did not improve HDAC inhibition activity; in fact such 
increase is detrimental to function in some cases. For compounds with C6 and C7 linkers, 
a head-to-head comparison between 14- and 15-membered macrolides revealed that the 
14-membered compounds are about 2-5 folds better HDACi than their 15-membered 
counterparts (Table 2-4, see 23c and 31c for example). However, this preference 
dissipated with increase in linker length. This is presumably due to a relief of steric clash 
between the macrocyclic ring and the phenyl ring of Phe338 at the enzyme outer rim, 
conferred by the longer linkers. 
 
2.2.4 HDAC Isoform- and Cell-Selectivity Studies of Nonpeptide Macrocyclic 
HDAC Inhibitors 
 
To obtain preliminary evidence for the HDAC isoform selectivity of the 
macrocyclic HDACi described herein, we tested their HDAC8 inhibition activity. We 
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chose HDAC8 because it is in the same sub-class as HDACs 1 and 2, the principal 
HDACs contained in the HeLa cell nuclear extract used in assay kit employed in this 
study. There are very few examples of HDACi that are selective for HDAC isoforms 
within the same class; hence this choice should permit a quick, yet rigorous assessment of 
HDAC isoform selectivity of our compounds. Compared to SAHA, all non-peptide 
macrocyclic hydroxamates tested are more selective for HDAC1/2. This observation is in 
agreement with the literature reports which suggest that complex head groups tend to 
promote isoform selectivity.4, 9 However, C7-linked, 14-membered compounds 31c and 
31d are several folds more selective than their 15-membered counterparts (Table 2-4). 
Although HDLP and HDAC8 shared similar amino acid sequences and topology at the 
active site, observation from the analysis of X-ray data however revelaed significant 
inhibitors specific changes in the enzyme active site topology of HDAC8.6b Our docking 
analysis operates in the rigid receptor mode and it is incapable of capturing such 
crystallographically observed ligand induced conformational changes.  Nevertheless, we 
performed molecular docking analysis of 23b  on HDAC8 structure reported by Somoza 
et al.6b In contrast to its docked structure on HDLP, the orientation of 16b which has a 
chance of making any interaction with the active site Zn2+ ion is that which adopted a 
closed conformation nestled atop of the entrance to the enzyme active site.  In this 
conformation, the linker group wrapped around the macrocyclic ring to orient the 
hydroxamate moiety toward the Zn2+ ion, albeit much farther away to make any 
stabilizing interaction (Figure 2-5).  An alternative lower energy conformation of 23b 
oriented the hydroxamate moiety away from the Zn2+ ion.  It is therefore possible that the 
observed isoform selectivity may be due to the inability of the nonpeptide macrocylic  
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                   (a) 
 
                   (b) 
 
 
Figure 2-5.  Docking structure of 23d in the active site of HDAC8.  (a) Surface 
representation of docked Structure of 23d at the entrance of HDAC8 active site. (b) Ball 
and stick model of the orientation of the hydroxamate group of 23d with respect to the 
active site Zn2+ ion (grey ball).  
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hydroxamates herein described to efficiently induce active site conformational changes 
that facilitate HDAC8 specific inhibitor association with the enzyme active site.41a 
Alternatively, HDAC8 activity has been observed to depend on the sequence of its 
peptide substrate22b, hence it is also conceivable that the extent of enzyme inhibition, and 
consequently isoform selectivity, may depend on the substrate used in the inhibition 
study. 
To further test for HDAC isoform selectivity, we investigated the effect of 
selected macrocyclic HDACi on the deacetylase activity of HDAC6, a representative 
member of class II HDAC.  For this preliminary study, we chose compounds 23b and 
23d, and 31c and 31d, the most potent representative 15- and 14-membered macrocyclic 
HDACi respectively (Table 2-4).  Cell free HDAC6 inhibition assay was performed as 
recommended by the supplier.19 Unlike SAHA which equally inhibit HDAC 1/2 and 
HDAC6, we observed that the macrocyclic HDACi still displayed significant preference 
for HDAC1/2 (Table 2-5).  This observation is in agreement with the literature reports 
which suggest that complex head groups tend to promote isoform selectivity.4, 41c 
 
Table 2-5.  In vitro HDAC inhibition (IC50) and isoform selectivity of nonpeptide 
macrocyclic HDACi.  
Compound HDAC 1/2 (nM) HDAC 6 (nM) Isoform 
Selectivitya
23c 13.9 78.0 6 
23d 10.6 117.4 11 
31c 4.1 89.3 22 
31d 1.9 148.5 78 
SAHA 65.0 85.5 1 
IC50 values were determined using a cell free kit assay.19 Each data is obtained from two 
independent experiments, performed by William Guerrant. acalculated by dividing  the 
IC50 of HDAC 6 with the IC50 of HDAC 1/2 
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To screen for the whole cell activity of compounds described in this study, we 
studied their effect on the viability of SK-MES-1 (human NSCLC cell line), NCI-H69 
(human SCLC cell line), DU-145 (a human prostate cancer cell line,) and non-
transformed human primary lung fibroblasts and mammary epithelial cell lines. The non-
transformed cell lines were investigated to obtain evidence for compound selective  
 
Table 2-6. Cell growth inhibition data for nonpeptide macrocyclic HDACi.  
Compound SKMES 1 
(µM) 
NCI-H69 
(µM) 
DU-145 
(µM) 
lung 
fibroblast 
(µM) 
HMEC 
(µM) 
 a a a a15 N.T. N.T. >25 N.T. N.T.
 a  a a a17 N.T. N.T. <25 N.T. N.T.
23a 1.79 1.92 1.45 >10 >10 
23b 1.68 1.77 1.24 >10 >10 
23c 2.33 3.45 1.88 >10 >10 
23d 2.56 3.01 1.97 >10 >10 
23e 4.89 4.56 5.89 >10 >10 
23f 4.67 3.99 5.68 >10 >10 
23g 7.54 8.45 >10 >10 >10 
31a 2.15 2.67 2.98 >10 >10 
31b 1.95 1.92 3.29 >10 >10 
31c 1.33 1.45 1.12 >10 >10 
31d 1.28 1.49 1.05 >10 >10 
31e 4.89 5.67 6.97 >10 >10 
31f 4.45 5.09 5.78 >10 >10 
31g 7.12 7.29 8.14 >10 >10 
SAHA 2.42 2.06 2.12 >10 >10 
EC50 values were determined from trypan blue exclusion data. Each data is obtained from 
a duplicate of four simultaneous experiments, performed by William Guerrant. aN.T. = 
not tested 
 
 
toxicity. Drug concentrations necessary for 50 % inhibition of cell viability (EC50) were 
quantitatively measured using trypan blue exclusion27, as previously described.39 Table 3-
2 shows the EC50 values of each compound. The EC50 values obtained for SAHA are in 
close agreement with the reported values under similar experimental conditions.28  
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Macrocyclic methyl ester 14, the precursor to compound 15 (Scheme 2-3), has no effect 
on cell viability. This result may not be unexpected since compound 14 has no HDAC 
inhibition activity (Table 2-4). However, all macrocyclic hydroxamates inhibit the 
proliferation of all transformed cells studied. Most importantly, compounds 23b, 31c, and 
31d are at least twice as potent as SAHA in DU-145 cells (Table 2-6). Gratifyingly, none 
of the macrocyclic hydroxamates tested shows any growth inhibitory effects on the 
normal human primary lung fibroblast and mammary epithelial cell lines at 
concentrations in excess of 10 μM. This data showed that the macrocyclic compounds are 
selectively toxic to the transformed cells, a trait that tracks with that of many HDACi. 
 
2.2.5 Design and Synthesis of Isotopically Labeled Nonpeptide Macrocylic HDAC 
Inhibitors for In Vivo Studies 
 
 Macrolide, especially 15-membered azithromycin, are known to selectively 
accumulate in target organs such as the lungs, tonsil and cervix.42 It is therefore 
conceivable that the nonpeptide macrocyclic HDACi could possess targeted anti-cancer 
activity due to selective tissue distribution conferred by the appended macrolide moiety.  
To test this possibility, we designed and synthesized two classes of isotopically labeled 
analogs of 15-membered macrocyclic HDACi compounds 32a-b and 34c-d.  Compounds 
32a-b are 15N-labeled analogs of compounds 23a and 23c, respectively, while 34c-d are 
O-3’-14C-acetylated derivatives of 23a and 23c, respectively.  The synthesis of 32a-b 
followed essentially the same route described for the synthesis of 23a and 23c except that 
the corresponding 15N-azide 24a and 24b were used in the cycloaddition reaction with 4’-
ethynylbenzyl azithromycin 19 (Scheme 2-5).  The synthesis of 14C-acetylated 
compounds 34c-d was analogously accomplished using O-3’-14C-acetylated 4’-
40 
 
ethynylbenzyl azithromycin 33 (Scheme 2-5). The isotopically-labeled compounds 32a-b 
and 34c-d are currently being used as probes to establish the organ distribution profile of 
the nonpeptide macrocyclic HDACi in healthy Balb c mice. 
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Scheme 2-5. Synthesis of isotopically labeled nonpeptide macrocyclic HDACi. *This 
indicated the location of the isotopic 14 15C- or N-labels.  
 
2.3 Nuclear Targeting HDAC Inhibitors 
 As mentioned before, most of the HDACi, including SAHA, non-selectively 
inhibit the deacetylase activity of class I/II HDAC enzymes. This broad HDAC inhibition 
is associated with reduced potency and toxic side effects. So far, several attempts aimed 
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at identifying isoform selective HDACi have been modestly successful, resulting in very 
few HDACi that are only partially isoform selective.43 Because HDACs 1 and 2, the 
primary targets for the anticancer activity of HDACi, are exclusively localized in the 
nucleus2b, 44 , we propose that an alternative approach to isoform selective HDACi is the 
development of a strategy for nuclear delivery and localization of HDACi. 
 
2.3.1 Design and Synthesis of Nucleus Localizatsion Signal peptide-HDAC Inhibitors 
Conjugates 
 
 To test our hypothesis, we first sought peptide-HDACi conjugates that are capable 
of crossing both the plasma and nuclear membrane.45 Most of the nuclear membrane-
penetrating peptides described in the literatures are derived from viral sources.  Common 
examples include the Simian virus nuclear localization peptides (NLS)45-47, HIV 1 Tat-
protein derived peptides48, and peptides derived from adenovirus fiber protein.  NLS 
peptides are peptides utilized by viruses to cross many cellular membranes especially the 
nuclear membrane.  In addition, we reasoned that NLS, with lysine-enriched sequences, 
could act as a substrate-mimetic to HDAC by mimicking the N-terminal tail lysine 
residues of the core histones. Hence, NLS-HDACi conjugates could be ideal “near-
substrate” inhibitors of nuclear HDAC 1 and 2. 
 Our design approach is to attach an HDAC inhibition group, such as our triazole-
based SAHA-like aliphatic-hydroxamates 4, directly to the NLS peptides through another 
triazole ring.  This very simple, initial design could facilitate a facile, high yielding 
synthesis of the proposed NLS-HDACi conjugates.  Accordingly, we prepared 
compounds 40a-c having a second 1,2,3-triazole ring connecting a NLS-derived peptide 
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Scheme 2-6.  Synthesis of NLS-HDACi conjugates.  Conditions:  (a) 4-ethynylaniline, 
CuI, DIPEA, THF, (b) NaNO , NaN ,2 3  17.2% HCl(aq), (c) LiOH•H O, THF/H2 2O, (d) o-
tritylhydroxylamine, EDCI, HOBT, NMM, DMF, (e) alkyne-terminated NLS peptides, 
CuI, TBTA, DIPEA, THF/DMF, (f) 90:5:5 TFA/TIPS/Phenol 
 
 
to the cap group of the triazole-based aliphatic hydroxamates (Scheme 2-6).  The Cu(I)-
catalyzed reaction of 4-ethynylaniline with azido esters 2c-e gave the desired cycloadduct 
35a-c in excellent yields.10, 39  The diazotization of aryl amine 35a-c by treatment with 
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sodium nitrite and sodium azide led to the desired azido derivative 36a-c in good yields.  
However, a portion of azido derivatives 36 was hydrolyzed into carboxylic acid giving a 
mixture of both ester and carboxylic acid derivatives.  To hydrolyze the rest of the ester, 
lithium hydroxide hydrates were added to the mixture giving a complete conversion to 
the azido carboxylic acid derivative 37 in excellent yields.  The reaction of acid 37a-c 
with O-trityl hydroxylamine gave the desired O-trityl azido-triazolylhydroxamates 38a-c 
that were subsequently coupled to the alkyne-terminated N-Boc protected NLS peptide 
PCS-37689-PI.  The resulting cycloadducts 39a-c were then subjected to TFA treatment 
to remove all protecting groups yielding the desired NLS-HDACi conjugates 40a-c in 
quantitative yield.    
 
Table 2-7.  Preliminary in vitro inhibition data for NLS-HDACi conjugates 40. TSA and 
SAHA with IC50 values of 5 nM and 65 nM, respectively, were used as controls.     
 
Compound n IC50 (nM)a
40a 1 36.0 
40b 2 14.0 
40c 3 24.0 
               a Data represent mean values of at least three independent  
                          experiments in Fluor de Lys assay, performed by Josh Canzoneri.  
 
 We then tested the HDAC inhibition activity of 40a-c using a cell free kit assay 
(Fluor de Lys).19 We found that the the NLS-HDACi conjugates displayed potent HDAC 
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inhibition activities that is somewhat linker-length dependent against HDAC 1 and 2 
from HeLa cell nuclear extract (Table 2-7).  An increase in the linker length from C6 to 
C7 conferred a better anti-HDAC activity.  Investigation of HDAC isoform selectivity and 
whole cell anti-proliferative activities of the NLS-HDACi conjugates is currently 
underway.  Also, we are interested in probing the intracellular trafficking of these NLS-
HDACi conjugates.  The next section discusses the design and synthesis of fluorescent 
NLS and HDACi probes that will enable us to accomplish this objective. 
 
2.3.2 Design and Synthesis of Fluorescent Tagged Nuclear Localization Signal 
Peptides and HDAC Inhibitors 
 
 To monitor the intracellular trafficking of the NLS-HDACi conjugates, we first 
sought NLS and HDACi that are independently labeled with a fluorescent tag.  NLS is 
known to facilitate nuclear localization of assorted ligands.45-47 A demonstration of 
nuclear localization with the fluorescently tagged NLS coupld be used to inferred nuclear 
localization of the unlabeled NLS-HDACi.  Similarily, fluorescently tagged HDACi 
could shed more light on the intracellular distribution of the unmodified HDACi.  We 
chose a BODIPY-based dye49 as the fluorescent tag for the proposed labeled NLS and 
HDACi.  The application of BODIPY dyes in bioimaging is well-established.  They  
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provide sharp fluorescence peak with high quantum yields.  Their relative insensitivity to 
polarity and pH of their environment and stability in physiological conditions has led to 
their wide use in both proteins and DNA labeling.49 The synthesis of NLS-BODIPY 47  
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Scheme 2-8.  Synthesis of NLS-BODIPY 47.  Conditions:  (a) 4-azidobenzyl alcohol, 
CuI, DIPEA, THF, (b) MsCl, Et oN, CH Cl , (c) NaN , DMF, 653  2 2 3 C, (d) alkyne-terminated 
NLS peptides, CuI, TBTA, DIPEA, THF/DMF, (e) 90:5:5 TFA/TIPS/Phenol 
46 
 
was accomplished as shown in scheme 2-8.  Alkyne BODIPY 42 was synthesized from 
alkynyl aldehyde 41 and 2,4-dimethylpyrrole by adapting literature protocols (Scheme 2-
7).50 Cu(I)-catalyzed cycloaddition reaction between 42 and 4-azidobenzyl alcohol gave 
triazole 43, which was subsequently transformed to azido-triazole 45 through mesylate 
44.  The Cu(I)-catalyzed cycloaddition of azido-triazole 45 and alkyne-terminated N-Boc 
protected NLS peptide PCS-37689-PI gave the desired cycloadduct 46 in good yields.10, 
39  The deprotection of the NLS side chain was accomplished with TFA treatment, 
leading to desired NLS-BODIPY 47 in quantitative yields (Scheme 2-8).  Similarily, 
HDACi-BODIPY 49 was synthesized by the Cu(I)-catalyzed cycloaddition between the 
O-trityl azido-triazolylhydroxamate 38a and alkyne BODIPY 42, followed by 
deprotection with TFA treatment, to give the unprotected cycloadduct 49 in good yields 
(Scheme 2-9).  Bioimaging experiments with HDACi-BODIPY 49 and NLS-BODIPY 47 
are currently ongoing.   
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Scheme 2-9.  Synthesis of HDACi-BODIPY 49.  Conditions:  (a) CuI, TBTA, DIPEA, 
THF/DMF, (b) 90:5:5 TFA/TIPS/Phenol 
47 
 
 2.4 Conclusion 
 
 We have established that 1, 2, 3-triazole ring is suitable as a surface recognition 
cap group linking-moiety in SAHA-like HDACi. The structure-activity relationship of 
the resulting triazole-linked hydroxamates displays a cap group dependent preference for 
either five- or six-methylene spacer groups. We identified compounds that are several 
folds more potent than SAHA. A subset of these compounds also inhibited the 
proliferation of DU-145 cells. Due to their anticipated resistance to intracellular 
peptidases, these triazole-linked HDACi may display improved in vivo activity relative to 
the common amide based inhibitors.  
 More significantly, we have identified a new class of non-peptide HDACi derived 
from the macrocyclic skeletons of clinically useful macrolides. These compounds will 
enable a molecular description of the interaction between the HDAC enzyme outer rim 
and the inhibitors’ macrocyclic cap-groups thereby further aid our understanding of the 
roles of this interaction in inhibitors binding affinity and possibly HDAC isoform 
selectivity. In addition, due to the selective tissue distribution that may be conferred by 
the appended macrolide moiety, some of these HDACi are anticipated to have targeted 
anti-cancer activity. Specifically, compounds incorporating azithromycin skeleton could 
be selectively accumulated in the lungs42, thereby possess lung-selective anti-cancer 
activity. The prospect of tissue-specific HDACi delivery is a particularly enticing 
alternative to isoform selective HDACi and could lead to the identification of new 
chemotherapeutic agents for use in targeted cancer therapy applications. Efforts are 
underway in our lab to profile the tissue distribution of the new class of the macrocyclic 
HDACi described here.  Additionally, efforts are in progress to investigate the 
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intracellular trafficking of NLS-HDAC conjugates and the consequence of nuclear 
accumulation on the anti-proliferative activity of HDACi. 
 
2.5 General Procedure and Experimental 
2.5.1 General Procedure  
 4-bromobutyric acid, 5-bromovaleric acid, 6-bromohexanoic acid, 7-
bromoheptane-nitrile, 8-bromooctanoic acid, ethyl 6-bromohexanoate, ethyl 7-
bromoheptanoate, methyl 10-bromodecanoate, 4-ethynylbenzyl alcohol, sodium azide-
15N , and acetic anhydride-carbony-141 C (0.25 mCi) were purchased from Sigma Aldrich.  
Clarithromyin and azithromycin were purchased from Greenfield Chemical and Pfizer, 
respectively. 9-bromononanoic acid was purchased from Karl Industries Inc.  Alkyne-
terminated N-Boc NLS peptide (PCS-37689-PI) was synthesized by solid phase method 
at Peptide International, Louisville, Kentucky.  
 Common reaction solvents were either high performance liquid chromatography 
(HPLC) grade or American Chemical Society (ACS) grade, and used without further 
purification. HDAC Fluorimetric Assay kit and recombinant HDACs were procured from 
BIOMOL® International, PA. Analtech silica gel plates (60 F254) were used for analytical 
TLC, and Analtech preparative TLC plates (UV 254, 2000 µm) were used for 
purification.  UV light was used to examine the spots.  200-400 Mesh silica gel was used 
in column chromatography.  Nuclear magnetic resonance (NMR) spectra were recorded 
on a Varian-Gemini 400 magnetic resonance spectrometer.  1H NMR spectra were 
recorded in parts per million (ppm) relative to the peak of CDCl , (7.24 ppm), CD3 3OD 
(3.31 ppm), DMSO-d6 (2.49 ppm) or acetone-d6 (2.04 ppm).  13C spectra were recorded 
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relative to the central peak of the CDCl  triplet (77.0 ppm), CD3 3OD (49.0 ppm), DMSO-
d6 septet (39.7 ppm), or acetone-d6 (2.04 ppm) and were recorded with complete hetero-
decoupling. High-resolution mass spectra were recorded at the Georgia Institute of 
Technology mass spectrometry facility in Atlanta.  Melting points were recorded on a 
MelTemp II and are uncorrected.   
 Methyl bromoalkanoates 1a-d, azido alkylesters, 15N-labeled azido alkylester, 4-
ethynylbenzyl methylsulfonate 18, and alkynl aldehyde 41 were synthesized by adapting 
literature protocol.12-14, 50  The Bestmann-Ohira reagent was prepared as described by 
Ghosh et al.17 Aryl alkynes that we could not obtain from commercial sources were 
synthesized using the Bestmann-Ohira reagent as described by Chen et al.51 Tris-
(benzyltriazolylmethyl)amine (TBTA) is prepared by using the procedure described by 
Chan et al.52 6-Azido-O-silyl hexahydroxamate 21 was prepared from the corresponding 
azido carboxylic acid, t-BuPh2SiCl and NaH, according to the procedure described by 
Muri et al.53  
 
2.5.2 SAHA-Like Triazole-Linked HDACi Experimental 
Methyl 4-(phenyl)triazolylbutanoate (3a). Methyl 4-azidobutanoate 2a (0.125 g, 0.87 
mmol) and phenylacetylene (0.21 mL, 1.92 mmol) were dissolved in anhydrous THF (10 
mL) and stirred under argon at room temperature.  Copper (I) iodide (0.011 g, 0.07 
mmol) and Hunig’s base (0.1 mL) were then added to the reaction mixture, and stirring 
continued for 24 h.  The reaction mixture was diluted with CH Cl2 2 (20 mL) and washed 
with 1:4 NH OH/saturated NH Cl (3 x 30 mL) and saturated NH4 4 4Cl (30 mL).  The 
organic layer was dried over Na  and concentrated in vacuo.  The crude product was 2SO4
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purified by flash chromatography (silica, gradient 2:1; 3:2 Hexane/EtOAc) to give 117 
mg (55%) of 3a as white solid. 1H-NMR (CDCl3, 400MHz) δ 2.24 (2H, m), 2.36 (2H, t, J 
= 6.4 Hz), 3.65 (3H, s), 4.45 (2H, t, J = 6.8 Hz), 7.28-7.33 (1H, m), 7.37-7.41 (2H, m), 
7.75 (1H, s), 7.78-7.81 (2H, m); 13C NMR (CDCl3, 100 MHz) δ 25.5, 30.4, 49.2, 51.8, 
119.5, 125.5, 127.9, 128.6, 130.3, 147.6, 172.5; HRMS (FAB, thioglycerol) calcd for 
[C13H15N3O2 + H]+ 246.1242, found 246.1245. 
 
Methyl 5-(phenyl)triazolylpentanoate (3b). Reaction of methyl 5-azidopentanoate 2b 
(0.211 g, 1.34 mmol) and phenylacetylene (0.3 mL, 2.79 mmol) within 24 h as described 
for the synthesis of 3a, followed by flash chromatography (silica, 1:1 Hexane/EtOAc), 
gave 180 mg (52%) of 3b as white solid. 1H NMR (CDCl3, 400 MHz) δ 1.66-1.70 (2H, 
m), 1.97-2.01 (2H, m), 2.36 (2H, t, J = 7.2 Hz), 3.65 (3H, s), 4.40 (2H, t, J = 6.8 Hz), 
7.31 (1H, t, J = 8.0 Hz), 7.40 (2H, t, J = 8.4 Hz) 7.74 (1H, s), 7.81 (2H, d, J = 8.4 Hz); 
HRMS (FAB, thioglycerol) calcd for [C14H17N3O2 + H]+ 260.1399, found 260.1386. 
 
Methyl 6-(phenyl)triazolylhexanoate (3c). Reaction of methyl 6-azidohexanoate 2c 
(0.075 g, 0.43 mmol) and phenylacetylene (1.0 mL, 0.87 mmol) within 24 h as described 
for the synthesis of 3a, followed by prep TLC (silica, 1:1 Hexane/EtOAc) gave 94 mg 
(79%) of 3c as white solid. 1H NMR (CDCl3, 400 MHz) δ 1.26-1.33 (2H, m), 1.56-1.64 
(2H, m), 1.84-1.91 (2H, m), 2.24 (2H, t, J = 7.2 Hz), 3.58 (3H, s), 4.30 (2H, t, J = 7.2 
Hz), 7.26 (1H, t, J = 7.2 Hz), 7.35 (2H, t, 7.6 Hz), 7.74 (1H, s), 7.77 (2H, d, J = 7.6 Hz); 
13C NMR (CDCl3, 100 MHz) δ 23.9, 25.6, 29.7, 33.3, 49.7, 51.3, 117.4, 125.3, 127.8, 
128.5, 130.4, 147.3, 173.5. 
51 
 
Methyl 6-(4-anilyl)triazolylhexanoate (6a). Reaction of methyl 6-azidohexanoate 2c 
(0.075 g, 0.44 mmol) and 4-ethynyl-N,N-dimethylaniline 5a (131 mg, 0.90 mmol) within 
24 h as described for the synthesis of 3a,  followed by prep TLC (silica, 1:1 
Hexane/EtOAc) gave 114 mg (83%) of 6a as pale yellowish solid. 1H NMR (CDCl3, 400 
MHz) δ 1.30-1.36 (2H, m), 1.60-1.66 (2H, m), 1.87-1.93 (2H, m), 2.26 (2H, t, J = 7.2 
Hz), 2.93 (6H, s),  3.61 (3H, s), 4.30 (2H, t, J = 7.2 Hz), 6.72 (2H, d, J = 8.8 Hz), 7.58 
(1H, s), 7.66 (2H, d, J = 9.2 Hz); 13C NMR (CDCl3, 100 MHz) δ 24.0, 25.8, 29.8, 33.5, 
40.3, 49.8, 51.4, 112.3, 117.9, 118.7, 126.4, 148.0, 150.2, 173.7. 
 
Methyl 6-(2,6-dimethoxyphenyl)triazolylhexanoate (6m). Reaction of methyl 6-
azidohexnoate 2c (0.15 g, 0.88 mmol) and  2-ethynyl-1,3-dimethoxybenzene 5j (0.16 g, 
0.99 mmol) within 24 h as described for the synthesis of 3a, followed by flash 
chromatography (silica, gradient 2:1; 1:1; 1:2; Hexane/EtOAc) gave 114 mg (39%) of 6m 
as a white solid. 1H-NMR (CDCl3, 400MHz) δ 1.38-1.46 (2H, m), 1.66-1.73 (2H, m), 
1.95-2.02 (2H, m), 2.33 (2H, t, J = 7.2 Hz), 3.66 (3H, s), 3.80 (6H, s), 4.40 (2H, t, J = 7.2 
Hz), 6.65 (2H, d, J = 8.4 Hz), 7.29 (1H, t, J = 9.2 Hz), 7.68 (1H, s); 13C-NMR (CDCl3, 
100MHz) δ 24.1, 25.8, 29.8, 33.5, 49.6, 51.2, 55.7, 103.8, 108.4, 123.7, 129.2, 139.3, 
157.8, 173.2; HRMS (FAB, thioglycerol) calc for [C17H23N3O  + H]+ 4 334.1766, found 
334.1776. 
 
Methyl 6-(2-thiopyl)triazolylhexnoate (6n). Reaction of methyl 6-azidohexnoate 2c 
(0.2 g, 1.16 mmol) and 2-ethynylthiophene 5e (0.1 mL, 1.02 mmol) within 24 h as 
described for the synthesis of 3a, followed by flash chromatography (silica, gradient 2:1; 
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1:1 Hexane/EtOAc) gave 209 mg (74%) of 6n as a white solid.  1H-NMR (CDCl3, 
400MHz) δ 1.24-1.31 (2H, m), 1.54-1.62 (2H, m), 1.81-1.89 (2H, m), 2.22 (2H, t, J = 7.2 
Hz), 3.57 (3H, s), 4.28 (3H, t, J = 5.4 Hz), 7.29 (1H, dd, J = 4.8, 2.8 Hz), 7.38 (1H, dd, J 
= 4.8, 1.2 Hz), 7.59 (1H, dd, J = 3.2, 1.2 Hz), 7.63 (1H, s); 13C-NMR (CDCl3, 100MHz) δ 
24.0, 25.7, 29.8, 33.5, 49.8, 51.3, 119.1, 120.5, 125.4, 125.9, 131.6, 143.4, 173.2; HRMS 
(FAB, thioglycerol) calc for [C + 280.1244, found 280.1223. 13H17N O S + H]3 2
 
Methyl 6-(4-biphenyl)triazolylhexnoate (6o). Reaction of Methyl 6-azidohexanoate 2c 
(0.2 g, 1.17 mmol) and 4-ethynylbiphenyl 5h (0.317 g. 1.75 mmol) within 24 h as 
described for the synthesis of 3a, followed by flash chromatography (silica, gradient 2:1; 
1:1 Hexane/EtOAc) to give 90 mg (22%) of 6o as a pale yellowish solid.  1H-NMR 
(CDCl3, 400MHz) δ 1.31-1.39 (2H, m), 1.61-1.69 (2H, m), 1.89-1.95 (2H, m), 2.28 (2H, 
t, J = 7.2 Hz), 3.62 (3H, s), 4.35 (2H, t, J = 7.2 Hz), 7.32 (1H, t, J = 8.0 Hz), 7.41 (2H, t, 
J = 8.0 Hz), 7.58-7.63 (4H, m), 7.76 (1H, s), 7.87 (2H, d, J = 8.0 Hz); 13C-NMR (CDCl3, 
100MHz) δ 24.1, 25.9, 29.9, 33.6, 49.9, 51.4, 119.4, 125.7, 126.6, 127.1, 128.5, 129.4, 
140.1, 140.4, 147.0, 173.3; HRMS (FAB, thioglycerol) calc for [C21H23N3O  + H]+ 2
350.1868, found 350.1885. 
 
Methyl 6-(3-biphenyl)triazolylhexnaoate (6p). Reaction of methyl 6-azidohexnoate 2c 
(0.2 g, 1.16 mmol) and  3-ethynylbiphenyl 5i  (0.32 g, 1.79 mmol) within 24 h as 
described for the synthesis of 3a, followed by flash chromatography (silica, gradient 2:1; 
1:1 Hexane/EtOAc) gave 300 mg (74%) of 6p as a white solid.  1H-NMR (CDCl3, 
400MHz) δ 1.27-1.35 (2H, m), 1.58-1.65 (2H, m), 1.85-1.93 (2H, m), 2.25 (2H, t, J = 7.6 
53 
 
Hz), 3.60 (3H, s), 4.31 (2H, t, J = 7.2 Hz), 7.32 (1H, t, J = 7.2 Hz), 7.39-7.46 (3H, m), 
7.52 (1H, d, J = 8.0 Hz), 7.62 (2H, d, J = 7.6 Hz), 7.77 (1H, d, J = 7.6 Hz), 7.82 (1H, s), 
8.08 (1H, s); 13C-NMR (CDCl3, 100MHz) δ 23.9, 25.7, 29.7, 33.4, 49.7, 51.2, 119.5, 
123.9, 124.1, 126.3, 126.7, 127.0, 128.3, 128.8, 130.8, 140.2, 141.2, 147.0, 173.2; HRMS 
(FAB, thioglycerol) calc for [C21H23N3O2 + H]+ 350.1868, found 350.1870. 
 
Methyl 6-(2-biphenyl)triazolylhexanoate (6r). Reaction of methyl 6-azidohexnoate 2c 
(0.16 g, 0.93 mmol) and 2-ethynylbiphenyl 5g (0.11 g, 0.62 mmol) within 24 h as 
described for the synthesis of 3a, followed by flash chromatography (silica, gradient 2:1; 
1:1 Hexane/EtOAc) gave 161 mg (75%) of  6r as a white solid.  1H-NMR (CDCl3, 
400MHz) δ 1.09-1.17 (2H, m), 1.49-1.57 (2H, m), 1.61-1.69 (2H, m), 2.21(2H, t, J = 7.6 
Hz), 3.59 (3H, s), 4.09 (2H, t, J = 6.8 Hz), 6.35 (1H, s), 7.16-7.18 (2H, m), 7.24-7.34 
(5H, m), 7.39 (2H, t, J = 7.2 Hz); 13C NMR (CDCl3, 100 MHz) δ 24.0, 25.6, 29.6, 33.4, 
49.5, 51.3, 121.8, 126.9, 127.4, 127.5, 128.0, 128.2, 128.8, 128.9, 129.7, 139.8, 141.3, 
145.8, 173.2; HRMS (FAB, thioglycerol) calc for [C21H23N3O  + H]+ 2 350.1868, found 
350.1877. 
 
Methyl 6-(6-methoxynapthalyl)triazolylhexanoate (6u). Reaction of methyl 6-
azidohexnoate 2c (0.2 g, 1.16 mmol) and 2-ethynyl-6-methoxy-napthalene 5f (0.32 g, 
1.76 mmol) within 24 h as described for the synthesis of 3a, followed by flash 
chromatography (silica, gradient 2:1; 1:1; 1:2; 0:1 Hexane/EtOAc) gave 284 mg (70%) of 
6u as a white solid. 1H-NMR (CDCl3, 400MHz) δ 1.32-1.39 (2H, m), 1.61-1.69 (2H, m), 
1.87-1.99 (2H, m), 2.28, (2H, t, J = 7.2 Hz), 3.62 (3H, s), 3.89 (3H, s), 4.36 (2H, t, J = 6.8 
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Hz), 7.10-7.14 (2H, m), 7.74 (2H, d, J = 10.8 Hz), 7.78 (1H, s), 7.85 (2H, d, J = 8.4 Hz), 
8.22 (1H, s); 13C-NMR (CDCl3, 100MHz) δ 24.2, 25.9, 30.0, 33.6, 50.0, 51.5, 55.2, 
105.6, 119.0, 119.2, 124.0, 124.1, 125.7, 127.1, 128.7, 129.4, 134.0, 147.6, 157.5, 173.4; 
HRMS (FAB, thioglycerol) calc for [C20H23N3O  + H]+ 354.1817, found 354.1819. 3
 
Representative Procedure for Conversion of Methyl Ester to Hydramic Acid.  4-
(phenyl)triazolylbutahydroxamic acid (4a). To a solution of methyl 4-
(phenyl)triazolylbutanoate 3a (0.05 g, 0.204 mmol) in 1:1 THF (1.5 mL) and methanol 
(1.5 mL) was added aqueous hydroxylamine (0.13 mL, 2.11 mmol) and KCN ( 0.004 g, 
0.062 mmol), and the stirring continued for 24 h.  The reaction was diluted with EtOAc 
(30 mL) and washed with saturated NaHCO3 (2 x 30 mL) and saturated brine (30 mL).  
The organic layer was dried over Na SO2 4 and concentrated in vacuo to give 40 mg (80%) 
of 4a as white solid. 1H NMR (DMSO-d6, 400 MHz) δ 2.98 (2H, t, J = 7.2 Hz), 2.04-2.11 
(2H, m), 4.39 (2H, t, J = 6.8 Hz), 7.31 (1H, t, J = 6.8 Hz), 7.43 (2H, t, J = 8.0 Hz), 7.82 
(2H, d, J = 8.4 Hz), 8.55 (1H, s); 13C NMR (CDCl3, 100 MHz) δ 25.9, 29.1, 49.2, 93.8, 
121.1, 124.9, 127.6, 128.7, 130.6, 146.1; HRMS (FAB, thioglycerol) calcd for 
[C12H14N4O2 + H]+ 247.1195, found 247.1195. 
 
5-(phenyl)triazolylpentahydroxamic acid (4b). Reaction of methyl 5-
(phenyl)triazolylpentanoate 3b (0.06 g, 0.231 mmol) and aqueous hydroxylamine (0.15 
ml, 2.44 mmol) within 24 h as described for the synthesis of 4a, gave 30 mg (50%) of 4b 
as white solid. 1H NMR (DMSO-d6, 400 MHz) δ 1.45-1.49 (2H, m), 1.80-1.84 (2H, m), 
1.98 (2H, t, J = 6.8 Hz), 4.38 (2H, t, J = 6.8 Hz), 7.30 (1H, t, J = 8.0 Hz), 7.42 (2H, t, J = 
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7.2 Hz), 7.81 (2H, d, J = 7.6 Hz), 8.54 (1H, s), 8.67 (1H, s), 10.3 (1H, s); 13C NMR 
(CDCl3, 100 MHz) δ 22.1, 29.2, 31.5, 49.1, 121.0, 124.8, 127.5, 128.6, 130.6, 146.0, 
168.3; HRMS (FAB, thioglycerol) calcd for [C13H16N4O  + H]+2  261.1351, found 
261.1354;  M.P. = 151.0-152.0 oC. 
 
6-(phenyl)triazolylhexahydroxamic acid (4c). Reaction of methyl 6-
(phenyl)triazolylhexanoate 3c (0.15 g, 0.522 mmol) and aqueous hydroxylamine (0.37 
ml, 6.03 mmol) within 24 h as described for the synthesis of 4a, gave 79 mg (55%) of 4c 
as white solid. 1H NMR (DMSO-d6, 400 MHz) δ 1.18-1.26 (2H, m), 1.48-1.55 (2H, m), 
1.81-1.88 (2H, m), 1.93 (2H, t, J = 7.2 Hz), 4.36 (2H, t, J = 7.2 Hz), 7.31 (1H, t, J = 7.2 
Hz), 7.42 (2H, t, J = 6.8 Hz), 7.82 (2H, d, J = 8.0 Hz), 8.56 (1H, s), 8.68 (1H, s), 10.3 
(1H, s); 13C NMR (CDCl3, 100 MHz) δ 24.5, 25.4, 29.3, 32.0, 49.3, 121.0, 124.8, 127.5, 
128.6, 130.6, 146.0, 168.6; HMS (FAB, thioglycerol) calcd for [C14H18N4O  + H]+2  
275.1508, found 275.1513. 
 
6-(4-anilyl)triazolylhexahydroxamic acid (7a). Reaction of methyl 6-(4-
anilyl)triazolyl-hexanoate 6a (0.1 g, 0.303 mmol) and aqueous hydroxylamine (0.6 ml, 
9.78 mmol) within 24 h as described for the synthesis of 4a, gave 50 mg (53%) of 7a as 
white solid. 1H NMR (CD3OD, 400 MHz) δ 1.20-1.26 (2H, m), 1.48-1.56 (2H, m), 1.79-
1.86 (2H, m), 1.93 (2H, t, J = 6.8 Hz), 2.917 (6H, s), 4.32 (2H, t, J = 6.8 Hz), 6.76 (2H, d, 
J = 8.8 Hz), 7.63 (2H, d, J = 8.8 Hz), 8.32 (1H, s), 8.66 (1H, s), 10.3 (1H, s); 13C NMR 
(DMSO-d , 100 MHz) δ 25.3, 26.3, 30.2, 32.8, 50.0, 112.9, 119.4, 119.9, 126.6, 147.4, 6
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150.5, 169.4; HRMS (FAB, thioglycerol) calcd for [C16H23N4O  + H]+2  318.1930, found 
318.1929; M.P. = 165.0-166.0 oC. 
 
6-(2,6-dimethoxyphenyl)triazolylhexahydroxamic acid (7m). Reaction of methyl 6-
(2,6-dimethoxyphenyl)triazolylhexanoate 6m (0.1 g, 0.30 mmol) and aqueous 
hydroxylamine (0.4 mL, 6.52 mmol) within 24 h as described for the synthesis of 4a, 
gave 90 mg (90%) of 7m as a white solid. .  1H-NMR (DMSO-d6, 400MHz) δ 1.33-1.41 
(2H, m), 1.63-1.71 (2H, m), 1.92-1.99 (2H, m), 2.10 (2H, t, J = 7.2 Hz), 3.76 (6H, s), 
4.42 (2H, t, J = 6.8 Hz), 6.71 (2H, d, J = 8.4 Hz), 7.32 (1H, t, J = 8.4 Hz), 7.96 (1H, s); 
13C-NMR (DMSO-d6, 100MHz) δ 26.1, 27.0, 31.0, 33.5, 51.0, 55.2, 104.9, 108.9, 126.1, 
131.1, 140.7, 148.9, 159.4, 172.3; HRMS (FAB, thioglycerol) calc for [C16H22N4O  + H]+ 4
335.1719, found 335.1724; M.P. = 98.0-100.0 oC. 
 
6-(2-thiopyl)triazolylhexahydroxamic acid (7n). Reaction of methyl 6-thiopyl-
triazolylhexanoate 6n (0.1 g, 0.35 mmol) and aqueous hydroxylamine (0.2 mL, 3.26 
mmol) within 24 h as described for the synthesis of 4a, gave 54 mg (55%) of 7n as a 
white solid.  1H-NMR (DMSO-d6, 400MHz) δ 1.17-1.24 (2H, m), 1.47-1.55 (2H, m), 
1.79-1.86 (2H, m), 1.92 (2H, t, J = 7.2 Hz), 4.35 (3H, t, J = 6.8 Hz), 7.48 (1H, d, J = 5.2 
Hz), 7.62 (1H, dd, J = 5.2, 3.2 Hz), 7.80 (1H, d, J = 2.8 Hz), 8.42 (1H, s), 8.68 (1H, s), 
10.36 (1H, s); 13C-NMR (DMSO-d6, 100MHz) δ 24.4, 25.3, 29.3, 31.9, 49.1, 120.3, 
120.7, 125.4, 126.8, 131.8, 142.4; HRMS (FAB, thioglycerol) calc for [C12H16N O4 2S + 
H]+ 281.1072, found 281.1087; M.P. = 148.0-149.0 oC. 
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6-(4-biphenyl)triazolylhexahydroxamic acid (7o). Reaction of methyl 6-(4-biphenyl)-
triazolylhexanoate 6o (0.09 g, 0.258 mmol) and aqueous hydroxylamine (0.2 mL, 3.26 
mmol) within 24 h as described for the synthesis of 4a, gave 35 mg (39%) of 7o as a 
white solid.  1H-NMR (DMSO-d6, 400MHz) δ 1.50-1.60 (2H, m), 1.87 (2H, t, J = 7.2 
Hz), 1.94 (2H, t, J = 7.6 Hz), 2.30 (2H, t, J = 7.6 Hz), 4.39 (2H, t, J = 6.8 Hz), 7.36 (1H, 
t, J = 7.2 Hz), 7.46 (2H, t, J = 7.6 Hz), 7.72 (4H, q, J = 17.6, 8.0 Hz), 7.921 (2H, t, J = 
8.0 Hz), 8.61 (1H, s), 10.3 (1H, s); HRMS (FAB, thioglycerol) calc for [C20H22N O4 2 + 
H]+ 351.1828, found 351.1864. [Note:  Strong aggregation prevent collection of 13C 
NMR.] 
 
6-(3-biphenyl)triazolylhexahydroxamic acid (7p). Reaction of methyl 6-(3-biphenyl)-
triazolylhexanoate 6p (0.12 g, 0.34 mmol) and aqueous hydroxylamine (0.4 mL, 6.52 
mmol) within 24 h as described for the synthesis of 4a, gave 73 mg (61%) of 7p as a 
white solid.  1H-NMR (DMSO-d6, 400MHz) δ 1.18-1.21 (2H, m), 1.48-1.51 (2H, m), 
1.81-1.85 (2H, m), 1.92 (2H, t, J = 6.4 Hz), 4.36 (2H, t, J = 6.8 Hz), 7.36 (1H, t, J = 6.0 
Hz), 7.44-7.54 (3H, m), 7.59 (1H, d, J = 8.0 Hz), 7.68 (2H, d, J = 7.2 Hz), 8.06 (1H, s), 
8.59 (1H, s), 8.85 (1H, br s), 10.48 (1H, s); 13C-NMR (DMSO-d6, 100MHz) δ 24.9, 25.8, 
29.7, 32.5, 50.0, 121.9, 123.6, 124.5, 126.6, 127.0, 128.0, 129.3, 130.0, 131.4, 140.0, 
141.1, 146.5, 169.7; HRMS (FAB, thioglycerol) calc for [C20H22N4O  + H]+ 2 351.1821, 
found 351.1832; M.P. = 101.0-102.0 oC. 
 
6-(2-biphenyl)triazolylhexahydraxomic acid (7r). Reaction of methyl 6-(2-biphenyl)-
triazolylhexanoate 6r (0.1 g, 0.28 mmol) and aqueous hydroxylamine (0.4 mL, 6.52 
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mmol) within 24 h as described for the synthesis of 4a, gave 42 mg (43%) of 7r as a 
white solid.  1H-NMR (DMSO-d6, 400MHz) δ 0.85-1.01 (2H, m), 1.37-1.43 (2H, m), 
1.56-1.59 (2H, m), 1.88 (2H, t, J = 7.2 Hz), 4.15 (2H, t, J = 6.4 Hz), 7.00 (1H, s), 7.12 
(2H, d, J = 6.8 Hz), 7.32 (4H, d, J = 5.2 Hz), 7.40-7.46 (2H, m), 7.76 (1H, d, J = 8.0 Hz), 
8.79 (1H, br s), 10.44 (1H, s); 13C-NMR (DMSO-d6, 100MHz) δ 24.9, 25.6, 29.7, 32.5, 
49.5, 123.2, 127.5, 128.0, 128.5, 128.6, 129.1, 129.2, 129.4, 130.4, 140.4, 141.1, 145.6, 
169.5; HRMS (FAB, thioglycerol) calc for [C20H22N4O  + H]+ 2 351.1821, found 
351.1842; M.P. = 115.0-117.0 oC. 
 
6-(6-methoxynapthalyl)triazolylhexahydroxamic acid (7u). Reaction of methyl 6-(6-
methoxynapthalenyl)triazolylhexanoate 6u (0.095 g, 0.27 mmol) and aqueous 
hydroxylamine (0.2 mL, 3.26 mmol) within 24 h as described for the synthesis of 4a, 
gave 31 mg (33%) of 7u as a white solid. 1H-NMR (DMSO-d6, 400MHz) δ 1.23-1.27 
(2H, m), 1.51-1.57 (2H, m), 1.85-1.97 (4H, m), 2.28, 3.88 (3H, s), 4.40 (2H, t, J = 6.4 
Hz), 7.19 (1H, d, J = 10.4 Hz), 7.33 (1H, s), 7.90 (3H, dd, J = 22.4, 9.2 Hz), 8.30 (1H, s), 
8.63 (2H, d, J = 12.0 Hz), 10.32 (1H, s); 13C-NMR (DMSO-d6, 100MHz) δ 24.5, 25.4, 
29.3, 32.0, 49.3, 55.1, 105.8, 118.9, 120.9, 123.1, 123.9, 125.7, 127.1, 128.3, 129.2, 
133.6,146.2,157.1; HRMS (FAB, thioglycerol) calc for [C19H22N4O  + H]+ 3 355.1809, 
found 355.1806; M.P. = 166.0-167.0 oC. 
 
2.5.3 Nonpeptide Macrocyclic HDACi Experimental 
Synthesis of Methyl 8-(4-(hydroxymethyl)phenylamino)-8-oxooctanoate (10). To a 
solution of (4-aminophenyl)methanol 9 (0.314 g, 2.500 mmol) in anhydrous pyridine (5 
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mL) was added chlorotrimethylsilane (0.32 mL, 2.500 mmol) at room temperature and 
stirring continued for 2 h. The reaction was cooled in ice bath to 0oC and to the mixture 
was added methyl 8-chloro-8-oxooctanoate 8 (0.32 mL, 2.200 mmol) and a catalytic 
amount of DMAP. The reaction was allowed to warm to room temperature and stirring 
continued overnight. Water (5 mL) and 1 M TBAF in tetrahydrofuran (THF) (0.25 mL, 
0.250 mmol) were added and stirring continued for additional 30 min. EtOAc (50 mL) 
and 1N HCl (30 mL) were added, the two layers were separated, the organic layer was 
washed with 1N HCl (30 mL) and saturated brine (30 mL) and dried over Na SO2 4. 
Solvent was evaporated off and the crude was purified by preparative TLC, eluting with 
EtOAc/hexanes 2:1 to give 275 mg (43 %) compound 10 as a yellow-white solid. 1H-
NMR (DMSO-d6, 400 MHz) δ 1. 26 (4H, m), 1.47-1.56 (4H, m), 2.26 (4H, m), 3.55 (3H, 
s), 4.40 (2H, d, J = 5.6 Hz), 5.06 (1H, t, J = 5.6 Hz), 7.19 (2H, d, J = 8.8 Hz), 7.51 (2H, d, 
J = 8.8 Hz), 9.79 (1H, s); 13C NMR (DMSO-d6, 100MHz) δ 24.3, 24.9, 28.2, 28.3, 33.2, 
36.3, 51.2, 62.6, 118.8, 126.9, 136.9, 138.0, 171.2, 173.4; HRMS (FAB, thioglycerol) 
calc for [C16H23NO4 + H]+   294.1705, found 294.1652 
 
4’-Desmethyl azithromycin (13).  To a solution of azithromycin (2.000 g, 2.548 mmol) 
and sodium acetate (1.78 g, 21.500 mmol) in 80% aqueous methanol (30 mL) at 90 °C 
was added iodine (0.700 g, 2.756 mmol) in three batches within 5 min. The reaction was 
maintained at pH 8-9 by addition of 1M NaOH (2 ml, once at 10 min of reaction time) 
and stirring continued for 3 h. The reaction was poured into cold water containing 5% 
sodium thiosulfate (80 mL) and extracted with CH Cl2 2 (2 x 40 mL). The aqueous layer 
was basified with concentrated NH OH, extracted with 10 % MeOH in CH Cl  (3 x 40 4 2 2
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mL) and the organic layer was dried over dried over Na2SO4. Solvent was evaporated off 
to give 1.57 g of compound 13 as an off white solid (>90 % purity, TLC: 
CHC OH 12:1:0.1). The crude 13 was used without further purification. Cl /MeOH/ NH2 2 4
 
Azithromycin-arylalkyl methyl ester (14). To a solution of compound 10 (0.175 g, 
0.597 mmol) in CH Cl2 2 (7 mL) and triethylamine (Et3N) (0.24 mL, 1.800mmol) was 
added mesyl chloride (0.10 mL, 1.200 mmol) at 0°C and the reaction was allowed to 
warm to room temperature. Stirring continued for 1 h during which TLC revealed a 
quantitative conversion into a higher R  product. CH Clf 2 2 (40 mL) and saturated sodium 
bicarbonate (30 mL) were added, the two layers were separated. The organic layer was 
washed with sodium bicarbonate (2 x 30 mL), saturated brine (30 mL) and dried over 
Na . Solvent was evaporated off to give compound 11 as white solid. SO2 4
 A mixture of 4’-desmethylazithromycin 13 (0.315 g, 0.430 mmol) and crude 
compound 11, in anhydrous DMSO (7 mL) and Hunig’s base (0.7 mL) was stirred at 
85oC for 1.5 h. The reaction was cooled and diluted with EtOAc (60 mL) and washed 
with saturated NaHCO3 (40 mL) and saturated brine (40 mL). The organic layer was 
dried over Na2SO4, concentrated in vacuo and the crude was purified by preparative TLC, 
eluting with EtOAc/hexanes/ Et3N 3:2:0.1 to give 152 mg (35 %) of compound 14 as a 
white solid. 1H-NMR (CDCl3, 400MHz) δ 0.78-0.82 (7H, m), 0.94-1.03 (11H, m), 1.09-
1.32 (22H, m), 1.34-1.58 (5H, m), 1.59- 1.73 (4H, m), 1.77-2.01 (5H, m), 2.12 (3H, s), 
2.20-2.28 (8H, m), 2.42-2.53 (2H, m), 2.54-2.71 (3H, m), 2.87-3.01 (2H, m), 3.11 (3H, 
s), 3.25-3.33 (3H, m), 3.42 (2H, m), 3.54-3.65 (6H, m), 3.97 (1H, m), 4.18 (1H, m), 4.36 
(1H, d, J = 6.8 Hz), 4.61 (2H, m), 5.03 (1H, d, J = 4.4 Hz), 7.14 (2H, d,  J = 8.4 Hz), 7.42 
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(2H, d, J = 8.4 Hz), 7.73 (1H, s), 8.97 (1H, bs); 13C-NMR (CDCl3, 100MHz) δ 7.5, 9.1, 
11.3, 14.8, 16.2, 16.9, 18.2, 20.5, 21.2, 21.4, 21.5, 21.9, 24.6, 25.3, 26.7, 27.5, 28.7, 29.6, 
33.9, 34.7, 36.2, 36.7, 37.3, 39.1, 41.9, 42.2, 45.1, 48.5, 49.3, 51.4, 57.3, 62.2, 64.3, 65.4, 
68.5, 69.9, 70.5, 72.7, 73.5, 73.8, 74.1, 77.7, 77.9, 83.4, 94.4, 102.6, 119.5, 129.0, 134.2, 
137.0, 171.0, 173.8, 178.4 MS; HRMS (FAB, mnba) calc for [C53H91N3O15 + H]+  
1010.6529, found 1010.6450   
 
Azithromycin-arylalkyl hydroxamic acid (15). To a solution of compound 14 (0.050 g, 
0.050 mmol) in 1:1 THF/MeOH (2 mL) was added hydroxylamine (50 % in H2O) (0.07 
mL, 1.260 mmol) and a catalytic amount of KCN. The mixture was stirred at room 
temperature for 24 h.  The reaction was partitioned between 5 % MeOH in CH Cl2 2 (30 
mL) and saturated sodium bicarbonate (25 mL), the two layers were separated and the 
aqueous layer was extracted with 5 % MeOH in CH Cl2 2 (2 x 20 mL). The combined 
organic layer was washed with saturated brine (40 mL) and dried over Na SO2 4. Solvent 
was evaporated off and the crude was purified by preparative TLC, eluting with 
CH Cl /MeOH/NH2 2 4OH 10:1:0.1 to give 26 mg (52 %) compound 15 as brown-white 
solid. 1H-NMR (CD3OD, 400MHz) δ 0.87-0.92 (6H, m), 1.03-1.12 (12H, m), 1.17-1.37 
(m), 1.43-1.69 (m), 1.75-1.88 (6H, m), 1.99 (4H, m). 2.08 (3H, m), 2.13-2.19 (3H, m), 
2.24-2.41 (13H, m), 2.54 (1H, d, J = 11.2 Hz), 2.75-2.80 (4H, m) , 3.00 (1H, d, J = 9.6 
Hz), 3.19 (4H, m), 3.47-3.51 (1H, m), 3.60-3.78 (6H, m), 4.14-4.22 (3H, m), 4.50 (1H, d, 
J = 7.2 Hz), 5.02 (1H, d, J = 4.8 Hz), 7.29 (2H, d, J = 8.0 Hz), 7.49 (2H, d, J = 8.4 Hz); 
13C-NMR (Acetone-d6, 100MHz) δ 7.6, 9.7, 11.6, 14.3, 15.3, 17.4, 18.9, 21.7, 21.9, 22.2, 
22.5, 26.0, 26.1, 27.3, 27.9, 30.9, 32.6, 33.2, 35.5, 36.5, 36.8, 37.6, 43.0, 43.1, 46.1, 49.6, 
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58.6, 63.1, 64.1, 64.5, 66.2, 68.9, 70.0, 71.6, 73.3, 73.6, 74.2, 74.9, 75.3, 78.0, 78.9, 84.3, 
95.6, 103.7, 119.8, 130.0, 135.0, 139.5, 171.9, 178.8; HRMS (EI) calc for [C52H90N O4 15 + 
H]+ 1011.6481, found 1011.6580  
 
Desclasinose azithromycin-arylalkyl hydroxamate (17). A mixture of compound 14 
(0.050 g, 0.050 mmol) in 0.25 N HCl (15 mL) was stirred at room temperature for 20 h 
and poured into EtOAc (20 mL). The two layers were separated and the aqueous layer 
was washed with EtOAc (2 x 20 mL), basified with concentrated NH4OH and then 
extracted with 5 % MeOH in CH Cl2 2 (2 x 30 mL). The combined organic layer was 
washed with saturated brine (30 mL) and dried over Na2SO4. Solvent was evaporated off 
to give compound 16 which was used for the next reaction without further purification. 
 To a solution of compound 16 in 1:1 THF/MeOH (2 mL) was added 
hydroxylamine (50 % in H2O) (0.05 mL, 0.790 mmol) and a catalytic amount of KCN. 
The mixture was stirred at room temperature for 24 h.  The reaction was partitioned 
between 5 % MeOH in CH Cl2 2 (30 mL) and saturated brine (20 mL), the two layers were 
separated and the organic layer was dried over Na2SO4. Solvent was evaporated off and 
the crude was purified by preparative TLC, eluting with CH Cl / MeOH/NH2 2 4OH 9:1:0.1 
to give 7 mg (16 %) compound 17 as brown-white solid. 1H-NMR (CD3OD, 400MHz) δ 
0.78 (3H, m), 0.85 (3H, d, J = 7.2 Hz), 0.91 (3H, d, J = 8.0 Hz), 0.99 (3H, s), 1.08-1.14 
(10H, m), 1.18-1.79 (20H, m), 1.87 (2H, m), 1.98 (2H, t, J = 7.4 Hz), 2.05-2.13 (2H, m), 
2.17 (3H, s), 2.25 (2H, t, J = 7.4 Hz), 2.52-2.65 (4H, m), 2.95 (1H, bs), 3.24 (m), 3.37-
3.56 (6H, m), 3.67 (1H, d, J = 13.2 Hz), 4.53 (2H, d, J = 7.6 Hz), 7.19 (2H, d, J = 8.4 
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Hz), 7.39 (2H, d, J = 8.4 Hz); HRMS (EI) calc for [C44H76N4O12 + H]+ 853.5538, found 
853.5488  
 
4’-Ethynylbenzyl azithromycin (19). To a solution of 4’-desmethylazithromycin 13  
(0.940 g, 1.280 mmol) in anhydrous DMSO (15 ml) was added Hunig’s base (1.5 ml) and 
4-ethynylbenzyl methanesulfonate 18 (0.380 g, 1.800 mmol). The reaction mixture was 
heated with stirring under argon at 85°C for 2 h. The reaction was cooled and diluted 
with EtOAc (100 mL) and washed with saturated NaHCO3 (3 x 60 mL) and saturated 
brine (60 mL). The organic layer was dried over Na SO2 4 and concentrated in vacuo.  The 
crude product was purified by flash chromatography (silica, 12:1:0.05 
CH OH) to give 850 mg (78%) of 19 as a brown-white solid. 1Cl /MeOH/conc. NH2 2 4 H-
NMR (CDCl3, 400MHz) δ 0.86 (6H, m), 0.99 (3H, d, J = 7.6 Hz), 1.05 (7H, m), 1.11-
1.32 (19H, m), 1.36-1.55 (2H, m), 1.68-1.77 (2H, m), 1.81-2.07 (4H, m), 2.22 (3H, s), 
2.27-2.31 (4H, m), 2.51 (2H, m), 2.65-2.75 (2H, m), 2.87 (1H, bs), 2.98 (1H, t, J = 9.8 
Hz), 3.04 (1H, s), 3.10 (3H, s), 3.29-3.34 (2H, m), 3.40-3.47 (2H, m), 3.58 (1H, d, J = 6.8 
Hz), 3.65 (1H, s), 3.74 (1H, d, J = 13.2 Hz), 3.99 (1H, m), 4.21 (1H, dd, J = 2 Hz, 4.4 
Hz), 4.38 (1H, d, J = 7.2 Hz), 4.65 (1H, dd, J = 2.8 Hz, 10 Hz), 5.06 (1H, d, J = 4.4 Hz), 
7.23 (2H, d, J = 8 Hz), 7.41 (2H, d, J = 8 Hz) ; 13C-NMR (CDCl3, 100MHz) δ 7.5, 9.2, 
11.3, 14.9, 16.3, 18.3, 21.3, 21.4, 21.6, 22.0, 26.8, 27.6, 29.6, 34.7, 36.3, 36.9, 42.0, 42.3, 
45.2, 49.2, 57.7, 62.3, 63.7, 65.4, 68.5, 70.0, 70.6, 72.7, 73.5, 73.8, 74.2, 77.1, 77.9, 78.0, 
83.4, 83.7, 94.5, 102.6, 120.8, 128.5, 132.0, 139.6, 178.3; HRMS (FAB, mnba) calc for 
[C46H76N2O12 + H]+  849.5476, found 849.5411 
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Descladinose-4’-ethynylbenzyl azithromycin (20). A solution of 4’-ethynylbenzyl 
azithromycin 19 (0.12 g, 0.14 mmol) in 0.25 N HCl (15 mL) was stirred at room 
temperature for 20 h and poured into EtOAc (20 mL). The two layers were separated and 
the aqueous layer was washed with EtOAc (2 x 20 mL), basified with concentrated 
NH OH and then extracted with 5 % MeOH in CH Cl4 2 2 (2 x 30 mL). The combined 
organic layer was washed with saturated brine (30 mL) and dried over Na SO2 4. Solvent 
was evaporated off to give 89 mg (91%) of descladinose compound 20 as a white solid.   
1H-NMR (CDCl3, 400MHz) δ 0.80-1.52 (16H, m), 1.65-1.90 (2H, m), 1.97 (3H, s), 2.20-
2.30 (6H, m), 2.42-2.69 (3H, m), 2.77 (1H, s), 2.89 (1H, s), 3.02 (1H, s), 3.18 (1H, s), 
3.30-3.37 (3H, m), 3.49-3.63 (6H, m), 3.72 (2H, d, J = 10.6 Hz), 3.84 (1H, s), 3.89 (2H, 
s), 4.04 (3H, q, J = 14.4, 7. 2 Hz), 4.41 (1H, d, J = 7.2 Hz), 4.64 (1H, d, J = 10.8 Hz), 
7.15 (2H, d, J = 8.0 Hz), 7.37 (2H, d, J = 8.4 Hz); 13C NMR (CDCl3, 100 MHz) δ 7.7, 
7.9, 10.9, 14.2, 16.1, 20.9, 21.0, 21.2, 25.8, 26.6, 29.2, 35.9, 36.4, 37.0, 42.0, 44.5, 57.6, 
60.3, 62.4, 65.3, 69.8, 70.4, 70.9, 73.0, 74.1, 75.4, 79.4, 83.3, 94.9, 106.4, 120.8, 128.2, 
131.9, 139.2, 171.0, 177.2; HRMS (FAB, thioglycerol) calc for [C38H62N2O9 + H]+ 
691.4533, found 691.4513 
 
Azithromycin-N-benzyltriazolyl-O-silyl-hexahydroxamate (22). 4’-Ethynylbenzyl 
azithromycin 19 (0.045 g, 0.050 mmol) and 6-azido-O-silyl hexahydroxamate 21 (0.060 
g, 0.146 mmol) were dissolved in anhydrous THF (5 mL) and stirred under argon at room 
temperature.  Copper (I) iodide (0.010 g, 0.050 mmol), Hunig’s base (0.5 mL) and tris[(1-
benzyl-1H-1,2,3-triazol-4-yl)methyl]amine, (TBTA) (0.016 g, 0.030 mmol) were then 
added to the reaction mixture, and stirring continued for 2 h. The reaction mixture was 
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diluted with CH Cl  (40 mL) and washed with 1:4 NH OH/saturated NH2 2 4 4Cl (2 x 30 mL) 
and saturated NH Cl (30 mL).  The organic layer was dried over Na4 2SO4 and 
concentrated in vacuo.  The crude product was purified by prep TLC (silica, 12:1:0.1 
CH Cl /MeOH/conc. NH2 2 4OH) to give 38 mg (60%) of silyl protected compound 22 as a 
brown-white solid. 1H-NMR (CDCl3, 400MHz) δ 0.82-1.52 (39H, m) 1.71- 2.04 (13H, 
m), 2.21 (3H, s), 2.28 (6H, s), 2.44-2.57 (2H, m), 2.65-2.70 (2H, m), 2.96 (1H, br s), 3.09 
(2H, s), 3.31-3.35 (2H, m), 3.40-3.48 (6H, m), 3.56-3.60 (1H, m), 3.76 (1H, d, J = 13.2 
Hz), 4.00 (1H, br s), 4.20 (3H, br s), 4.39 (1H, d, J = 6.8 Hz), 4.64 (1H, d, J = 9. 2 Hz), 
5.09 (1H,  br s) 7.29-7.41 (10H, m), 7.64-7.83 (5H, m); 13C NMR (CDCl3, 100 MHz) 
δ 7.4, 9.1, 11.3, 14.7, 16.3, 18.2, 21.3, 21.4, 21.5, 22.0, 26.7, 27.5, 29.6, 29.7, 29.9, 34.6, 
36.2, 36.9, 42.2, 45.2, 49.3, 49.9, 57.6, 62.4, 64.1, 65.4, 68.5, 69.9, 70.5, 72.7, 73.5, 74.1, 
77.7, 77.9, 83.4, 94.3, 102.7, 119.2, 125.5, 127.6, 129.0, 135.5, 147.1, 178.4; HRMS 
(ESI) calcd for [C68H106N6O14Si + H]+1259.7609, found 1259.7570 
 
Methyl azithromycin-N-benzyltriazolylhexanoate (26a). 4’-Ethynylbenzyl 
azithromycin 19 (0.045 g, 0.053 mmol) and azido-ester 25 (0.014 g, 0.080 mmol) were 
dissolved in anhydrous THF (5 mL) and stirred under argon at room temperature.  
Copper (I) iodide (0.010 g, 0.053 mmol), and Hunig’s base (0.05 mL) were then added to 
the reaction mixture, and stirring continued for 12 h.  The reaction mixture was diluted 
with CH Cl  (30 mL) and washed with 1:4 NH OH/saturated NH2 2 4 4Cl (3 x 25 mL) and 
again with saturated NH Cl (25 mL).  The organic layer was dried over Na4 2SO4 and 
concentrated under vacuum.  The crude product was purified by preparative TLC, eluting 
with Hexane/EtOAc/Et N 3:2:0.1 to give 50 mg (92%) of 26a as a white-brown solid.  3
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1H-NMR (CDCl3, 400MHz) δ 0.82-0.90 (3H, m), 0.98 (3H, d, J = 7.6 Hz), 1.05-1.52 
(24H, m), 1.60-1.74 (6H, m), 1.80-2.06 (9H, m), 2.22-2.37 (9H, m), 2.56 (3H, m), 2.67 
(3H, m), 2.95 (2H, t, J = 9.8 Hz), 3.07 (3H, m), 3.29-3.34 (1H, m), 3.46 (3H, m), 3.54 
(1H, d, J = 6.8 Hz), 3.61 (3H, s), 3.68 (1H, bs), 3.77 (1H, m), 3.97 (1H, m), 4.18 (1H, m), 
4.34-4.38 (3H, m), 4.69 (1H, m), 5.06 (1H, d, J = 4 Hz), 7.32 (2H, d, J = 6.4 Hz), 7.73-
7.75 (3H, m); 13C-NMR (CDCl3, 100MHz) δ 8.7, 9.2, 11.3, 14.2, 14.7, 16.5, 18.2, 21.4, 
21.5, 22.2, 24.2, 25.9, 26.6, 27.3, 29.7, 30.0, 33.6, 34.6, 36.4, 36.9, 42.4, 45.3, 45.8, 49.3, 
50.0, 51.5, 57.7, 63.9, 65.5, 68.6, 69.4, 70.5, 72.7, 73.8, 74.2, 77.2, 77.6, 78.0, 83.4, 94.4, 
102.7, 119.3, 125.5, 129.1,  129.4, 147.2, 173.4, 178.1. HRMS (FAB, mnba) calc for 
[C53H89N5O14 + H]+  1020.6484, found 1020.6430  
 
 Methyl descladinoseazithromycin-N-benzyltriazolylhexanoate (26b). Compound 20 
(0.080 g, 0.115 mmol) and azido-ester 25 (0.030 g, 0.173 mmol) were dissolved in 
anhydrous THF (5 mL) and stirred under argon at room temperature.  Copper (I) iodide 
(0.010 g, 0.053 mmol), and Hunig’s base (0.05 mL) were then added to the reaction 
mixture, and stirring continued for 12 h.  The reaction mixture was diluted with CH Cl2 2 
(30 mL) and washed with 1:4 NH OH/saturated NH4 4Cl (3 x 25 mL) and again with 
saturated NH Cl (25 mL).  The organic layer was dried over Na4 2SO4 and concentrated in 
vacuo.  The crude product was purified by preparative TLC, eluting with 
Hexane/EtOAc/Et N 3:2:0.1 to give 65 mg (65%) of 26b as a white-brown solid.  13 H-
NMR (CDCl3, 400MHz) δ 0.79-0.86 (6H, m), 1.00-1.07 (6H, m), 1.17-1.26 (m), 1.42-
1.51 (m), 1.55-1.72 (6H, m), 1.80-1.94 (6H, m), 2.00-2.05 (2H, m), 2.1 (3H, s), 2.23-2.27 
(4H, m), 2.33 (3H, s), 2.47 (1H, d, J = 10.4 Hz), 2.58-2.72 (5H, m), 3.32-3.41 (3H, m), 
67 
 
3.52-3.73 (6H, m), 3.92-4.00 (2H, m), 4.34 (2H, t, J = 7.0 Hz), 4.41 (1H, d, J = 7.6 Hz), 
4.69 (1H, d, J = 10.8 Hz), 7.24 (2H, d, J = 8.4 Hz), 7.71(2H, d, J = 8 Hz), 7.73 (1H, s); 
13C NMR (CDCl3, 100MHz) δ 7.7, 7.9, 8.7, 10.9, 16.1, 16.1, 20.9, 21.2, 24.2, 25.8, 25.9, 
26.6, 29.2, 29.6, 30.0, 33.6, 36.0, 36.3, 37.1, 42.0, 44.5, 45.8, 50.0, 51.5, 57.7, 62.6, 65.1, 
69.9, 70.4, 73.1, 74.1, 75.3, 79.4, 94.8, 106.4, 119.3, 125.5, 128.9, 129.6, 138.2, 147.1, 
173.4, 177.2. HRMS (EI) calc for [C45H75N5O11 + H]+  862.5541, found 862.5566   
 
Representative Procedure for Conversion of Methyl or Ethyl Ester to Hydroxamic 
Acid.  6-Azidohexahydroxamic acid (24a). To a solution of ethyl 6-azidohexanoate 
(1.00 g, 5.840 mmol) in 1:1 THF (5 mL) and anhydrous methanol (5 mL) was added 
aqueous hydroxylamine (4 mL, 70.100 mmol) and KCN ( 0.070 g, 1.170 mmol), and the 
stirring continued for 24 h.  The reaction was diluted with EtOAc (30 mL) and washed 
with saturated NaHCO3 (2 x 30 mL) and saturated brine (30 mL).  The organic layer was 
dried over Na2SO4 and concentrated in vacuo to give 797 mg (80%) of 24a as white 
solid.  1H-NMR (DMSO-d6, 400MHz) δ 1.24-1.30 (2H, m), 1.45-1.53 (4H, m), 1.93 (2H, 
t, J = 7.2 Hz), 3.29 (2H, t, J = 6.8 Hz), 8.65 (1H, s), 10.3 (1H, s); 13C NMR (CDCl3, 100 
MHz) δ 24.8, 26.1, 28.4, 32.6, 51.1, 171.4; HRMS (ESI) calc for [C6H12N4O2 + H]+  
173.0947, found 173.0983  
 
7-Azidoheptahydroxamic acid (24b). Reaction of ethyl 7-azidoheptanoate (1.00 g, 
5.400 mmol) and aqueous hydroxylamine (4 ml, 70.100 mmol) within 24 h as described 
for the synthesis of 24a, gave 820 mg (82%) of 24b as white solid. 1H NMR (DMSO-d6, 
400 MHz) δ 1.23-1.32 (4H, m), 1.45-1.52 (4H, m), 1.92 (2H, t, J =7.6 Hz), 3.29 (2H, t, J 
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= 7.2 Hz), 8.63 (1H, br s), 10.3 (1H, br s); 13C NMR (CDCl3, 100 MHz) δ 25.1, 26.2, 
28.5, 28.6, 32.7, 51.2, 171.6; HRMS (FAB, thioglycerol) calc for [C7H14N4O2 + H]+  
187.1195, found 187.1163  
 
8-Azidooctahydroxamic acid (24c). Reaction of methyl 8-azidooctanoate (0.580 g, 
2.910 mmol) and aqueous hydroxylamine (2.49 ml, 37.800 mmol) within 24 h as 
described for the synthesis of 24a, gave 432 mg (74%) of 24c as white solid. 1H NMR 
(CDCl3, 400 MHz) δ 1.33-1.38 (6H, m), 1.54-1.63 (4H, m), 2.13 (2H, t, J = 7.6 Hz), 3.24 
(2H, t, J = 6.8 Hz), 8.85 (1H, br s); 13C NMR (CDCl3, 100MHz) δ 25.5, 26.7, 29.0, 29.1, 
29.2, 33.1, 51.6, 172.0; HRMS (FAB, thioglycerol) calc for [C8H16N4O  + H]+2  201.1351, 
found 201.1352 
 
9-Azidononahydroxamic acid (24d).  Reaction of methyl 9-azidononanoate (0.290 g, 
1.370 mmol) and aqueous hydroxylamine (1.18 ml, 17.900 mmol) within 24 h as 
described for the synthesis of 24a, gave 225 mg (77%) of 24d as white solid. 1H NMR 
(CDCl3, 400 MHz) δ 1.30-1.40 (8H, m), 1.56-1.61 (4H, m), 2.13 (2H, t, J = 7.2 Hz), 3.25 
(2H, t, J = 8); 13C NMR (CDCl3, 100MHz) δ 25.6, 26.8, 29.0, 29.2, 29.3, 33.1, 51.6, 
172.2; HRMS (FAB, thioglycerol) calc for [C + H9 18N O  + H] 215.1508, found 215.1529 4 2
 
10-Azidodecahydroxamic acid (24e).  Reaction of methyl 10-azidodecanoate (0.300 g, 
1.310 mmol) and aqueous hydroxylamine (1.13 ml, 17.100 mmol) within 24 h as 
described for the synthesis of 24a, gave 254 mg (84 %) of 24e as white solid. 1H NMR 
(CDCl , 400 MHz) δ 1.24-1.39 (8H, m), 1.54-1.65 (4H, m), 2.12 (2H, t, J = 7.6 Hz), 3.24 3
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(2H, t, J = 7.2 Hz), 9.0 (1H, br s); 13C NMR (CDCl3, 100MHz) δ 25.6, 26.9, 29.0, 29.2, 
29.3, 29.4, 29.5, 33.2, 51.7, 172.2 ; HRMS (FAB, thioglycerol) calc for [C10H20N O4 2 + 
H]+ 229.1665, found 229.1666 
 
15 156- N-Azidohexahydroxamic acid (24f). Reaction of ethyl 6- N-azidohexanoate 
(0.210g, 1.129 mmol) and aqueous hydroxylamine (0.8 mL, 13.548 mmol) within 24 h as 
described for the synthesis of 24a, gave 80 mg (38%) of 24f as clear oil.  1H-NMR 
(DMSO-d6, 400MHz) δ 1.22-1.30 (2H, m), 1.44-1.52 (4H, m), 1.92 (2H, t, J = 6.4 Hz), 
3.28 (2H, t, J = 6.8 Hz), 8.63 (1H, s), 10.3 (1H, s); HRMS (ESI) calc for [C 15H6 12N O3 2 N 
+ Na+ H]2+  196.0828, found 196.0824  
 
15 157- N-Azidoheptahydroxamic acid (24g). Reaction of ethyl 7- N-azidoheptanoate 
(0.372 g, 1.860 mmol) and aqueous hydroxylamine (0.7 ml, 22.32 mmol) within 24 h as 
described for the synthesis of 24a, gave 162 mg (44%) of 24g as clear oil. 1H NMR 
(DMSO-d6, 400 MHz) δ 1.18-1.34 (4H, m), 1.44-1.58 (4H, m), 1.91 (2H, t, J = 6.4 Hz), 
3.29 (2H, t, J = 6.8 Hz), 8.64 (1H, s), 10.3 (1H, s); HRMS (FAB, thioglycerol) calc for 
[C 157H14N3O N + H]+  188.1165, found 188.1172  2
 
 
Azithromycin-N-benzyltriazolylhexahydroxamic acid (23a)   
Method A: To a solution of compound 26a (0.040 g, 0.040 mmol) in 1:1 THF/MeOH (3 
mL) was added hydroxylamine (50 % in H2O) (0.03 mL, 0.540 mmol) and a catalytic 
amount of KCN. The mixture was stirred at room temperature for 24 h.  The reaction was 
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partitioned between 5 % MeOH in CH Cl2 2 (30 mL) and saturated sodium bicarbonate (25 
mL), the two layers were separated and the aqueous layer was extracted with 5 % MeOH 
in CH Cl2 2 (2 x 20 mL). The combined organic layer was washed with saturated brine (40 
mL) and dried over Na SO2 4. Solvent was evaporated off and the crude was purified by 
preparative TLC, eluting with CH Cl / MeOH/NH2 2 4OH 10:1:0.1 to give 6.5 mg (16 %) of 
compound 23a as a brown-white solid.  
 
Method B: 4’-Ethynylbenzyl azithromycin 19 (0.100 g, 0.109 mmol) and 6-
azidohexahydroxamic acid 24a (0.081 g, 0.117 mmol) were dissolved in anhydrous THF 
(5 mL) and stirred under argon at room temperature.  Copper (I) iodide (0.011 g, 0.070 
mmol) and Hunig’s base (0.5 mL) were then added to the reaction mixture, and stirring 
continued for 4 h. The reaction mixture was diluted with CH Cl2 2 (40 mL) and washed 
with 1:4 NH OH/saturated NH Cl (3 x 30 mL) and saturated NH4 4 4Cl (30 mL).  The 
organic layer was dried over Na2SO4 and concentrated in vacuo.  The crude product was 
purified by prep TLC (silica, 12:1:0.1 CH Cl /MeOH/conc. NH2 2 4OH) to give 71 mg 
(59%) of 23a as a brown-white solid. 
 
Method C: To a solution of silyl protected compound 22  (0.025 g, 0.020 mmol) in THF 
(1 mL) was added 1 M TBAF in THF (0.030 mL, 0.030 mmol) and the mixture was 
stirred at room temperature for 2 h during which TLC revealed a near quantitative 
conversion to a lower Rf product. The reaction was partitioned between CH Cl2 2 (30 mL) 
and saturated NH4Cl (25 mL), the two layers were separated and the organic layer dried 
over Na  and concentrated in vacuo.  The crude product was purified by prep TLC 2SO4
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(silica, 12:1:0.1 CH Cl /MeOH/Et2 2 3N) to give 15 mg (73%) of 23a as a brown-white 
solid. 1H-NMR (Acetone-d6, 400MHz) δ 0.83-0.92 (6H, m), 1.02 (3H, d, J = 7.6 Hz), 
1.08-1.11 (8H, m), 1.14 (3H, d, J = 7.6 Hz), 1.18 (3H, d, J = 6 Hz), 1.24-1.29 (15H, m), 
1.33-1.47 (3H, m), 1.54 (1H, dd, J = 4.8 Hz, 15.2 Hz), 1.60-1.69 (5H, m), 1.80-2.01 (m), 
2.06-2.12 (1H, m), 2.18-2.24 (1H, m), 2.26 (3H, s), 2.28-2.31 (1H, m), 2.35-2.41 (4H, 
m), 2.51 (1H, d, J = 10 Hz), 2.65-2.96 (m), 3.12 (3H, s), 3.22-3.29 (1H, m), 3.47 (1H, m), 
3.54-3.69 (6H, m), 3.81 (1H, d, J = 13.2 Hz), 4.11 (1H, m), 4.24 (1H, m), 4.45 (3H, t, J = 
7.0 Hz), 4.50 (1H, d, J = 6.8 Hz), 4.75 (1H, d, J = 7.2 Hz), 4.97 (1H, d, J = 5.2 Hz), 7.42 
(2H, d, J = 8.0 Hz), 7.84 (2H, d, J = 8.0 Hz), 8.35 (1H, s). 13C NMR (CDCl3, 100 MHz) 
δ 6.5, 8.7, 11.5, 14.4, 16.7, 17.7, 21.3, 21.6, 21.8, 24.6, 25.7, 26.7, 27.0, 29.2, 29.6, 29.9, 
33.0, 34.5, 35.6, 36.7, 41.8, 42.7, 45.3, 49.3, 50.0, 53.4, 57.8, 62.6, 63.4, 65.9, 68.6, 69.3, 
70.4, 72.6, 73.3, 73.8, 77.8, 78.3, 78.4, 83.4, 94.5, 102.8, 119.6, 125.7, 129.3, 129.7, 
138.6, 147.4, 171.3, 178.4; HRMS (ESI) calcd for [C52H88N6O14 + H]+ 1021.6437, found 
1021.6409; M.P. = 127.0-130.0 oC.       
 
Desclasinose azithromycin-N-benzyltriazolylhexahydroxamic acid (23b).  
Method A: To a solution of compound 26b (0.040 g, 0.050 mmol) in 1:1 THF/MeOH (3 
mL) was added hydroxylamine (50 % in H2O) (0.04 mL, 0.540 mmol) and a catalytic 
amount of KCN. The mixture was stirred at room temperature for 24 h.  The reaction was 
partitioned between 5 % MeOH in CH Cl2 2 (30 mL) and saturated sodium bicarbonate (25 
mL), the two layers were separated and the aqueous layer was extracted with 5 % MeOH 
in CH Cl2 2 (2 x 20 mL). The combined organic layer was washed with saturated brine (40 
mL) and dried over Na SO . Solvent was evaporated off and the crude was purified by 2 4
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preparative TLC, eluting with CH Cl /MeOH/NH2 2 4OH 10:1:0.1 to give 9.0 mg (23 %) of 
compound 23b as brown-white solid.  
 
Method B: Reaction of descladinose compound 20 (0.134 g, 0.188 mmol) and 6-
azidohexahydroxamic acid 24a (0.130 g, 0.755 mmol) within 8 h, according to the 
protocols of Method B described for the synthesis of compound 23a, followed by prep 
TLC (silica, 10:1:0.1 CH Cl2 2/MeOH/conc. NH4OH) gave 73 mg (43%) of 23b as a 
brown-white solid. 1H-NMR (Acetone-d6, 400MHz)  δ 0.82-0.90 (9H, m), 1.02 (3H, d, J 
= 7.2 Hz), 1.07 (3H, s), 1.09 (3H, d, J = 6.8 Hz), 1.18-1.23 (m), 1.28 (3H, s), 1.31-1.39 
(m), 1.46-1.56 (4H, m), 1.61-1.65 (3H, m), 1.80-1.99 (7H, m), 2.05-2.11 (2H, m), 2.18-
2.21 (1H, m), 2.24 (3H, s), 2.25-2.29 (1H, m), 2.35 (3H, s), 4.47 (1H, d, J = 9.2 Hz), 
2.61-2.67 (1H, m), 2.70-2.77 (1H, m), 3.30-3.34 (1H, m), 3.41 (1H, m), 3.52-3.65 (5H, 
m), 3.81 (1H, d, J = 13.2 Hz), 4.44 (2H, t, J = 7.0 Hz), 4.59 (1H, d, J = 7.6 Hz), 4.87 (1H, 
dd, J = 1.8 Hz, 11.0 Hz), 7.43 (2H, d, J = 8.4 Hz), 7.83 (2H, d, J = 8.4 Hz), 8.34 (1H, s); 
13C NMR (CDCl3, 100 MHz) δ 7.3. 7.9, 10.7, 16.0, 16.2, 20.9, 21.1, 24.4, 25.6, 25.7, 
26.5, 29.0, 29.6, 29.7, 35.8, 36.3, 36.8, 42.1, 44.4, 50.0, 57.9, 62.7, 64.0, 69.8, 70.5, 70.8, 
73.3, 74.1, 75.0, 79.5, 94.8, 106.5, 120.0, 125.8, 129.2, 129.5, 138.4, 147.3, 170.5, 177.5; 
HRMS (ESI) calcd for [C44H74N6O11 + H]+ 863.5494, found 863.5544; M.P. = 109.0-
112.0 oC.   
Azithromycin-N-benzyltriazolylheptahydroxamic acid (23c). Reaction of 4’-
ethynylbenzyl azithromycin 19 (0.134 g, 0.158 mmol) and 7-azidoheptahydroxamic acid 
24b (0.125 g, 0.672 mmol) within 4 h, according to the protocols of Method B described 
for the synthesis of compound 23a, followed by prep TLC (silica, 12:1:0.1 
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OH) gave 93 mg (56%) of 23c as a brown-white solid. 1CH Cl /MeOH/conc. NH2 2 4 H-
NMR (CDCl3, 400MHz) δ 0.81-1.51 (30H, m), 1.54-1.65 (6H, m), 1,70-2.14 (9H, m), 
2.20-2.38 (9H, m), 2.46-2.56 (2H, m), 2.60-2.70 (2H, m), 3.00 (3H, s), 3.31 (2H, t, J = 
8.8 Hz), 3.38-3.54 (6H, m), 3.60 (1H, s), 3.78 (1H, d, J = 12.8 Hz), 3.98-4.20 (2H, m), 
4.36 (3H, d, J = 7.2 Hz), 4.49 (1H, d, J = 7.2 Hz), 5.11 (1H, d, J = 4.0 Hz), 7.32 (2H, d, J 
= 7.6 Hz), 7.73 (1H, s), 7.75 (2H, d, J = 7.6 Hz); 13C NMR (CDCl3, 100 MHz) δ 6.6, 8.8, 
11.5, 14.4, 16.6, 17.7, 21.3, 21.6, 21.8, 25.1, 26.0, 26.7, 27.1, 28.2, 29.2, 29.6, 30.0, 33.1, 
34.5, 35.7, 36.7, 41.8, 42.7, 45.3, 49.3, 50.3, 50.7, 57.9, 62.7, 63.0, 65.8, 68.6, 69.4, 70.4, 
72.6, 73.2, 73.8, 77.8, 78.1, 78.2, 83.5, 94.4, 102.8, 119.3, 125.7, 129.4, 129.7, 138.4, 
147.4, 171.3, 178.4; HRMS (ESI) calcd for [C53H90N6O14 + H]+ 1035.6587, found 
1035.6628; M.P. = 115.0-119.0 oC.     
 
Descladinose azithromycin-N-benzyltriazolylheptahydroxamic acid (23d). Reaction 
of descladinose-4’-ethynylbenzyl azithromycin 20 (0.130 g, 0.188 mmol) and 7-
azidoheptahydroxamic acid 24b (0.130 g, 0.755 mmol) within 8 h, according to the 
protocols of Method B described for the synthesis of compound 23a, followed by prep 
TLC (silica, 10:1:0.1 CH Cl2 2/MeOH/conc. NH4OH) gave 78 mg (47%) of 23d as a 
brown-white solid. 1H-NMR (CDCl3, 400MHz) δ 0.66-2.32 (42H, m), 2.47 (2H, d, J = 
10.8 Hz), 2.63-2.70 (4H, m), 3.34-3.51 (6H, m), 3.62-3.69 (5H, m), 4.20-4.40 (5H, m), 
4.74 (2H, br s), 7.26 (2H, br s), 7.73 (3H, br s); 13C NMR (CDCl3, 100 MHz) δ 7.4, 7.9, 
10.7, 16.0, 16.1, 20.9, 21.1, 25.0, 25.7, 26.5, 28.0, 28.9, 29.8, 35.8, 36.3, 36.9, 42.0, 44.4, 
50.1, 57.9, 62.7, 63.9, 69.9, 70.4, 70.8, 73.3, 74.1, 75.2, 79.5, 94.9, 106.6, 119.7, 125.7, 
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129.2, 129.6, 138.4, 147.3, 177.5; HRMS (ESI) calcd for [C45H76N6O11 + H]+ 877.5645, 
found 877.5665; M.P. = 105.0-109.0 oC.   
 
Azithromycin-N-benzyltriazolyloctahydroxamic acid (23e). Reaction of 4’-
ethynylbenzyl azithromycin 19 (0.100 g, 0.120 mmol) and 8-azidooctahydroxamic acid 
17c (0.047 g, 0.240 mmol) within 2.5 h, according to the protocols of Method B 
described for the synthesis of compound 23a, followed by prep TLC (silica, 12:1:0.1 
CH OH) gave 72 mg (58 %) of 23e as brown-white solid.  1Cl /MeOH/conc. NH2 2 4 H NMR 
(CDCl3, 400 MHz) δ 0.85 (3H, t, J = 4.0 Hz), 0.87-1.22 (18H, m), 1.29 (9H, s), 1.30-2.28 
(18H, m), 2.29 (6H, s), 2.30-3.00 (8H, m), 3.10 (3H, s), 3.20-3.79 (9H, m), 3.99-4.03 
(1H, m), 4.35-4.40 (3H, m), 4.65 (1H, d, J = 8.0 Hz), 5.11 (1H, d, J = 4.8 Hz), 7.34 (2H, 
d, J = 8.0 Hz), 7.72 (1H, s), 7.77 (2H, d, J = 8.0 Hz); 13C NMR (DMSO-d6, 100MHz) δ 
7.5, 9.8, 11.6, 15.4, 18.2, 19.1, 21.5, 22.1, 22.7, 25.6, 26.3, 26.6, 28.7, 29.0, 29.6, 30.2, 
32.0, 32.8, 35.2, 36.4, 37.2, 42.2, 45.3, 49.2, 50.1, 58.3, 63.2, 65.4, 67.7, 70.8, 73.3, 74.2, 
77.0, 78.4, 83.4, 102.8, 121.6, 125.6, 129.7, 130.0, 135.0, 147.0, 177.8; HRMS (FAB, 
thioglycerol) calc for [C54H92N6O14 + H]+ 1049.6749, found 1049.6648; M.P. = 110.0-
123.0 oC. 
 
Descladinose azithromycin-N-benzyltriazolyloctahydroxamic acid (23f). Reaction of 
descladinose-4’-ethynylbenzyl azithromycin 20 (0.100 g, 0.144 mmol) and 8-
azidooctahydroxamic acid 24c (0.049 g, 0.246 mmol) within 2.5 h, according to the 
protocols of Method B described for the synthesis of compound 23a, followed by prep 
TLC (silica, 10:1:0.1 CH OH) gave 94 mg (73 %) of 23f as a Cl2 2/MeOH/conc. NH4
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brown-white solid. 1H NMR (CDCl3, 400 MHz) δ 0.84-0.91 (9H, m), 1.04-1.11 (9H, m), 
1.23-1.30 (12H, m), 1.37-2.16(14H, m), 2.2 (3H, s), 2.35 (3H, s), 2.49-2.74 (5H, m), 
3.22-3.75 (6H, m), 4.10-4.12 (1H, m), 4.34-4.42 (3H, m), 4.77 (1H, d, J = 12 Hz), 7.30 
(2H, d, J = 7.6 Hz), 7.79 (3H, m); 13C NMR (CDCl3, 100MHz) δ 7.6, 8.2, 11.0, 14.4, 
16.2, 16.4, 21.1, 21.4, 25.2, 25.9, 26.1, 26.7, 28.4, 28.8, 28.9, 29.1, 29.9, 30.2, 36.1, 36.6,  
42.3, 44.6, 50.5, 51.6, 58.2, 60.6, 63.0, 64.0, 70.1, 70.7, 73.6, 74.4, 75.4, 79.7, 95.1, 
106.8, 120.0, 126.0, 129.5, 129.9, 138.6, 147.6, 170.6, 177.8; HRMS (FAB, thioglycerol) 
calc for [C46H78N6O11 + H]+ 891.5806, found 891.5776; M.P. = 80.0-90.0 oC.   
 
Azithromycin-N-benzyltriazolylnonahydroxamic acid (23g). Reaction of 4’-
ethynylbenzyl azithromycin 19 (0.100 g, 0.120 mmol) and 9-azidononahydroxamic acid 
24d (0.043 g, 0.200 mmol) within 2.5 h, according to the protocols of Method B 
described for the synthesis of compound 23a, followed by prep TLC (silica, 12:1:0.1 
CH OH) gave 64 mg (51 %) of 23g as brown-white solid.  1Cl /MeOH/conc. NH2 2 4 H NMR 
(CDCl3, 400 MHz) δ 0.84- 1.30 (30H, m), 1.33-2.26 (20H, m), 2.30 (6H, s), 2.38-2.68 
(8H, m), 2.99 (3H, s), 3.32-3.84 (9H, m), 4.03-4.08 (1H, m), 4.35-4.41 (3H, m), 4.53 (1H, 
d, J = 8.0 Hz), 5.13 (1H, d, J = 4.0 Hz), 7.35 (2H, d, J = 8.0 Hz), 7.75 (1H, s), 7.78 (2H, 
d, J = 8.0 Hz); 13C NMR (DMSO-d6, 100MHz) δ 6.9, 9.0, 11.6, 14.7, 16.9, 18.0, 21.6, 
21.8, 22.1, 25.6, 26.4, 26.9, 27.3, 28.8, 29.0, 29.1, 29.5, 29.9, 30.4, 34.8, 36.0, 37.0, 42.1, 
43.0, 45.6, 49.5, 50.5, 58.1, 63.5, 66.1, 68.8, 70.7, 72.9, 74.1, 78.1, 78.3, 78.5, 83.7, 94.4, 
94.7, 103.1, 119.6, 126.0, 129.7, 130.0, 147.6, 178.7; HRMS (ESI) calc for [C55H94N O6 14 
+ H]+ 1063.6900, found 1063.6861; M.P. = 117.0-133.0 oC.   
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Azithromycin-N-benzyltriazolyldecahydroxamic acid (23h). Reaction of 4’-
ethynylbenzyl azithromycin 19 (0.100 g, 0.120 mmol) and 10-azidodecahydroxamic acid 
24e (0.045 g, 0.20 mmol) within 4.5 h, according to the protocols of Method B described 
for the synthesis of compound 23a, followed by prep TLC (silica, 12:1:0.1 
CH OH) gave 70 mg (56 %) of 23h as a brown-white solid.  1Cl /MeOH/conc. NH2 2 4 H 
NMR (CDCl3, 400 MHz) δ 0.85-1.36 (30H, m), 1.41-2.24 (22H, m), 2.28, 2.36 (6H, s), 
2.33-3.10 (8H, m), 3.05 (3H, s), 3.23-3.82 (9H, m), 4.06-4.10 (1H, m), 4.36-4.41 (3H, 
m), 4.49 (1H, d, J = 8.0 Hz), 5.15 (1H, d, J = 4.0 Hz), 7.34 (2H, d, J = 8 Hz), 7.75 (1H, 
s), 7.78 (2H, d, J = 8.0 Hz); 13C NMR (DMSO-d6, 100MHz) δ6.7, 9.0, 11.7, 14.6, 16.9, 
17.9, 21.6, 21.9, 22.0, 25.6, 26.4, 26.8, 27.0, 27.3, 28.8, 29.0, 21.9, 29.3, 29.5, 29.9, 30.3, 
33.6, 34.9, 35.8, 37.0, 42.1, 43.0, 45.6, 49.6, 50.6, 51.6, 58.0, 62.8, 63.9, 66.2, 68.9, 69.6, 
70.7, 72.9, 73.5, 74.0, 74.1, 78.2, 78.6, 83.6, 94.6, 103.0, 119.6, 126.0, 129.6, 129.9, 
138.9, 147.6, 178.6; HRMS (MALDI) calc for [C56H96N6O14 + H]+ 1077.7057, found 
1077.6971; M.P. = 100.0-127.0 oC.   
 
4’-Desmethyl clarithromycin (27).  To a solution of clarithromycin (3.320 g, 4.440 
mmol) and sodium acetate (3.280 g, 39.900 mmol) in 80% aqueous methanol (50 mL) at 
85 °C was added iodine (1.240 g, 4.890 mmol) in three batches within 5 min.  The 
reaction was maintained at pH 8-9 by additions of 1M NaOH (2 x 3 ml, once at 10 min 
and 45 min of reaction time). Stirring was continued at 85 °C for 3 h and TLC analysis 
indicated about 90% consumption of the starting material. A solution of 5% sodium 
thiosulfate (120 mL) and dichloromethane (80 mL) were added and the two layers were 
separated.  The aqueous layer was extracted with CH Cl  (60 mL), the combined organic 2 2
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layers was washed with saturated brine, dried over Na2SO4, and concentrated in vacuo to 
give 2.4 g of 27, which was used without further purification.  
 
4’-Ethynylbenzyl clarithromycin (28). To a solution of 4’-desmethyl clarithromycin 27 
(2.400 g, 3.340 mmol) in anhydrous DMSO (30 ml) was added Hunig’s base (3 ml) and 
4-ethynylbenzyl methanesulfonate 18 (0.920 g, 4.340 mmol).  The reaction mixture was 
then heated with stirring under argon at 85°C for 2.5 h. The reaction was cooled and 
diluted with EtOAc (100 mL) and washed with saturated NaHCO3 (3 x 60 mL) and 
saturated brine (60 mL). The organic layer was dried over Na SO2 4 and concentrated in 
vacuo. The crude product was purified by flash chromatography (silica, gradient 12:1; 
10:1; 8:1; CH /acetone) to give 1.8 g (63%) of 28 as a brown-white solid.  1Cl2 2 H-NMR 
(CDCl3, 400MHz) δ 0.82 (3H, t, J = 7.2 Hz), 1.03-1.28 (18H, m), 1.37 (3H, s), 1.40-1.55 
(3H, m), 1.65-1.90 (6H, m), 2.03 (1H, d, J =  10.0 Hz), 2.22 (3H, s), 2.30 (1H, d, J = 15.2 
Hz), 2.40-2.60 (2H, m), 2.80-2.90 (2H, m), 2.94-3.00 (6H, m), 3.04 (1H, s), 3.09 (3H, s), 
3.16 (1H, s), 3.24-3.29 (1H, m), 3.38-3.46 (3H, m), 3.59 (1H, d, J = 6.8 Hz), 3.70-3.75 
(3H, m), 3.88-3.95 (1H, m), 4.37 (1H, d, J = 7.2 Hz), 4.88 (1H, d, J = 4.4 Hz), 5.02 (1H, 
dd, J = 11.6, 2.4 Hz), 7.23 (2H, d, J = 12.0 Hz), 7.42 (2H, d, J = 8.0 Hz); 13C NMR 
(CDCl3, 100 MHz) δ 9.2, 10.7, 12.4, 16.1, 18.1, 18.7, 19.9, 21.1, 21.5, 29.3, 32.4, 34.8, 
36.9, 37.2, 39.2, 45.0, 45.2, 49.3, 50.6, 53.4, 57.6, 63.3, 65.6, 68.5, 69.0, 70.6, 72.5, 
74.2,76.5,  77.8, 78.1, 78.2, 80.8, 95.8, 102.5, 120.9, 128.6, 132.0, 133.5, 139.4, 175.4; 
HRMS (ESI) calc for [C46H73NO13 + H]+ 848.5155, found 848.5181 
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Descladinose-4’-ethynylbenzyl clarithromycin (29). To a solution of 4’-ethynylbenzyl 
clarithromycin 28 (0.500 g, mmol) in ethanol (20 mL) was added 1N HCl (20 mL), and 
stirring continued for 22 h at room temperature.  The reaction mixture was basified with 
concentrated NH4OH to about pH = 9.  The reaction mixture was diluted with distilled 
water (40 mL) and extracted with EtOAc (3 x 60 mL).  The combined organic layers 
were washed with saturated brine (40 mL), dried over Na2SO4, and concentrated in 
vacuo.  The crude product was purifed by flash chromatography (silica, 8:1 
CH /acetone) to give 320 mg (79%) of 29 as a brown-white solid. 1Cl H-NMR (CDCl2 2 3, 
400MHz) δ 0.82 (3H, t, J = 7.6 Hz), 1.09-1.28 (12H, m), 1.34 (3H, s), 1.40-1.55 (3H, m), 
1.70-1.74 (2H, m),1.87-1.94 (3H, m),  2.08-2.15 (6H, m), 2.54-2.66 (2H, m), 2.94-2.98 
(3H, m), 3.05 (1H, s), 3.25 (1H, s), 3.31-3.42 (2H, m), 3.48-3.56 (2H, m), 3.66 (2H, d, J 
= 10.0 Hz), 3.82 (1H, s), 3.90 (1H, s), 4.35 (1H, d, J = 7.6 Hz), 5.14 (1H, dd, J = 10.8, 2.0 
Hz), 7.18 (2H, d, J = 8.0 Hz), 7.42 (2H, d, J = 8.4 Hz); 13C NMR (CDCl3, 100 MHz) δ 
8.4, 10.5, 12.7, 15.3, 16.3, 17.8, 18.8, 21.4, 29.2, 35.9, 36.6, 37.5, 38.7, 44.5, 45.5, 49.6, 
57.8, 65.0, 69.7, 70.1, 70.6, 74.1, 77.9, 78.9, 83.3, 88.5, 106.5, 121.0, 128.4, 132.1, 139.1, 
174.7; HRMS (ESI) calc for [C + 38H59NO10 + H] 690.4212, found 690.4259 
 
Clarithromycin-N-benzyltriazolyl-O-silyl-hexahydroxamate (30). 4’-Ethynylbenzyl 
clarithromycin 28 (0.100 g, 0.118 mmol) and 6-azido-O-silyl hexahydroxamate 21  
(0.103 g, 0.251 mmol) were dissolved in anhydrous THF (6 mL) and stirred under argon 
at room temperature.  Copper (I) iodide (0.011 g, 0.057 mmol), TBTA (0.060 g, 0.094 
mmol), and Hunig’s base (0.1 mL) were then added to the reaction mixture, and stirring 
continued for 24 h.  The reaction mixture was diluted with CH Cl  (30 mL) and washed 2 2
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with 1:4 NH OH/saturated NH Cl (3 x 30 mL) and saturated NH4 4 4Cl (30 mL).  The 
organic layer was dried over Na2SO4 and concentrated in vacuo.  The crude product was 
purified by prep TLC (silica, 20:1 CH Cl2 2/MeOH) to give 147 mg (99%) of compound 
30 as a brown-white solid. 1H-NMR (CDCl3, 400MHz) δ 0.81 (3H, t, J =  7.2 Hz), 1.03-
1.51 (30H, m), 1.67-1.88 (12H, m) 2.10-2.29 (8H, m), 2.53-2.58 (3H, m), 2.82-2.90 (2H, 
m), 2.93-3.01 (6H, m), 3.10 (3H, s), 3.17 (2H, s), 3.28-3.32 (1H, m), 3.40-3.48 (3H, m), 
3.60-3.78 (4H, m), 3.91-3.97 (1H, m), 4.22 (1H, br s), 4.41 (2H, d, J = 8.0 Hz ), 4.87 (1H, 
d, J = 4.8 Hz), 5.03 (1H, d, J = 10.8 Hz), 7.21-7.23 (2H, m), 7.30-7.42 (10H, m), 7.64-
7.76 (3H, m); 13C NMR (CDCl3, 100 MHz) δ 9.1, 10.6, 12.3, 16.0, 18.0, 18.6, 19.8, 21.0, 
21.3, 21.5, 26.7, 29.3, 29.6, 29.9, 34.7, 36.8, 37.1, 39.0, 39.2, 45.0, 45.2, 47.0, 49.3, 49.9, 
50.5, 53.4, 54.0, 65.5, 68.5, 68.9, 70.6, 72.3, 74.1, 76.4, 77.7, 78.1, 78.2, 80.7, 95.7, 
102.5, 119.3, 123.5, 125.4, 127.7, 128.4, 128.8, 129.1, 133.5, 134.4, 135.5, 143.9, 147.0, 
175.4; HRMS (ESI) calcd for [C68H103N5O15Si + H]+1258.7292, found 1258.7313 
 
Clarithromycin-N-benzyltriazolylhexahydroxamic acid (31a).  
Method A: 4’-Ethynylbenzyl clarithromycin 28 (0.100 g, 0.120 mmol) and 6-
azidohexahydroxamic acid 24a (0.080 g, 0.470 mmol) were dissolved in anhydrous THF 
(5 mL) and stirred under argon at room temperature.  Copper (I) iodide (0.011 g, 0.057 
mmol) and Hunig’s base (0.5 mL) were added to the reaction mixture, and stirring 
continued for 2.5 h.  The reaction mixture was diluted with CH Cl2 2 (50 mL) and washed 
with 1:4 NH OH/saturated NH Cl (3 x 30 mL) and saturated NH4 4 4Cl (30 mL).  The 
organic layer was dried over Na  and concentrated in vacuo.  The crude product was 2SO4
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purified by prep TLC (silica, 12:1:0.1 CH Cl /MeOH/conc. NH2 2 4OH) to give 70 mg 
(58%) of 31a as a brown-white solid.  
 
Method B: To a solution of compound 30 (0.085g, 0.067 mmol) in anhydrous THF (1.5 
mL) was added 1M TBAF in THF (0.1 mL, 0.100 mmol). The reaction was stirred under 
argon for 2 h.  The reaction mixture was diluted with 5% MeOH in dichloromethane (10 
mL) and washed with saturated NH4Cl (15mL).  The organic layer was dried over 
Na SO2 4 and concentrated in vacuo.  The crude product was purified on prep TLC (silica, 
12:1:0.1 CH Cl2 2/MeOH/Et3N). The purified product was dissolved in 5% MeOH in 
CH Cl2 2 (10 mL) and washed with distilled water (10 mL) and saturated brine (10 mL) to 
remove the last trace of associated TBAF.  The organic layer was dried over Na2SO4 and 
concentrated in vacuo to give 26 mg (38%) of 31a as a brown-white product. 
1H-NMR (CDCl3, 400MHz) δ 0.81 (3H, t, J =  7.6 Hz), 1.03-1.52 (21H, m), 1.62-
1.92 (12H, m) 2.04-2.29 (8H, m), 2.48-2.60 (3H, m), 2.82-2.90 (2H, m), 2.93-2.99 (6H, 
m), 3.09 (3H, s), 3.19 (2H, s), 3.28-3.33 (1H, m), 3.42-3.46 (3H, m), 3.60 (1H, d, J = 7.6 
Hz), 3.70-3.80 (3H, m), 3.90-3.98 (1H, m), 4.37-4.40 (3H, m), 4.87 (1H, d, J = 4.8 Hz), 
5.03 (1H, dd, J = 11.6, 2.4 Hz), 7.34 (2H, d, J = 7.6 Hz), 7.77 (2H, d, J = 7.6 Hz), 7.82 
(1H, s); 13C NMR (CDCl3, 100 MHz) δ 9.1, 10.5, 12.2, 15.9, 17.9, 18.5, 19.7, 20.9, 21.2, 
21.4, 24.3, 25.5, 29.4, 29.6, 34.7, 36.8, 37.1, 39.0, 39.1, 45.0, 45.1, 49.3, 49.9, 50.5, 53.3, 
57.5, 63.6, 65.5, 68.5, 69.0, 70.7, 72.4, 74.2, 77.8, 78.2, 80.9, 95.9, 102.6, 119.8, 125.6, 
129.4, 147.4, 175.8; HRMS (ESI) calcd for [C52H85N5O15 + H]+ 1020.6114, found 
1020.6121; M.P. = 120.0-124.0 oC.   
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Descladinose clarithromycin-N-benzyltriazolylhexahydroxamic acid (31b). Reaction 
of descladinose-4’-ethynylbenzyl clarithromycin 29 (0.075 g, 0.109 mmol) and 6-
azidohexahydroxamic acid 24a (0.040 g, 0.233 mmol) within 4 h, according to the 
protocols of Method A described for the synthesis of compound 31a, followed by prep 
TLC (silica, 10:1:0.1 CH Cl2 2/MeOH/conc. NH4OH) gave 47 mg (51%) of 31b as a 
brown-white solid.  1H-NMR (CDCl3, 400MHz) δ 0.79 (3H, t, J = 7.2 Hz), 1.08-1.32 
(22H, m), 1.39-1.64 (3H, m), 1.71-1.81 (2H, m), 1.82-1.96 (3H, m), 2.04-2.18 (6H, m), 
2.51-2.70 (4H, m), 2.92-2.98 (3H, m), 3.18-3.38 (3H, m), 3.45-3.55 (2H, m), 3.60-3.74 
(3H, m), 3.81 (3H, s), 3.90 (1H, s), 4.33 (3H, br s), 5.13 (1H, d, J = 10.4 Hz), 7.29 (2H, 
br s), 7.74 (2H, br s); 13C NMR (CDCl3, 100 MHz) δ 8.6, 10.7, 12.9, 15.5, 16.4, 18.0, 
19.0, 21.5, 21.6, 29.5, 29.9, 36.1, 36.7, 37.7, 39.0, 44.7, 45.7, 49.8, 50.3, 58.2, 64.6, 70.0, 
70.3, 70.9, 74.4, 78.3, 79.1, 88.5, 106.7, 120.3, 126.1, 129.6, 129.9, 147.7, 175.4; HRMS 
(ESI) calcd for [C44H71N5O12 + H]+ 862.5172, found 862.5155; M.P. = 104.0-108.0 oC.   
 
Clarithromycin-N-benzyltriazolylheptahydroxamic acid (31c). Reaction of 4’-
ethynylbenzyl clarithromycin 28 (0.130 g, 0.153 mmol) and 7-azidoheptahydroxamic 
acid 24b (0.105 g, 0.565 mmol) within 2.5 h, according to the protocols of Method A 
described for the synthesis of compound 31a, followed by prep TLC (silica, 12:1:0.1 
CH OH) gave 105 mg (67%) of 31c as a brown-white solid.  1Cl /MeOH/conc. NH2 2 4 H-
NMR (CDCl3, 400MHz) δ 0.82 (3H, t, J =  8.0 Hz), 1.04-1.52 (21H, m), 1.67-1.92 (14H, 
m) 2.14-2.29 (8H, m), 2.52-2.60 (3H, m), 2.82-2.90 (2H, m), 2.95-3.00 (6H, m), 3.10 
(3H, s), 3.16 (2H, s), 3.27-3.32 (1H, m), 3.41-3.46 (3H, m), 3.59 (1H, d, J = 6.8 Hz), 
3.69-3.79 (3H, m), 3.90-3.95 (1H, m), 4.34-4.39 (3H, m), 4.87 (1H, d, J = 4.4 Hz), 5.02 
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(1H, d, J = 9.2 Hz), 7.33 (2H, d, J = 6.4 Hz), 7.77 (3H, d, J = 8.4 Hz); 13C NMR (CDCl3, 
100 MHz) δ 9.1, 10.5, 12.2, 15.9, 17.9, 18.5, 19.8, 20.9, 21.2 , 21.4, 24.7, 25.5, 27.7, 
29.8, 34.7, 36.8, 37.1, 39.1, 45.0, 45.2, 49.3, 50.0, 50.5, 57.6, 63.6, 65.6, 68.6, 69.0, 70.7, 
72.4, 74.2, 77.8, 78.3, 80.9, 95.9, 102.7, 119.5, 125.7, 129.4, 147.5, 175.8;  HRMS (ESI) 
calcd for [C53H87N5O15 + H]+ 1034.6271, found 1034.6246; M.P. = 115.0-119.0 oC.   
 
Descladinose clarithromycin-N-benzyltriazolylheptahydroxamic acid (31d). Reaction 
of descladinose-4’-ethynylbenzyl clarithromycin 29 (0.075 g, 0.109 mmol) and 7-
azidoheptahydroxamic acid 24b (0.040 g, 0.233 mmol) within 4 h, according to the 
protocols of Method A described for the synthesis of compound 31a, followed by prep 
TLC (silica, 10:1:0.1 CH Cl2 2/MeOH/conc. NH4OH) gave 80 mg (84%) of 31d as a 
brown-white solid.   1H-NMR (CDCl3, 400MHz) δ 0.78 (3H, t,  J = 7.2 Hz), 1.06-1.31 
(22H, m), 1.40-1.53 (5H, m), 1.71 (2H, d, J = 11.6 Hz), 1.80-1.91 (3H, m), 2.01-2.20 
(6H, m), 2.50-2.65 (4H, m), 2.91-2.97 (3H, m), 3.16 (1H, t, J = 6.4 Hz), 3.26-3.35 (2H, 
m), 3.42-3.54 (2H, m), 3.64-3.71 (3H, m), 3.80 (1H, br s), 3.90 (1H, br s), 4.30-4.34 (3H, 
m), 5.12 (1H, dd, J = 11.6, 2.4 Hz), 7.27 (2H, d, J = 8.0 Hz), 7.72 (2H, d, J = 7.2 Hz), 
7.80 (1H, s); 13C NMR (CDCl3, 100 MHz) δ 8.3, 10.3, 12.5, 15.2, 16.1, 17.6, 18.6, 21.1, 
21.3, 24.8, 25.1, 25.5, 26.2, 27.8, 28.5, 29.1, 29.6, 29.7, 32.3, 35.8, 36.3, 37.4, 38.6, 44.3, 
45.4, 49.5, 50.0, 51.2, 57.8, 64.2, 69.7, 69.9, 70.6, 74.1, 77.9, 78.7, 88.0, 106.3, 119.9, 
125.7, 129.3, 129.5, 138.3, 147.3, 175.1; HRMS (ESI) calcd for [C45H73N5O12 + H]+ 
876.5329, found 876.5301; M.P. = 85.0-89.0 oC.   
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Clarithromycin-N-benzyltriazolyloctahydroxamic acid (31e). Reaction of 4’-
ethynylbenzyl clarithromycin 28 (0.101 g, 0.120 mmol) and 8-azidooctahydroxamic acid 
24c (0.047 g, 0.240 mmol) within 2.5 h, according to the protocols of Method A 
described for the synthesis of compound 31a, followed by prep TLC (silica, 12:1:0.1 
CH OH) gave 92 mg (74%) of 31e as a brown-white solid.  1Cl /MeOH/conc. NH2 2 4 H 
NMR (CDCl3, 400 MHz) δ 0.81 (3H, t, J = 7.2 Hz), 1.04-2.05 (45H, m), 2.22 (3H, s), 
2.19-2.82 (m, 7H), 3.00 (3H, s), 3.08 (3H, s), 2.91-3.80 (6H, m), 3.95 (3H, m), 4.38 (3H, 
m), 4.88 (1H, d, J = 4.4 Hz), 5.04 (1H, dd, J = 10.8, 2.0 Hz), 7.33 (2H, d, J = 7.6 Hz), 
7.71 (1H, s), 7.77 (2H, d, J = 8.0 Hz); 13C NMR (CDCl3, 100MHz) δ 8.8, 9.4, 10.8, 12.5, 
16.2, 18.2, 18.8, 20.0, 21.2, 21.5, 21.6, 25.1, 26.0, 26.7, 28.2, 28.6, 28.9, 29.9, 30.1, 35.0, 
36.9,  37.4, 39.2, 39.4, 45.2, 45.4, 46.1, 49.6, 50.4, 50.8, 51.6, 58.1, 63.6, 65.9, 68.4, 69.3, 
70.9, 72.8, 74.4, 78.0, 78.5, 81.2, 96.1, 120.1, 102.6, 126.1, 130.2, 147.4, 176.0 ; HRMS 
(ESI) calc for [C54H90N5O15 + H]+ 1048.6486, found 1048.6427; M.P. = 87.0-97.0 oC.   
 
Descladinose clarithromycin-N-benzyltriazolyloctahydroxamic acid (31f). Reaction 
of descladinose-4’-ethynylbenzyl clarithromycin 29 (0.10 g, 0.144 mmol) and 8-
azidooctahydroxamic acid 24c (0.049 g, 0.246 mmol) within 2.5 h, according to the 
protocols of Method A described for the synthesis of compound 31a, followed by prep 
TLC (silica, 10:1:0.1 CH Cl2 2/MeOH/conc. NH4OH) gave 117 mg (90 %) of 31f as a 
brown-white solid. 1H NMR (CDCl3, 400 MHz) δ 0.81 (3H, t, J = 7.2 Hz), 1.10-2.09 
(37H, m), 2.18 (3H, s), 2.19-2.68 (7H, m), 2.98-3.73 (4H, m), 3.83 (2H, s), 3.93 (1H, m), 
4.36 (3H, m), 5.16 (1H, d, J = 8.0 Hz), 7.31 (2H, d, J = 8.0 Hz), 7.77 (2H, d, J = 8.0 Hz), 
7.79 (1H, s); 13C NMR (CDCl , 100MHz) δ 8.5, 10.6, 12.8, 15.4, 16.4, 17.9, 18.9, 21.4, 3
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21.6, 29.4, 36.1, 36.7, 37.7, 38.9, 44.7, 45.7, 49.8, 58.0, 65.2, 70.0, 70.4, 70.8, 74.4, 76.8, 
78.2, 79.2, 83.6, 88.8, 106.9, 121.3, 128.7, 132.5, 139.6, 175.2 ; HRMS (FAB, 
thioglycerol) calc for [C46H76N5O12 + H]+ 890.5490, found 890.5562; M.P. = 90.0-95.0 
oC.   
 
Clarithromycin-N-benzyltriazolylnonahydroxamic acid (31g). Reaction of 4’-
ethynylbenzyl clarithromycin 28 (0.100 g, 0.120 mmol) and 9-azidononahydroxamic acid 
24d (0.043 g, 0.20 mmol) within 2.5 h, according to the protocols of Method A described 
for the synthesis of compound 31a, followed by prep TLC (silica, 12:1:0.1 
CH OH) gave 54 mg (42%) of 31g as a brown-white solid.  1Cl /MeOH/conc. NH2 2 4 H 
NMR (CDCl3, 400 MHz) δ 0.81 (3H, t, J = 7.2 Hz), 1.04-2.02 (47H, m), 2.24 (3H, s), 
2.10-2.97 (7H, m), 3.00, 3.09 (6H, s), 3.20-3.82 (6H, m), 3.88 (3H, m), 4.39 (3H, m), 
4.88 (1H, d, J = 4.0 Hz), 5.05 (1H, d, J = 10.0 Hz), 7.35 (2H, d, J = 8.0 Hz), 7.77 (3H, d, 
J = 4.0 Hz);  13C NMR (CDCl3, 100MHz) δ 9.0, 9.3, 10.8, 12.5, 16.1, 18.2, 18.8, 21.2, 
21.5, 21.6, 21.7, 21.8, 26.3, 26.8, 28.7, 28.9, 29.1, 29.9, 30.3, 35.0, 37.0, 37.4, 39.3, 39.4, 
45.2, 45.4, 49.6, 50.5, 50.8, 51.6, 57.8, 63.8, 65.8, 68.8, 69.2, 70.9, 72.7, 74.5, 76.8, 78.1, 
78.4, 78.5, 81.1, 96.1, 102.9, 119.7, 125.9, 129.6, 129.9, 138.7, 147.6, 176.1; HRMS 
(ESI) calc for [C55H91N5O15 + H]+ 1062.6584, found 1062.6586; M.P. = 92.0-105.0 oC.     
 
Clarithromycin-N-benzyltriazolyldecahydroxamic acid (31h). Reaction of 4’-
ethynylbenzyl clarithromycin 28 (0.10 g, 0.120 mmol) and 10-azidodecahydroxamic acid 
24e (0.045 g, 0.197 mmol) within 2.5 h, according to the protocols of Method A 
described for the synthesis of compound 31a, followed by prep TLC (silica, 12:1:0.1 
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OH) gave 68 mg (53 %) of 31h as a brown-white solid.  1CH Cl /MeOH/conc. NH2 2 4 H 
NMR (CDCl3, 400 MHz) 0.82 (3H, t, J = 7.2 Hz), 1.05-2.12 (49H, m), 2.24 (3H, s), 2.26-
2.97 (7H, m), 3.01, 3.10 (6H, s), 3.19-3.80 (6H, m), 3.95 (3H, m), 4.39 (3H, m), 4.89 
(1H, d, J = 4.0 Hz), 5.04 (1H, d, J = 8.0 Hz), 7.35 (2H, d, J = 8.0 Hz), 7.76 (1H, s), 7.79 
(2H, d, J = 8.0 Hz); 13C NMR (CDCl3, 100MHz) δ 9.3, 10.8, 12.5, 16.1, 18.2, 18.8, 20.0, 
21.2, 21.5, 21.7, 25.4, 26.2, 28.9, 29.0, 29.3, 29.6, 29.9, 30.2, 35.0, 37.0, 37.4, 39.3, 39.4, 
45.2, 45.4, 49.6, 50.5, 50.8, 51.6, 57.8, 63.8, 65.8, 68.8, 69.2, 70.9, 72.7, 74.5, 76.8, 78.1, 
78.5, 81.1, 96.1, 102.9, 119.7, 125.9, 129.6, 129.8, 138.9, 147.6, 176.1 ; HRMS (ESI) 
calc for [C56H93N5O15 + H]+ 1076.6740, found 1076.6667; M.P. = 87.0-105.0 oC.   
 
15Azithromycin-N-benzyl- N-triazolylhexahydroxamic acid (32a). 
15Reaction of 4’-ethynylbenzyl azithromycin 19 (0.080 g, 0.094 mmol) and 6- N-
azidohexahydroxamic acid 24f (0.032 g, 0.185 mmol) within 4 h, according to the 
protocols of Method B described for the synthesis of compound 23a, followed by prep 
TLC (silica, 12:1:0.1 CH Cl2 2/MeOH/conc. NH4OH) gave 50 mg (53%) of 32a as a 
yellowish-green solid. 1H-NMR (CDCl3, 400MHz) δ 0.82-1.51 (28H, m), 1.60-1.77 (6H, 
m), 1.86-2.08 (9H, m), 2.24-2.36 (9H, m), 2.46-2.56 (2H, m), 2.62-2.70 (2H, m), 3.00 
(3H, s), 3.32 (2H, t, J = 8.8 Hz), 3.38-3.54 (6H, m), 3.60-3.78 (2H, m), 3.98-4.08 (2H, 
m), 4.36-4.50 (3H, m), 5.06-5.12 (2H, m), 7.33 (2H, d, J = 7.6 Hz), 7.77 (2H, d, J = 7.6 
Hz); HRMS (ESI) calcd for [C52H88N5O1415N + H]+ 1022.6401, found 1021.6365 
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15Azithromycin-N-benzyl- N-triazolylheptahydroxamic acid (32b). 
15Reaction of 4’-ethynylbenzyl azithromycin 19 (0.080 g, 0.094 mmol) and 7- N-
azidoheptahydroxamic acid 24g (0.050 g, 0.267 mmol) within 4 h, according to the 
protocols of Method B described for the synthesis of compound 23a, followed by prep 
TLC (silica, 12:1:0.1 CH Cl2 2/MeOH/conc. NH4OH) gave 72 mg (74%) of 32b as a 
yellowish-green solid. 1H-NMR (CDCl3, 400MHz) δ 0.82-1.53 (30H, m), 1.54-1.65 (6H, 
m), 1,70-2.14 (9H, m), 2.20-2.38 (9H, m), 2.46-2.56 (2H, m), 2.60-2.70 (2H, m), 3.00 
(3H, s), 3.31 (2H, t, J = 8.8 Hz), 3.38-3.54 (6H, m), 3.59 (1H, s), 3.79 (1H, d, J = 12.8 
Hz), 3.98-4.10 (2H, m), 4.35 (3H, d, J = 7.2 Hz), 4.49 (1H, d, J = 7.2 Hz), 5.11 (1H, d, J 
= 4.0 Hz), 7.32 (2H, d, J = 7.6 Hz), 7.73 (1H, s), 7.75 (2H, d, J = 7.6 Hz); HRMS (ESI) 
calcd for [C53H90N5O1415N + H]+ 1036.6558, found 1036.6580 
 
O-3’-Acetylated-4’-ethynylbenzyl azithromycin (33a).  To a solution of 4’-
ethynylbenzyl azithromycin 19 (0.140g, 0.164 mmol) in anhydrous CH Cl2 2 (3 mL) was 
added acetic anhydride (0.02 mL, 0.196 mmol).  The reaction mixture is heated to 40oC 
in a pressure tube and stirring continued for 48 h.  The reaction mixture was cooled and 
diluted with CH Cl  (5 mL) and washed with saturated NaHCO2 2 3 (2 x 10 mL), and 
saturated brine (10 mL).  The organic layer was dried over Na SO2 4. Solvent was 
evaporated off to give 140 mg (95%) of compound 33a as a yellowish solid (>95 % 
purity, TLC: CH /MeOH 12:1).  The crude 33a was used without further purification. Cl2 2
1H-NMR (CDCl3, 400MHz) δ 0.11 (3H, s), 0.81-0.86 (6H, m), 0.92-0.97 (10H, m), 1.10-
1.25 (19H, m), 1.36-1.56 (2H, m), 1.70-1.76 (2H, m), 1.94-2.17 (4H, m), 2.25-2.28 (7H, 
m), 2.51-2.78 (2H, m), 2.92-3.01 (3H, m), 3.05 (1H, s), 3.18 (3H, s), 3.37-3.47(4H, m), 
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3.60 (1H, br s), 3.65 (1H, s), 3.92-3.98 (1H, m), 4.11 (1H, br s), 4.43 (2H, d, J = 7.2 Hz), 
4.77-5.02 (2H, m), 7.15 (2H, d, J = 8.0 Hz), 7.35 (2H, d, J = 8.4 Hz) ; 13C-NMR (CDCl3, 
100MHz) δ 0.9, 7.8, 11.1, 11.7, 14.5, 17.9, 20.7, 20.9, 21.1, 21.2, 21.5, 21.6, 24.0, 24.6, 
27.0, 29.5, 31.1, 35.0, 36.6, 40.9, 42.9, 45.5, 49.2, 58.2, 60.8, 62.2, 65.6, 69.0, 71.1, 72.7, 
73.7, 75.6, 76.1, 77.8, 83.6, 84.8, 96.9, 101.5, 120.4, 128.2, 131.8, 140.7, 169.8, 170.2, 
176.3; HRMS (MALDI, CHCA) calc for [C48H78N2O13 + H]+ 891.5577, found 891.5374.  
 
O-3’-14C-Acetylated-4’-ethynylbenzyl azithromycin (33b).  Reaction of 4’-
ethynylbenzyl azithromycin 19 (0.140g, 0.164 mmol), acetic anhydride-carbonyl-14C 
(0.08 µL, 0.008 mml, 0.25 mCi), and acetic anhydride (0.02 mL, 0.174 mmol) within 48 
h, according to the protocols described for the synthesis of 33a, gave 140 mg (95%) of 
33b as a yellowish solid.  The crude 33b was used without further purification. [>95 % 
purity, TLC: CHC /MeOH 12:1] Cl2 2
 
O-3’-Acetylated-azithromycin-N-benzyltriazolylhexahydroxamic acid (34a).  O-3’-
Acetylated-4’-ethynylbenzyl azithromycin 33a (0.040 g, 0.045 mmol) and 6-
azidohexahydroxamic acid 24a (0.020 g, 0.115 mmol) were dissolved in anhydrous THF 
(5 mL) and stirred under argon at room temperature.  Copper (I) iodide (0.011 g, 0.070 
mmol), TBTA (0.038 g, 0.00 mmol), and Hunig’s base (0.2 mL) were then added to the 
reaction mixture, and stirring continued for 24 h. The reaction mixture was diluted with 
CH Cl  (20 mL) and washed with 1:4 NH OH/saturated NH2 2 4 4Cl (3 x 30 mL) and saturated 
NH Cl (30 mL).  The organic layer was dried over Na4 2SO4 and concentrated in vacuo.  
The crude product was purified by prep TLC (silica, 12:1:0.1 CH Cl /MeOH/conc. 2 2
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OH) to give 30 mg (63%) of 34a as a yellowish solid. 1NH H-NMR (CDCl4 3, 400MHz) δ 
0.82-2.39 (52H, m), 2.56-2.72 (4H, m), 2.93-3.01 (3H, m), 3.18 (3H, s), 3.40-3.69 (10H, 
m), 3.96-4.08 (2H, m), 4.33-4.44 (4H, m), 4.79-4.94 (1H, m), 7.26 (2H, d, J = 7.6 Hz), 
7.70 (2H, d, J = 7.6 Hz), 7.79 (1H, s); 13C-NMR (CDCl3, 100MHz) δ 11.3, 11.9, 14.4, 
17.0, 18.3, 21.1, 21.6, 21.7, 22.0, 22.9, 24.6, 25.1, 25.8, 29.9, 37.0, 58.6, 61.7, 64.1, 65.8, 
69.3, 71.4, 72.9, 74.3, 75.7, 76.2, 78.1, 94.4, 97.1, 101.6, 120.0, 125.8, 129.2, 147.9, 
170.3, 176.3; HRMS (MALDI, CHCA) calc for [C54H90N6O15 + H]+ 1063.6536, found 
1063.6329. 
 
O-3’-Acetylated-azithromycin-N-benzyltriazolylheptahydroxamic acid (34b).  
Reaction of O-3’-Acetylated-4’-ethynylbenzyl azithromycin 33a (0.040 g, 0.045 mmol) 
and 7-azidoheptahydroxamic acid 24b (0.020 g, 0.114 mmol)within 24 h, as described for 
the synthesis of compound 34a, followed by prep TLC (silica, 12:1:0.1 
CH OH) gave 20 mg (42%) of 34b as a yellowish solid. . 1Cl /MeOH/conc. NH2 2 4 H-NMR 
(CDCl3, 400MHz) δ 0.84-2.36 (54H, m), 2.62-2.74 (4H, m), 2.95-3.04 (3H, m), 3.21 (3H, 
s), 3.40-3.71 (10H, m), 3.97-4.12 (2H, m), 4.36-4.45 (4H, m), 4.79 (1H, m), 7.29 (2H, d, 
J = 8.0 Hz), 7.72 (2H, d, J = 7.6 Hz), 7.78 (1H, s); 13C-NMR (CDCl3, 100MHz) δ 8.0, 
11.1, 11.7, 14.1, 18.0, 20.8, 20.9, 21.3, 21.5, 23.9, 24.9, 25.6, 27.9, 29.6, 29.8, 30.7, 31.8, 
32.4, 35.0, 36.7, 45.4, 49.3, 50.0, 58.3, 61.0, 61.5, 65.5, 69.1, 71.1, 72.7, 74.0, 75.6, 76.1, 
77.9, 96.9, 101.6, 119.6, 121.5, 128.9, 129.0, 139.8, 147.7, 170.1, 176.3; HRMS 
(MALDI, CHCA) calc for [C55H92N6O15 + H]+ 1077.6693, found 1077.6488. 
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O-3’-14C-Acetylated-azithromycin-N-benzyltriazolylhexahydroxamic acid (34c).  
Reaction of O-3’-14C-acetylated-4’-ethynylbenzyl azithromycin 33b (0.070 g, 0.078 
mmol) and 6-azidohexahydroxamic acid 24a (0.040 g, 0.231 mmol)within 24 h, as 
described for the synthesis of compound 34a, followed by prep TLC (silica, 12:1:0.1 
CH Cl /MeOH/conc. NH2 2 4OH) gave 22 mg (27%) of 34c as a yellowish solid. [>95 % 
purity, TLC: CHC OH 12:1:0.1] Cl /MeOH/ NH2 2 4
 
O-3’-14C-Acetylated-azithromycin-N-benzyltriazolylheptahydroxamic acid (34d).  
Reaction of O-3’-14C-acetylated-4’-ethynylbenzyl azithromycin 33b (0.070 g, 0.078 
mmol) and 7-azidoheptahydroxamic acid 24b (0.040 g, 0.230 mmol)within 24 h, as 
described for the synthesis of compound 34a, followed by prep TLC (silica, 12:1:0.1 
CH Cl /MeOH/conc. NH2 2 4OH) gave 16 mg (19%) of 34d as a yellowish solid. [>95 % 
purity, TLC: CHC OH 12:1:0.1] Cl /MeOH/ NH2 2 4
 
HDAC Activity Assay. In Vitro HDAC inhibition was assayed using the HDAC 
Fluorimetric Assay/Drug Discovery Kit as previously described.17, 19  Briefly, 15 μl HeLa 
Nuclear extract was mixed with 5μl 10X compound and 5μl Assay Buffer.  Fluorogenic 
substrate was added and reaction was allowed to proceed for 15 min at room temperature 
and then stopped by addition of a developer containing TSA.  Fluorescence was 
monitored after 15 min at excitation and emission wavelengths of 360 and 460 nm, 
respectively. IC50 values were determined using logit plots. 
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Cell Culture and Viability. SK-MES-1 and NCI-H69 lung cancer cell lines and DU-145 
prostate cancer cell line were obtained from ATCC (Manassas, VA) and were maintained 
in the recommended complete growth mediums.  MCF-7 cell line (a generous gift from 
Dr. Al Merill) was maintained in EMEM containing 10% fetal bovine serum. Human 
mammary epithelial cells (HMEC) (Lonza Biosciences) were maintained in complete 
MEGM per product instructions.  Human normal lung fibroblasts (a generous gift from 
Dr. Barker) were maintained in EMEM containing 10 percent FBS. All cell lines were 
maintained in a 37 °C environment containing 5 % CO2.  All compounds to be tested 
were dissolved to a concentration of 10 mM in DMSO and stored at -80 °C.  For cell 
viability experiments, cells were passaged 24 h prior to dosing.  All compounds were 
diluted to appropriate concentrations in DMSO and fresh medium such that the final 
concentration of DMSO was 0.1%.  To control wells, only fresh medium was added.  
Viability was assessed after 72 h by Trypan Blue staining. 
 
2.5.4 Nuclear Targeting HDACi Experimental 
Ethyl 6-(4-anilyl)triazolylhexanoate (35a). Ethyl 6-azidohexanoate 2c (0.711 g, 3.84 
mmol) and 4-ethynylaniline (0. 300g, 2.56 mmol) were dissolved in anhydrous THF (7 
mL) and stirred under argon at room temperature.  Copper (I) iodide (0.011 g, 0.07 
mmol) and Hunig’s base (0.3 mL) were then added to the reaction mixture, and stirring 
continued for 24 h.  The reaction mixture was diluted with CH Cl2 2 (10 mL) and washed 
with 1:4 NH OH/saturated NH Cl (3 x 30 mL) and saturated NH4 4 4Cl (30 mL).  The 
organic layer was dried over Na2SO4 and concentrated in vacuo.  The crude product was 
purified by flash chromatography (silica, gradient 1:1; 1:2; 1:3 Hexane/EtOAc) to give 
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696 mg (90%) of 35a as yellowish solid. 1H NMR (CDCl3, 400 MHz) δ 1.19 (3H, t, J = 
7.2 Hz), 1.29-1.37 (2H, m), 1.59-1.67 (2H, m), 1.86-1.94 (2H, m), 2.25 (2H, t, J = 7.6 
Hz), 4.07 (2H, q, J = 14.0, 6.8 Hz), 4.32 (2H, t, J = 7.2 Hz), 6.68 (2H, d, J = 8.0 Hz), 7.58 
(3H, t, J = 3.6 Hz); 13C NMR (CDCl3, 100MHz) δ 14.1, 21.4, 25.8, 29.9, 33.8, 49.9, 60.2, 
115.1, 118.1, 121.0, 126.7, 146.4, 148.0, 173.3 
 
Ethyl 7-(4-anilyl)triazolylheptanoate (35b). Reaction of ethyl 7-azidoheptanoate 2d 
(0.711 g, 3.57 mmol) and 4-ethynylaniline (0. 300g, 2.56 mmol) within 24 h as described 
for the synthesis of 35a, followed by flash chromatography (silica, gradient 1:1; 1:2; 1:3 
Hexane/EtOAc) gave 700 mg (87%) of 35b as yellowish solid. 1H NMR (CDCl3, 400 
MHz) δ 1.15 (3H, t, J = 7.2 Hz), 1.20-1.30 (4H, m), 1.48-1.54 (2H, m), 1.78-1.82 (2H, 
m), 2.18 (2H, t, J = 7.2 Hz), 4.02 (2H, q, J = 14.4, 6.8 Hz), 4.22 (2H, t, J = 7.2 Hz), 6.62 
(2H, d, J = 8.4 Hz), 7.51 (1H, s), 7.53 (2H, d, J = 4.8 Hz); 13C NMR (CDCl3, 100MHz) δ 
13.9, 24.3, 25.8, 28.1, 29.8, 33.8, 49.8, 59.9, 114.9, 118.0, 120.6, 126.5, 146.4, 147.7, 
173.3 
 
Methyl 8-(4-anilyl)triazolyloctanoate (35c). Reaction of methyl 8-azidooctanoate 2e 
(1.200 g, 6.03 mmol) and 4-ethynylaniline (0. 500g, 4.27 mmol) within 24 h as described 
for the synthesis of 35a, followed by flash chromatography (silica, gradient 1:1; 1:2; 1:3 
Hexane/EtOAc) gave 923 mg (69%) of 35c as yellowish solid. 1H NMR (CDCl3, 400 
MHz) δ 1.24-1.32 (6H, m), 1.54-1.58 (2H, m), 1.84-1.87 (2H, m), 2.24 (2H, t, J = 7.6 
Hz), 3.61 (3H, s), 4.29 (2H, t, J = 7.2 Hz), 6.67 (2H, d, J = 8.4 Hz), 7.56 (2H, d, J = 2.0 
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Hz), 7.58 (1H, s); 13C NMR (CDCl3, 100MHz) δ 24.6, 26.1, 28.5, 28.7, 30.1, 33.8, 50.1, 
51.3, 115.0, 118.0, 121.0, 126.7, 146.4, 147.9, 174.0 
 
Ethyl 6-(4-azidophenyl)triazolylhexanoate (36a).  To a solution of ethyl 6-(4-
anilyl)triazolylhexanoate 35a (0.676 g, 2.238 mmol) in 17.2% aqueous HCl (15 mL) at 0 
°C was added NaNO2 (0.140 g, 2.027 mmol) and stirring continued at 0 °C for 1 h. 
Sodium azide (0.270 g, 4.153 mmol) was then added and stirring continued at 0 °C for 
additional 3 h.  The reaction was poured into cold water (30 mL) and extracted with 
CH Cl2 2 (3 x 30 mL). The combined organic layer was washed with saturated brine (30 
mL) and dried over dried over Na2SO4. Solvent was evaporated off to give 400 mg of 
compound 36a as a yellow solid. The crude 36a was used in the next step without further 
purification. 
 
Ethyl 7-(4-azidophenyl)triazolylheptanoate (36b).  To a solution of ethyl 7-(4-
anilyl)triazolylheptanoate 35b (0.300 g, 0.948 mmol) in 17.2% aqueous HCl (5 mL) at 0 
°C was added NaNO2 (0.062 g, 0.898 mmol) and stirring continued at 0 °C for 1 h. 
Sodium azide (0.120 g, 1.846 mmol) was then added and stirring continued at 0 °C for 
additional 3 h.  The reaction was poured into cold water (20 mL) and extracted with 
CH Cl2 2 (3 x 20 mL). The combined organic layer was washed with saturated brine (20 
mL) and dried over dried over Na2SO4. Solvent was evaporated off to give 132 mg of 
compound 36b as a yellow solid. The crude 36b was used in the next step without further 
purification. 
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Methyl 8-(4-azidophenyl)triazolyloctanoate (36c).  To a solution of methyl 8-(4-
anilyl)triazolyloctanoate 35c (0.519 g, 1.642 mmol) in 17.2% aqueous HCl (10 mL) at 0 
°C was added NaNO2 (0.107 g, 1.550 mmol) and stirring continued at 0 °C for 1 h. 
Sodium azide (0.207 g, 3.185 mmol) was then added and stirring continued at 0 °C for 
additional 3 h.  The reaction was poured into cold water (20 mL) and extracted with 
CH Cl2 2 (3 x 20 mL). The combined organic layer was washed with saturated brine (20 
mL) and dried over dried over Na2SO4. Solvent was evaporated off to give 332 mg of 
compound 36c as a yellow solid. The crude 36c was used in the next step without further 
purification. 
 
6-(4-azidophenyl)hexanoic acid (37a). To a solution of ethyl 6-(4-
azidophenyl)hexanoate 36a (0.180 g, 0.549 mmol) in 3:1 THF (6 mL) and distilled water 
(2 mL) was added lithium hydroxide monohydrate (0.066 g, 1.573 mmol) and the stirring 
continued for 24 h.  The reaction was partitioned between distilled water (10 mL) and 
EtOAc (20 mL).  The two layers were separated, and the aqueous layer was extracted 
with EtOAc (2 x 20 mL).  The aqueous layer was acidified to pH 2 in an ice bath with 1N 
HCl and extracted with EtOAc (3 x 20 mL).  The combined organic layer was dried over 
Na  and concentrated in vacuo to give 164 mg (100%) of 37a as a yellowish solid.  SO2 4
1H-NMR (DMSO-d6, 400MHz) δ 1.23-1.29 (2H, m), 1.48-1.55 (2H, m), 1.82-1.87 (2H, 
m), 2.19 (2H, t, J = 7.2 Hz), 4.36 (2H, t, J = 6.8 Hz), 7.18 (2H, d, J = 8.4 Hz), 7.86 (2H, 
d, J = 7.2 Hz), 8.57 (1H, s), 12.0 (1H, s); 13C NMR (DMSO-d6, 100MHz) δ 23.8, 25.4, 
29.3, 33.4, 49.4, 119.6, 121.1, 126.6, 127.8, 138.6, 145.5, 174.3 
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7-(4-azidophenyl)triazolylheptanoic acid (37b).  Reaction of ethyl 7-
(azidophenyl)triazolylheptanoate 36b (0.120 g, 0.350 mmol) and lithium hydroxide 
monohydrate (0.044g, 1.049 mmol) within 24 h as described for the synthesis of 37a 
gave 108 mg (100%) of 37b as pale yellowish solid. 1H NMR (DMSO-d6, 400 MHz) δ 
1.23-1.32 (4H, m), 1.43-1.50 (2H, m), 1.79-1.87 (2H, m), 2.17 (2H, t, J = 7.2 Hz), 4.36 
(2H, t, J = 7.6 Hz), 7.17 (2H, d, J = 8.8 Hz), 7.86 (2H, d, J = 8.4 Hz), 8.57 (1H, s), 11.9 
(1H, br s); 13C NMR (DMSO-d6, 100MHz) δ 24.2, 25.5, 27.8, 29.4, 33.5, 49.4, 119.6, 
121.1, 126.6, 127.8, 138.6, 145.4, 174.4 
 
 8-(4-azidophenyl)triazolyloctanoic acid (37c).  Reaction of methyl 8-
(azidophenyl)triazolyloctanoate 36c (0.332 g, 0.971 mmol) and lithium hydroxide 
monohydrate (0.122g, 2.909 mmol) within 24 h as described for the synthesis of 37a 
gave 317 mg (100%) of 37c as pale yellowish solid. 1H NMR (DMSO-d6, 400 MHz) δ 
1.26(6H, br s), 1.40-1.51 (2H, m), 1.79-1.87 (2H, m), 2.16 (2H, t, J = 7.2 Hz), 4.36 (2H, 
t, J = 7.6 Hz), 7.17 (2H, d, J = 8.8 Hz), 7.86 (2H, d, J = 8.4 Hz), 8.57 (1H, s), 11.9 (1H, 
br s); 13C NMR (DMSO-d6, 100MHz) δ 24.3, 25.7, 28.0, 28.3, 29.5, 33.5, 49.5, 119.6, 
121.1, 126.6, 127.8, 138.6, 145.5, 174.4 
 
6-(azidophenyl)triazolyl-O-trityl hexahydroxamate (38a). To a solution of 6-(4-
azidophenyl)triazolylhexanoic acid 37a (0.100 g, 0.333 mmol) in anhydrous DMF (3 mL) 
was added EDC (0.083 g, 0.433 mmol), HOBT (0.067 g, 0.496 mmol), and NMM (0.05 
mL, 0.455 mmol) in succession. Stirring continued under Ar for 20 mins.  O-trityl 
hydroxamine (0.120 g, 0.435 mmol) was then added to the reaction mixture, and stirring 
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continued under Ar for 24 h.  The reaction was diluted with CH Cl2 2 (10 mL) and wash 
with ½ saturated NaHCO3 (2 x 15 mL), distilled water (15 mL), and saturated brine (15 
mL).  The organic layer was dried over Na2SO4 and concentrated in vacuo. The crude 
product was purified by flash chromatography (silica, 1:1 Hexane/EtOAc) to give to give 
135 mg (73%) of 38a as a yellowish solid.  1H-NMR (CDCl3, 400MHz) δ 0.98-1.08 (2H, 
m), 1.23-1.32 (2H, m), 1.54-1.62 (2H, br s), 1.72-1.84 (2H, m), 4.29 (2H, t, J = 7.2 Hz), 
7.05 (2H, d, J = 8.4 Hz), 7.29 (15H, br s), 7.43 (1H, br s), 7.68 (1H, s), 7.80 (2H, d, J = 
8.8 Hz); 13C NMR (CDCl3, 100MHz) δ 22.4, 25.7, 29.9, 30.7, 50.0, 93.3, 119.4, 127.0, 
127.5, 128.1, 128.9, 139.6, 140.9, 141.7, 146.8, 176.6; HRMS (ESI) calcd for 
[C  33H31N7O + Na]+ 580.2437, found 580.2383 2
 
7-(azidophenyl)triazolyl-O-trityl heptahydroxamate (38b).  Reaction of 7-
(azidophenyl)triazolylheptanoic acid 37b (0.105 g, 0.334 mmol) and O-trityl 
hydroxylamine (0.120g, 0.435 mmol) within 24 h as described for the synthesis of 38a 
followed by flash chromatography (silica, 1:1 Hexane/EtOAc),  gave 140 mg (74%) of 
38b as yellowish solid. 1H NMR (CDCl3, 400 MHz) δ 1.06-1.23 (6H, m), 1.56-1.61 (2H, 
m), 1.81-1.87 (2H, m), 4.31 (2H, t, J = 6.4 Hz), 7.05 (2H, d, J = 8.4 Hz), 7.30 (15H, br s), 
7.44 (1H, br s), 7.67 (1H, s), 7.79 (2H, d, J = 8.4 Hz); 13C NMR (CDCl3, 100MHz) δ 
23.0, 26.0, 28.2, 29.6, 30.1, 31.0, 50.2, 119.2, 119.4, 127.0, 127.5, 128.1, 129.0, 139.6, 
141.0, 141.8, 146.9, 176.8; HRMS (ESI) calcd for [C  34H33N7O + Na]+2  594.2593, found 
594.2575 
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8-(azidophenyl)triazolyl-O-trityl octahydroxamate (38c).  Reaction of 8-
(azidophenyl)triazolyloctanoic acid 37c (0.100 g, 0.309 mmol) and O-trityl 
hydroxylamine (0.120g, 0.435 mmol) within 24 h as described for the synthesis of 38a 
followed by flash chromatography (silica, 1:1 Hexane/EtOAc),  gave 133 mg (74%) of 
38c as brown solid. 1H NMR (CDCl3, 400 MHz) δ 0.95-1.10 (2H, m), 1.25 (6H, br s), 
1.50-1.70 (2H, m), 1.86-1.90 (2H, m), 4.35 (2H, t, J = 6.8 Hz), 7.07 (2H, d, J = 8.0 Hz), 
7.32 (15H, br s), 7.45 (1H, br s), 7.71 (1H, s), 7.81 (2H, d, J = 8.0 Hz); 13C NMR (CDCl3, 
100MHz) δ 23.2, 26.1, 28.5, 29.6, 30.1, 31.0, 50.3, 119.1, 119.4, 127.0, 127.5, 128.1, 
129.0, 139.6, 141.0, 141.8, 146.9, 176.8; HRMS (ESI) calcd for [C  35H35N7O + H]+2  
586.2925, found 586.2944 
 
N-Boc NLS triazole-linked phenyltriazolyl-O-trityl hexahydroxamates (39a).  6-
(azidophenyl)triazolyl-O-trityl hexahydroxamate 38a (0.010 g, 0.018 mmol) and alkyne-
modified NLS peptides PCS-37689-PI (0.020 g, 0.010 mmol) were dissolved in 
anhydrous THF (4 mL) and anhydrous DMF (1 mL) stirred under argon at room 
temperature.  Copper (I) iodide (0.001 g, 0.006 mmol), TBTA (0.006 g, 0.011 mmol), 
and Hunig’s base (0.01 mL) were then added in succession to the reaction mixture, and 
stirring continued for 24 h.  The reaction mixture was diluted with CH Cl2 2 (10 mL) and 
washed with 1:4 NH OH/saturated NH Cl (3 x 30 mL) and saturated NH4 4 4Cl (30 mL).  
The organic layer was dried over Na SO2 4 and concentrated in vacuo.  The crude product 
was purified by prep TLC (silica, 12:1:0.1 CH Cl2 2/MeOH/NH4OH) to give 23 mg (99%) 
of 39a as brown solid. 1H-NMR (DMSO-d6, 400MHz) δ 0.81-1.98 (110H, m), 2.69-3.00 
(15H, m). 3.15 (3H, d, J = 5.2 Hz), 3.61 (2H, d, J = 6.0 Hz), 3.72 (6H, br s), 4.08-4.32 
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(8H, m), 6.71 (4H, br s), 7.30 (10H, br s), 7.78-8.21 (13H, m), 8.63 (2H, d, J = 5.2 Hz), 
10.1 (1H, s); HRMS (ESI) calc for [C122H179N27O26S + Na + H]2+ 2494.3200, found 
2494.2948 
 
N-Boc NLS triazole-linked phenyltriazolyl-O-trityl heptahydroxamates (39b).   
Reaction of  7-(azidophenyl)triazolyl-O-trityl heptahydroxamate 38b (0.010 g, 0.018 
mmol) and alkyne-modified NLS peptides PCS-37689-PI (0.020g, 0.010 mmol) within 
24 h as described for the synthesis of 39a, followed by prep TLC (silica, 12:1:0.1 
CH 1OH),  gave 23 mg (99%) of 39b as yellowish solid.  Cl /MeOH/NH2 2 4 H-NMR 
(DMSO-d6, 400MHz) δ 0.81-1.98 (112H, m), 2.61-2.98 (15H, m), 3.49 (3H, s), 3.61 (2H, 
d, J = 5.6 Hz), 3.68-3.78 (6H, m), 4.08-4.28 (4H, m), 4.32-4.39 (2H, m), 4.46 (2H, d, J = 
4.8 Hz), 6.72 (4H, br s), 7.30 (15H, br s), 7.57-8.45 (13H, m), 8.63 (1H, s), 8.67 (1H, s), 
10.1 (1H, s); HRMS (ESI) calc for [C123H181N27O26S + 2H]2+ 2486.3310, found 
2486.3338 
 
N-Boc NLS triazole-linked phenyltriazolyl-O-trityl octahydroxamates (39c).   
Reaction of  N-Boc 8-(azidophenyl)triazolyl-O-trityl octahydroxamate 38c (0.015 g, 
0.026 mmol) and alkyne-modified NLS peptides PCS-37689-PI (0.020g, 0.010 mmol) 
within 24 h as described for the synthesis of 39a, followed by prep TLC (silica, 12:1:0.1 
CH OH), gave 24 mg (100%) of 39c as yellowish solid.  1Cl /MeOH/NH2 2 4 H-NMR 
(DMSO-d6, 400MHz) δ 0.81-1.98 (114H, m), 2.65-2.98 (15H, m), 3.49 (3H, s), 3.61 (2H, 
d, J = 6.0 Hz), 3.68-3.78 (6H, m), 4.09-4.30 (4H, m), 4.39 (2H, t, J = 5.6 Hz), 4.47 (2H, 
d, J = 4.8 Hz), 6.73 (4H, br s), 7.29 (15H, br s), 7.58-8.25 (13H, m), 8.63 (1H, s), 8.68 
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(1H, s), 10.1 (1H, s); HRMS (ESI) calc for [C123H183N27O26S + Na]+ 2523.3155, found 
2523.3111 
 
NLS triazole-linked phenyltriaozlylhexahydroxamate (40a).  N-Boc NLS O-trityl 
hexahydroxamates 39a (0.010 g, 0.004 mmol) was dissolved in 90:5:5 TFA/TIPS/phenol 
(1 mL) and stirring continued for 2 h.  The reaction mixture was divided into two equal 
halves by volume and pipette into two 1.5 mL ependorf tubes.  Anhydrous diethyl ether 
(1 mL) was added into each ependorf tubes, and white precipitates were observed upon 
the addition of solvent.  The eppendorf tubes were then vortex for 1 min, and further 
centrifuge down at 5000 rpm for 5 mins.  The supernatant were removed and additional 
anhydrous diethyl ether (1 mL) was added into each eppendorf tube, followed by vortex 
and centrifugation.  This process was repeated one more time, and the residual 
precipitates were air-dried for 20 mins and concentrate in vacuo.  The residues were 
redissolved in distilled water, freezed in an acetone-dry ice bath, and lyophilized 
overnight to give 6 mg (100%) of 40a as pale yellowish solid.  Partial 1H-NMR (DMSO-
d6, 400MHz) δ 0.82 (8H, t, J = 6.4 Hz), 1.07 (8H, t, J = 8.4 Hz), 1.27-1.62 (30H, m), 
1.85-1.95 (14H, m), 2.23-2.72 (10H, m), 3.38-4.39 (14H, m), 6.72 (1H, d, J = 8.4 Hz), 
7.08-7.15 (3H, m), 7.31 (3H, s), 7.60-7.78 (11H, br s), 7.94-8.08 (8H, m), 8.18-8.24 (3H, 
m), 8.62 (1H, s), 8.68 (1H, s), 10.38 (1H, s); HRMS (ESI) calcd for [C70H117 N27O15 + 
H]+ 1576.9300, found 1576.9420 
NLS triazole-linked phenyltriaozlylheptahydroxamate (40b).   Reaction of N-Boc 
NLS O-trityl heptahydroxamates 39b (0.010 g, 0.004 mmol) within 2 h as described for 
the synthesis of 40a gave 6 mg (100%) of 40b as yellowish solid.  Partial 1H-NMR 
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(DMSO-d6, 400MHz) δ 0.83 (8H, t, J = 6.0 Hz), 1.03-1.62 (41H, m), 1.85-1.97 (14H, m), 
2.22-2.73 (10H, m) 3.36-4.39 (14H, m), 6.71 (1H, d, J = 8.4 Hz), 7.10 (3H, s), 7.32 (3H, 
s), 7.60-7.85 (11H, br s), 7.95-8.10 (8H, m), 8.20-8.25 (3H, m), 8.64 (1H, s), 8.69 (1H, s), 
10.34 (1H, s); HRMS (MALDI) calc for [C71H119N27O15 + H]+ 1590.9451, found 
1590.9450 
 
NLS triazole-linked phenyltriaozlyloctahydroxamate (40c).   Reaction of N-Boc NLS 
O-trityl octahydroxamates 39c (0.010 g, 0.004 mmol) within 2 h as described for the 
synthesis of 40a gave 6 mg (100%) of 40c as pale yellowish solid.  Partial 1H-NMR 
(DMSO-d6, 400MHz) δ 0.83 (8H, t, J = 4.4 Hz), 1.03-1.63 (43H, m), 1.85-2.02 (14H, m), 
2.22-2.74 (10H, m), 3.34-4.42 (14H, m), 6.71 (1H, d, J = 8.4 Hz), 7.10-7.18 (3H, m), 
7.32 (1H, s), 7.60-7.82 (11H, m), 7.95-8.10 (8H, m), 8.20-8.24 (3H, m), 8.64 (1H, s), 
8.70 (1H, s), 10.33 (1H, s); HRMS (MALDI) calc for [C72H121N27O15 + H]+ 1604.9699, 
found 1604.9608 
 
Alkyne BODIPY (42).  Alkyne aldehyde 41 (0.450 g, 2.22 mmol) and 2,4-
dimethylpyrrole (0.47 mL, 4.50 mmol) were dissolves in anhydrous CH Cl2 2 (40 mL).  
Two drops of trifluoroacetic acid were added, and the solution was stirred at room 
temperature (covered with tin foil) overnight.  A solution of 2,3-dichloro-5,6-dicyano-p-
benzoquinone (0.514 g, 2.22 mmol) in CH Cl2 2 (30 mL) was added and stirring continued 
at room temperature for 4 h.  Triethylamine (12 mL) was added to the reaction followed 
by a dropwise addition of BF o:OEt  (12 mL) within 30 mins at 03 2 C.  The reaction was 
graduatlly warmed to room temperature, and stirring continued overnight.  The reaction 
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was washed with dilute NaHCO3 (60 mL).  The organic layer was passed through a celite 
plug, which the celite was washed with more CH Cl2 2 (30 mL).  The combined organic 
layer was washed with distilled water, dried over Na SO2 4, and concentrated in vacuo.  
The crude product was purified by flash chromatography (silica, gradient 10:1; 8:1 
Hexane/EtOAc) to give 340 mg (54%) of 42 as reddish solid. 1H NMR (CDCl3, 400 
MHz) δ 1.40 (6H, s), 1.72-1.76 (2H, m), 1.91-1.97 (3H, m), 2.26-2.30 (2H, m), 2.52 (6H, 
s), 4.01 (2H, t, J = 6.0 Hz), 5.95 (2H, s), 6.96 (2H, d, J = 8.0 Hz), 7.12 (2H, d, J = 8.0 
Hz); 13C NMR (CDCl3, 100MHz) δ 14.5, 18.1, 25.0, 28.2, 67.3, 68.7, 83.9, 114.9, 121.0, 
126.9, 129.1, 131.8, 141.8, 143.1, 155.1, 159.5 
 
BODIPY-4-triazolylbenzyl alcohol (43).  Reaction of alkyne BODIPY 39 (0.050g, 
0.119 mmol) and 4-azidobenzyl alcohol (0.035g, 0.238 mmol) within 24 h as described 
for the synthesis of 35a, followed by flash chromatography (silica, 1:2 Hexane/EtOAc) 
gave 66 mg (99%) of 43 as reddish solid. 1H NMR (CDCl3, 400 MHz) δ 1.22 (2H, t, J = 
7.2 Hz), 1.38 (6H, s), 1.91-1.93 (2H, m), 2.50 (6H, s) 2.86 (2H, t, J = 7.6 Hz) 4.01-4.10 
(2H, m), 4.73 (2H, s), 5.93 (2H, s), 6.95 (2H, d, J = 8.4 Hz), 7.09 (2H, d, J = 8.4 Hz), 
7.46 (2H, d, J = 8.0 Hz), 7.66 (2H, d, J = 8.4 Hz), 7.75 (1H, s); 13C NMR (CDCl3, 
100MHz) δ 14.5, 20.9, 25.2, 25.9, 28.7, 29.6, 60.3, 64.1, 67.5, 114.9, 118.9, 120.3, 121.0, 
126.8, 127.9, 129.0, 131.7, 136.1, 141.6, 141.8, 143.1, 148.4, 155.1, 159.4 
 
BODIPY-4-triazolylbenzyl mesylate (44).  Triethylamine (0.06 mL, 0.400 mmol) was 
added to a solution of BODIPY-4-triazolylbenzyl alcohol 43 (0.076 g, 0.134 mmol) in 
anhydrous CH2Cl  (5 mL).  The reaction mixture was stirred for 15 minutes at 0oC, and 2
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then methanesulfonyl chloride (0.03 mL, 0.400 mmol) was added.  The reaction mixture 
is allowed to warm up to room temperature and stirring continued for 5 h.  The reaction 
mixture was quenched with ice cold distilled water (10 mL) and extracted with anhydrous 
diethyl ether (2 x 10 mL).  The combined organic layer was washed in succession with 1 
N HCl, distilled water, saturated NaHCO3, and then again with distilled water.  The 
organic layer was dried over Na2SO4, and concentrated in vacuo to give 85 mg (99 %) of 
crude 44 as reddish solid. 1H-NMR (CDCl3, 400MHz) δ 1.21 (2H, br s), 1.37 (6H, s), 
1.91 (2H, br s), 2.48 (6H, s), 2.84 (2H, br s), 3.63 (3H, s), 4.02 (2H, br s), 5.23 (2H, s), 
5.92 (2H, s), 6.94 (2H, d, J = 8.4 Hz), 7.07 (2H, d, J = 8.4 Hz), 7.52 (2H, d, J = 8.4 Hz), 
7.54 (2H, d, J = 8.4 Hz), 7.8 (1H, br s); 13C NMR (CDCl3, 100MHz) δ 14.4, 25.1, 25.8, 
29.5, 31.4, 38.0, 52.4, 67.4, 70.1, 114.8, 120.3, 120.9, 126.6, 128.9, 129.9, 131.6, 133.7, 
137.5, 141.8, 143.0 154.9, 159.4 
 
BODIPY-4-triazolylbenzyl azide (45).   Sodium azide (0.038 g, 0.593 mmol) was added 
to a solution of BODIPY-4-triazolylbenzyl mesylate 44 (0.096 g, 0.148 mmol) in 
anhydrous DMF (5 mL).  The reaction mixture was heated to 60oC and stirring continued 
for 3 h.  The reaction mixture was then cooled to room temperature and quenched with 
distill water (10 mL).  The cooled reaction mixture was extracted with dichloromethane 
(3 x 10 mL), and the combined organic layers were washed with distilled water (3 x 10 
mL), saturated brine (2 x 10 mL), and dried over Na SO2 4.  The solvent was removed and 
concentrated in vacuo.  The crude product was purified by prep TLC (silica, 1:1 
Hexane/EtOAc) to give 56 mg (64%) of 45 as reddish solid.  1H-NMR (CDCl3, 400MHz) 
δ 1.20-1.23 (2H, m), 1.38 (6H, s), 1.91-1.93 (2H, m), 2.50 (6H, m), 2.87 (2H, t, J = 6.8 
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Hz), 4.01-4.10 (2H, m), 4.38 (2H, s), 5.93 (2H, s), 6.95 (2H, d, J = 8.4 Hz), 7.09 (2H, d, J 
= 8.4 Hz), 7.43 (2H, d, J = 8.4 Hz), 7.72 (2H, d, J = 8.4 Hz), 7.77 (1H, s); 13C NMR 
(CDCl3, 100MHz) δ 14.4, 25.2, 25.8, 28.6, 29.5, 53.9, 60.3, 67.5, 114.9, 118.8, 120.5, 
121.0, 126.7, 129.0, 129.3, 131.7, 135.8, 136.8, 141.8, 143.0, 148.5, 155.0, 159.4; HRMS 
(FAB, thioglycerol) calcd for [C O] 594.2838, found 594.1867 32H33 BF N2 8
 
N-Boc NLS triazole-linked benzyltriazolyl-BODIPY (46).  Reaction of  BODIPY-4-
triazolylbenzyl azide 45 (0.010 g, 0.018 mmol) and alkyne-modified N-Boc NLS peptides 
PCS-37689-PI (0.015g, 0.008 mmol) within 24 h as described for the synthesis of 39a, 
followed by prep TLC (silica, 12:1:0.1 CH Cl /MeOH/NH2 2 4OH), gave16 mg (94%) of 46 
as orange solid.  Partial 1H-NMR (DMSO-d6, 400MHz) δ 0.81 (13H, br s), 1.08 (12H, t, J 
= 6.8 Hz), 1.19-1.46 (51H, m), 1.59 (7H, br s), 1.78-1.84 (11H, m), 1.99 (7H, s), 2.16-
2.20 (8H, m), 2.58-2.65 (7H, m), 2.78-2.85 (12H, m), 2.94-2.99 (7H, m), 3.62 (2H, d, J = 
5.6 Hz), 3.69-3.73 (6H, m), 4.07-4.46 (10H, m), 5.61 (2H, s), 6.15 (2H, s), 6.71 (3H, br 
s), 7.08 (3H, t, J = 8.4 Hz), 7.23 (3H, d, J = 6.8 Hz), 7.47 (2H, d, J = 8.0 Hz), 7.86-8.20 
(12H, m), 8.59 (1H, s); HRMS (ESI) calcd for [C121H181BN28O25 F S + 2H]2+ 2 2505.3680, 
found 2505.3240 
 
NLS triazole-linked benzyltriazolyl-BODIPY (47).  Reaction N-Boc NLS triazole-
linked benzyltriazolyl-BODIPY dye 46 (0.016 g, 0.006 mmol) within 2 h as described for 
the synthesis of 40a gave 11 mg (100%) of 47 as reddish solid.  1H-NMR (DMSO-d6, 
400MHz) δ 0.82 (6H, t, J = 6.0 Hz), 1.02 (2H, s), 1.28-1.93 (67H, m), 2.18 (5H, t, J = 8.4 
Hz), 3.04 (2H, br s) 3.62 (3H, d, J = 6.0 Hz), 3.70-3.74 (8H, m), 3.09 (5H, br s), 4.01-
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4.32 (9H, m), 5.61 (2H, s), 6.22 (1H, s), 6.47 (1H, s), 7.08 (1H, s), 7.14-7.17 (2H, m), 
7.31-7.34 (3H, m), 7.47 (2H, d, J = 8.0 Hz), 7.60-8.23 (12H, m), 8.59 (1H, s); HRMS 
(MALDI, CHCA) calcd for [C88H133BN28O25 F2S + 2H-BF ]2+2  1808.0824, found 
1808.0710 
 
BODIPY triazole-linked phenyltriazolyl-O-triyl hexahydroxamates (48).  Reaction of  
6-(azidophenyl)triazolyl-O-trityl hexahydroxamate 38a (0.095 g, 0.171 mmol) and 
alkyne BODIPY 42 (0.048g, 0.114 mmol) within 24 h as described for the synthesis of 
39a, followed by prep TLC (silica, 1:3 Hexane/EtOAc), gave 86 mg (77%) of 48 as 
reddish solid.  1H-NMR (CDCl3, 400MHz) δ 1.23 (6H, t, J = 6.8 Hz), 1.401 (6H, s), 1.52-
1.62 (2H, m), 1.70-2.01 (4H, m), 2.51 (6H, m), 2.90 (2H, t, J = 6.8 Hz), 4.03-4.12 (2H, 
m), 4.31 (2H, t, J = 6.8 Hz), 5.94 (2H, s), 6.97 (2H, d, J = 8.8 Hz), 7.12 (2H, d, J = 8.4 
Hz), 7.29 (15H, br s), 7.40 (1H, br s), 7.75-7.80 (4H, m), 7.96 (2H, d, J = 8.4 Hz); HRMS 
(ESI) calcd for [C  58H58N9O3 F B + H]+ 978.4797, found 978.4785 2
 
BODIPY triazole-linked phenyltriazolyl hexahydroxamates (49).  Reaction BODIPY 
O-trityl hexahydroxamates 48 (0.036 g, 0.036 mmol) within 2 h as described for the 
synthesis of 40a gave 11 mg (42%) of 49 as reddish solid.  1H-NMR (CD3OD, 400MHz) 
δ 1.16 (6H, t, J = 6.8 Hz), 1.30-1.41 (2H, m), 1.66-1.80 (2H, m), 1.81-2.00 (6H, br s), 
2.05-2.15 (2H, m), 2.43 (6H, s) 2.90 (2H, t, J = 6.8 Hz), 4.20 (2H, t, J = 5.2 Hz), 4.48 
(2H, t, J = 7.2 Hz), 6.42 (2H, s), 7.16 (2H, d, J = 8.8 Hz), 7.36 (2H, d, J = 8.8 Hz), 7.92 
(2H, d, J = 8.8 Hz), 8.02 (2H, d, J = 8.8 Hz), 8.41 (1H, s), 8.44 (1H, s); HRMS (FAB, 
thioglycerol) calcd for [C  39H44N9O3 F2B + 2H-BF ]2+ 688.3723, 688.3736 2
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CHAPTER 3 
 
TARGETED NUCLEAR DELIVERY OF GOLD NANOPARTICLES 
 
 
 
3.1 Gold Nanoparticles in Medicinal Application 
 
 Nanobiotechnology and nanomedicine are emerging fields engendered by 
convergence of multiple scientific fields for biologic applications and recently discovered 
novel properties of materials at the nanoscale.  Nanoparticles, because of their small sizes 
and unique properties, have been widely used in drug delivery,1-4 cellular imaging,5-9 and 
biomedical diagnostics and therapeutics.10-13  Plasmonic nanoparticles are especially 
useful for these applications because of their enhanced resonant absorption and scattering 
properties as well as strong Raman scattering, which are essential properties for their 
applications in photothermal therapy,14-25 optical imaging,26-31 and Raman probe 
design.32-38   
 Nuclear targeting of nanoparticles in live cells is generating widespread interest 
because of the prospect of developing novel diagnostic and therapeutic strategies such as 
gene therapy.  However, nuclear delivery of the nanoparticles requires bypassing the 
formidable barriers of the cellular membrane and the nuclear membrane.  The cellular 
membrane endocytoses non-specific particles on the cell surface, enveloping them with a 
phospholipid membrane and restricting interaction with the general cell cytoplasm.  The 
nuclear membrane is a double-layer membrane marked with nuclear pores that allow 
diffusion of molecules and selective uptake into the nucleus.  One common approach to 
targeted nuclear delivery is the conjugation of drug molecules and nanoparticles to 
nuclear membrane-penetrating peptides.   
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 Gold nanoparticles (AuNPs) are examples of extremely attractive candidate for 
attachment to such carrier peptides due to their small sizes, ease of preparation and 
bioconjugation,39.40 strong absorbing and scattering properties,41-44 as well as their well-
known biocompatibility.45  Tkachenko et al.,46, 47using video-enhanced color differential 
interference contrast microscopy, have demonstrated nuclear entry of 20 nm gold 
nanospheres indirectly conjugated to various nuclear localization signaling (NLS) 
peptides through a shell of bovine serum albumin (BSA) protein.  However, these gold 
nanospheres only absorb in the visible region, thus limiting their use in in vivo 
applications such as photothermal therapy, which requires near-infrared region where the 
light penetration is optimal. 
 Unlike gold (Au) nanospheres, Au nanorods possess unique optical properties 
ideal for in vivo applications.  They have two surface Plasmon absorption bands, a strong 
long-wavelength band due to longitudinal oscillation of their electrons and a weak short 
wavelength band around 520 nm due to the transverse electronic oscillation.42, 43, 48-51  
The longitudinal absorption band is very sensitive to the size of the nanorods.  By 
increasing the aspect ratio (length divide by width), the longitudinal absorption maximum 
red-shifts with an increase in the absorption intensity.  This provides the opportunity for 
their applications as near-infrared photoabsorbers and scatterers.23
 Au nanorods are provide a scaffold for observing surface-enhanced Raman 
scattering (SERS).52-59 The well-developed synthesis of nanorods with different aspect 
ratios provides the opportunity to tune the surface Plasmon band to the excitation laser to 
obtain the largest enhancement.   It has been shown that the enhancement factors on the 
order of 104-105 could be observed for the adsorbed molecules on Au nanorods, which no  
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such enhancement was observed on nanospheres.52 Biological species are known to have 
small Raman scattering cross section and sensitivity toward photochemical damage and 
interference from fluorescence when UV or visible laser excitation is used.  In order to 
overcome these difficulties, the size of Au nanorods can be adjusted to have its 
enhancement in the near-infrared region away from the biomolecular excitation transition 
that could lead to fluorescence or photo-chemical decomposition.  Moreover, the surface 
chemistry of Au nanorods allows for multiple functionalization so that the capping 
molecules, such as cetyltrimethylammonium bromide (CTAB), could be replaced or 
conjugated with many functional groups.60-63 
 In the present work, we describe the preparation of Au nanorods directly 
conjugated to a simian virus (SV40) NLS peptide through a thioalkyl-triazole linker.  
Using a simple conventional microscope in the dark field, we are able to image the 
intracellular localization of these nanorods.  Furthermore, cellular components are 
observed by surface-enhanced Raman scattering of these Au nanorod-peptide conjugates.  
Our results demonstrate that these nanorods are useful for cellular delivery applications, 
especially nuclear targeting and cellular component sensing.   
 
3.2 Peptide Conjugation to Gold Nanorods 
 The use of NLS for targeting of proteins, peptides, nucleic acids, and small 
organic molecules to the cell nucleus has been extensively investigated.46, 47, 67-72 One of 
the most studied is the NLS of SV40 Large T antigen, which has been shown to act as a 
“Trojan horse”, efficiently distributing appended payloads in to the cell nucleus.68 
However, the chemical syntheses of NLS-conjugated payloads are very difficult, often  
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Scheme 3-1.  Synthesis of thiolalkyl-triazole linked NLS peptide.  Conditions: (a) NaN3, 
DMF, 110oC; (b) MsCl, Et3N, CH2Cl2, rt; (c) potassium thioacetate, THF, reflux; (d) 
conc. HCl, methanol, reflux; (e) alkyne-modified NLS (PC-37044-PI), TBTA, CuI, 
DMF, rt.   
  
 
requiring technically challenging compound purification and characterization protocols.  
In the case of nanoparticle-peptide conjugates, an alternative synthetic approach has been 
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to indirectly couple these nanoparticles to carrier peptides through a secondary protein, 
such as bovine serum albumin (BSA) protein.46, 47 The resulting conjugates are large and 
possess highly branched polypeptides that are very difficult to characterize. 
 We observed in this study that thiol-terminated NLS peptides incorporating 
appropriate spacer groups could be easily accessed by Cu(I)-catalyzed cycloaddition 
reaction (click chemistry)71 between an alkyne-terminated NLS, such as PC-37044-PI, 
and an appropriate azidothiols (scheme 3-1).  Subsequent reaction of the resulting 
thioalkyl-triazole linked NLS 54 with Au nanorods which are stabilized with CTAB  
molecules yields peptide-conjugated Au nanorods by forming Au-S bonds between the 
peptide and the Au surface.  There are some other previous reports of bioconjugation to 
Au nanoparticles through Au-S bonds.  For example, HS-mPEG has been reported to 
rapidly assemble onto Au nanoshells through Au-S bonds within 1 h.14 In this case, there 
are no capping molecules on the surface of the Au layer.  In comparison to a bare Au 
surface, it takes a longer time to assemble thiolated molecules to the surface of Au 
nanorods.  The adsorption of HS-mPEG onto Au nanorods requires stirring for 24 h,61 
while thiolated DNA is bound to Au nanorods after 72 h of incubation.73 Au nanorods are 
capped with CTAB surfactants, which form a bilayer structure around the Au surface.74 
The inner layer of the surfactant is bound to the Au surface via the surfactant head 
groups.  In our work, the thiolated peptide and Au nanorod solution are left for up to 72 
h.  The absorption spectra in Figure 3-1 show that there is no change in the peak position 
after CTAB replacement, but the peak intensity decreases slightly.  This intensity 
damping is due to the increase of the positive charge on the capping molecules when 
positive CTAB is replace by more positively charged peptide molecules 
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Figure 3-1. (A) Absorption spectra of Au nanorods (solid line) and peptide 
conjugated Au nanorods (dashed line), (B) TEM image of Au nanorods.  Scale bar:  
50 nm.  Experiment performed by Dr. Xiaohua Huang 
 
 
3.3 SERS of Peptide-Conjugated Gold Nanorods 
 Figure 3-2 shows a comparison of the Raman spectrum of the peptide-conjugated 
Au nanorods with that of the pure peptide and CTAB-capped Au nanorods.  It can be 
seen that the Raman spectrum of the peptide-conjugated Au nanorods show some signals 
from CTAB molecules, which indicated that a small proportion of the CTAB molecules 
remained on the rod surface.  It is very interesting to note that the amide I C=O stretching 
vibration of the peptide at 1665 cm-1 is not enhanced when it is bound to the nanorod 
surface.  The CH bending at 1432 cm-1 for the peptide is shifted to 1440 cm-1 on the rod 
surface.  The amide III C—N stretching at 1240 cm-1 is the same for peptide and peptide 
bound to Au nanorods.  The amide II N—H vibrations (1500-1570 cm-1 region) are not 
observed in both the peptide powder and the peptide bound onto Au nanorods.  The 
thioalkyl-triazole linker shows a strong CH2 rocking vibration75 at 760 cm-1 and C—C 
stretch75, 76 at 1092 cm-1.  The CH bending is found to overlap with the CH bending in the 
peptide at 1440 cm-1.52 The C—N stretch in CTAB molecules overlaps with C-N stretch  
A 
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Figure 3-2. SERS of CTAB capping molecules on Au nanorod, thioalkyl—triazole—
peptide on Au nanorod and Raman spectrum of peptide. (A): 300-1400 cm-1 region; (B): 
1400-3000 cm-1 region. Experiment performed by Dr. Xiaohua Huang 
 
 
in the thioalkyl-triazole to give a strong peak at 1002 cm-1.52 The C-H stretching 
vibrations of the peptide, the thioalkyl-triazole, and the CTAB are at 2836 cm-1 and 2930 
cm-1.52, 76 The peptide residues show their strong COO- deformation at 722 cm-1.77 The 
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signal at 831 cm-1 is assigned to the proline and valine C—C stretch, and the 1031 cm-1 
signal is assigned to C—N stretch vibrations from glycine and proline.77 
 The CTAB capping molecules show strong Raman bands at 1137 cm-1 for the 
C—C stretch vibrations, 1267 cm-1 for  δ (CH) of the CH2—N+(CH3)3 group and 1450 
cm-1 and 1490 cm-1 for CH2 bending vibration.52 From Figure 3-2, it can be seen that 
these bands are still observed in the Raman spectrum of the peptide-conjugated Au 
nanorods due to the incomplete replacement of the CTAB molecules.  In comparison to 
the Raman spectrum of the antibody-conjugated Au nanorods in which CTAB molecules 
are replaced,78 the intensity of these bands in the peptide-conjugated Au nanorods are 
much weaker due to the replacement of the capping molecules with the thiolated 
peptides. 
 
3.4 Light Scattering Images of Peptide-Conjugated Gold Nanorods Inside Cells 
 Figure 3-3 shows that dark field light scattering images of cells after incubation 
with 1 nM CTAB capped nanorods and 1 nM thioalkyl—triazole—peptide conjugated 
Au nanorods for 2 h.  It can be seen clearly that, while the CTAB-capped Au nanorods 
are not efficiently absorbed by the bells, the thiolalkyl—triazole—peptide conjugated Au 
nanorods enter both cell lines with much higher efficiency.  This result indicated that 
peptide conjugate enhances the cellular uptake of the Au nanorods.  Importantly, it is 
worth noting that the observed enhancement of Au nanorod uptake took place in medium 
containing a very low concentration of peptide-conjugated nanorods (∼ 1 nM) within a 
very short incubation time (2 h).  This enhanced Au nanorod uptake may be due to the 
receptor-mediated endocytosis.  Moreover, we observed that the thioalkyl—triazole—  
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Figure 3-3. Dark field images of cells after incubation with Au nanorods and peptide- 
conjugated Au nanorods for 2 h. (A) HaCaT normal cells incubated with Au nanorods, 
(B) HSC cancer cells incubated with Au nanorods, (C) HaCaT normal cells incubated 
with peptide conjugated Au nanorods, (D) HSC cancer cells incubated with peptide 
conjugated Au nanorods. Peptide conjugation promotes the cellular uptake of Au 
nanorods.  Scale bar:  10µm.  Experiment performed by Dr. Xiaohua Huang 
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peptide conjugated nanorods are distributed into both nucleus and cytoplasm in either 
normal or cancer cells.  However, the nanorods are more concentrated in the nucleus of 
the cancer cells.  Reasons for increased nuclear distribution particles in the malignant 
cells could reflect increased specific and active uptake of the NLS peptide or decreased 
regulation of passive uptake of cytoplasmic components due to the disruption of the 
normal cellular process.  It is quite possible that the nuclear pores of the nuclear 
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membrane which routinely restrict entrance into the nucleus may be faulty and thereby 
facilitate the penetration of the peptide-conjugated nanorods into the nucleus.  
Identification of alterations in cellular pathways, such as nuclear pore function, by this 
multimodal method suggest further avenues of investigation that may yield novel 
methods of exploiting cellular defects of carcinogensis for therapeutic applications.   
 
3.5 SERS of Peptide-Conjugated Gold Nanorods Inside Cells. 
 The Raman spectra of cells incubated with the peptide-conjugated Au nanorods 
are also measured (Figure 3-4).  The Raman laser spot covers the major part of a single 
cell.  Statistically, over twenty cells for each cell line are measured.  They gave similar 
spectra with slight differences in some peak intensities.  Shown in Figure 3-4A, B are 
five typical spectra for both normal and cancer cells.  Figure 3-4C compares a typical 
spectrum of normal and cancer cell as well as the spectrum when the peptide-conjugated 
nanorods are outside the cells.  Spectra of the peptide-conjugated Au nanorods reveal a 
difference pre- and post-cellular uptake.  New bands at 620, 655, and 1158 cm-1 are 
observed after cellular translocation of the conjugates.  The 620 cm-1 band is due to 
protein COO- wag vibration and tyrosine δ (ring) vibration.79 The 655 cm-1 band is due to 
an overlapping of a strong tyrosine vibration and the guanine bands.36, 80 The DNA 
backbone vibrations are reflected most likely at bands in the region between 1030 
and1137 cm-1, such as 1058 cm-1 for the DNA C—O stretch76 and 1094 cm-1 for O—P—
O vibrations.81 The 1151 cm-1 band could be assigned to chromatin and histone octamer 
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Figure 3-4. Raman spectra of peptide conjugated Au nanorods inside HaCat normal cells 
(A) and HSC cancer cells (B). The Raman spectrum of the peptide conjugated Au 
nanorods outside cells is shown in (C) as the bottom curve for comparison. Raman 
spectra from five cells for each cell line are shown. Experiment performed by Dr. 
Xiaohua Huang 
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Raman signals.80 The intensities around 820 and 850 cm-1 bands are greatly increased 
inside the cells.  This indicates that such residues as phenylalanine (830 cm-1, CH2 rock) 
and tyrosine (850 cm-1, ring breath) in cell proteins77 are probably enhanced.  The lysine 
Raman signal77 at 900 cm-1 in the peptide is shifted to 914 cm-1 when it is present inside 
the cells, suggesting interaction of this residue with the cell components.  The Raman 
intensity of the thioalkyl-triazole C—N stretch band at 760 cm-1 inside the cell is greatly 
decreased in comparison to that outside the cells.  This suggests a change in linker 
conformation upon nanorod translocation into the cells. 
 The normal and cancer cells show some differences in their Raman signals as 
well. The 731 cm-1 line which is assigned to adenine82 is stronger in the cancer cells than 
that in the normal cells.  In addition, a peak at 398 cm-1 is observed only in cancer cells.  
All these spectral differences might be useful for cancer diagnostics. 
 Feld, Kneipp, and some other groups have demonstrated that individual and 
aggregated Au nanospheres could be useful for single cell micro-Raman microscopy.32-38 
However, the inability of controlled delivery of the particles within the cell has limited 
their applications.  The data in this project suggest that the intracellular distribution of the 
particles inside the cell can be controlled and simultaneously provides information 
regarding the local biochemical environment.  Identification of spectral differences, such 
as an increased adenine signal within the cancer cell nucleus, provides detailed 
biochemical information at the molecular level with concurrent imaging of the particles 
in subcellular compartments.  This multimododal and ultrasensitive probe has a 
significant potential for a range of investigative and medical diagnostic applications. 
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3.6 Targeted Nuclear Delivery of Gold Nanoparticles into Malignant Cells 
 Cells-selectivity is necessary to further explore the diagnostic and therapeutic 
applications of NLS-AuNPs conjugates. To ensure cells-selectivity, we incorporate other 
delivery peptides, such as RGD peptides,47, 83 acting as a ligand that selectively and 
potently bind to an unique cell surface receptors on tumor cells called αvβ3 integrins. It is 
heterodimeric proteins that mediate cell-cell attachment and cellular adhesion to the 
extracellular matrix.  They are overexpressed in both invasive tumor cells and the 
endothelium of the tumor vasculature.84 It is however important that the RGD peptide be 
linked through an appropriate linking moiety as improper conjugation of RGD to the  
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Figure 3-5.  Representative schematic of modified RGD/NLS-conjugated Au 
nanosphere. 
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AuNPs has been observed to result in loss of RGD-mediated RME into the tumor cells.47, 
83, 85 To eliminate the linker issue, we designed a 15mers 55 (RGDRGDRGDRGDPGC) 
that contained repeated sequence of RGD tripeptides with terminal cysteine residue  
 
 
A B C 
D E F 
Figure 3-6.  Dark field images of cells after incubation with RGD/NLS-conjugated Au 
nanospheres for 2 h. (A) HaCat normal cells incubated with only RGD-conjugated Au 
nanosphere, (B) HaCat normal cells incubated with only NLS-conjugated Au nanosphere, 
(C) HaCat normal cells incubated with RGD/NLS-conjugated Au naospheres, (D) HSC 
cancer cells incubated with only RGD-conjugated Au nanosphere, (E) HSC cancer cells 
incubated with only NLS-conjugated Au nanospheres, (F) HSC cancer cells incubated 
with RGD/NLS-conjugated Au naospheres.  Combination of RGD and NLS promote 
selective nuclear delivery of Au nanosphere into HSC cancer cells. Experiment 
performed by Dr. Xiaohua Huang 
 
 
forconjugation on the Au surface (Figure 3-5).  Preliminary whole cell studies have 
indicated that 40 nm Au nanosphere conjugated with both thioalkyl-triazole linked NLS 
54 and cysteine-terminated RGD peptides 55 exhibit both cellular selectivity and nuclear 
delivery toward HSC cancer cells within 2 h.  As controls, stand alone modified RGD-Au 
nanosphere conjugates displayed selective delivery into HSC cancer cells, and NLS-
conjugated Au nanosphere confirmed early results with NLS-Au nanorod conjugates 
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(Figure 3-6).  Further studies are currently ongoing for the RGD/NLS-Au nanosphere 
conjugates to be utilized in diagnostic application and experimental therapeutic 
techniques such as photothermal therapy. 
 
 
3.7 Conclusions 
 We have demonstrated in this work that Au nanorods as well as nanosphere 
directly conjugated to a SV40 virus NLs peptide through a thioalkyl-triazole linker and/or 
modified RGD peptides could be efficiently and selectively delivered into cells within a 
very short time.  The RGD/NLS-conjugated Au nanospheres are selectively translocated 
into both the cytoplasm and the nucleus portion.  Raman spectra reveal enhanced signal 
of the NLS peptides as well as molecules from both the cytoplasm and the nucleus.  In 
addition, the Raman signal distinguishes the malignant from nonmalignant cells.  The 
study demonstrated that Au nanorods can be used for nuclear targeting as a novel type of 
imaging-based contrast agent and an ultrasensitive Raman probe for intracellular 
molecular sensing as well.   
 However, the successful implementations of the promised applications of AuNPs 
are still limited in part by the formidable barriers imposed by the complexity of a whole 
organism in contrast to simple cell based studies that formed the bed rock of most of the 
proof-of-principle investigations. The recent results from the phase I clinical trial on 
AurimuneTM, indicating a safe and targeted delivery of AurimuneTM in and around tumor 
sites86, are particularly intriguing and encouraging. This has provided a very important 
evidence that AuNPs-based therapeutic agents could overcome the barriers presented by 
the human immune and circulatory systems to achieve delivery at diseased sites without 
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uptake by healthy tissues. In principle, such improved targeted delivery could make other 
AuNPs-based experimental therapeutic techniques, such as photothermal therapy, 
practicable. With the “right” combination of delivery agents and particle size, AuNPs-
based therapeutics could effectively kill the diseased cells while eliminating the 
horrendous side effects of the conventional chemotherapeutic agents. Nevertheless, more 
still needs to be done regarding our understanding of the pharmacokinetics and toxicity 
profiles of AuNPs. 
 
3.8 General Procedure and Experimental 
 
 11-Bromoundecan-1-ol and all chemicals used for the synthesis of gold nanorods 
are purchased from Sigma Aldrich.  Anhydrous solvents and other reagents are purchased 
and used without purification.  Analtech silica gel plate (60 F254) is used for analystical 
TLC, and UV light is used to examine the spots.  Tris-(benzyltriazolylmethyl)amine 
(TBTA) is prepared by using the procedure described by Chan et al.64 Alkyne-modified 
NLS (PCS-37044-PI) and cysteine-terminated RGD peptides 52 (PCS-37420-PI) are 
synthesized by the solid-phase method at Peptide International, Louisville, Kentucky.  
NMR spectra are recorded on a Varian-Germini 400 magnetic resonance spectrometer.  
1H NMR spectra are recorded in parts per million (ppm) relative to the peak of CDCl3 
(7.24 ppm).  Mass spectra are recorded at the Georgia Institute of Technology mass 
spectrometry facility in Atlanta. 
 
 
1-Azidoundecan-11-ol (50).  This compound was synthesized by adapting the method of 
Shon et al.65 Briefly, sodium azide (1.2 g, 18.5 mmol) is added to a solution of 1-
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bromoundecan-11-ol (2.0 g, 7.96 mmol) in anhydrous DMF (20 mL).  The reaction 
mixture is heated to 110oC in a pressure tube and stirring continued for 24 h.  The 
reaction mixture is then cooled to room temperature and quenched with distill water (30 
mL).  The cooled reaction mixture was extracted with anhydrous diethyl ether (3 x 20 
mL), and the combined organic layers were washed with distilled water (3 x 20 mL), and 
dried over Na2SO4.  The solvent is removed and concentrated in vacuo to give 1.275 g 
(75 %) of 50 as pale yellowish oil.  1H-NMR (CDCl3, 400MHz) δ1.25-1.38 (14H, m), δ 
1.50-1.60 (4H, m), δ3.22 (2H, t, J = 7.2 Hz), δ 3.61 (2H, t, J = 7.2 Hz). 
 
 
1-Azidoundecan-11-methylsulfonate (51).  Triethylamine (4.35 mL, 31.2 mmol) is 
added to a solution of 1-azidoundecan-11-ol 50 (2.42 g, 11.3 mmol) in anhydrous CH2Cl2 
(100 mL).  The reaction mixture is stirred for 15 minutes at 0oC, and then 
methanesulfonyl chloride (2.41 mL, 31.2 mmol) is added.  The reaction mixture is 
allowed to warm up to room temperature and stirring continued for 2 h.  The reaction 
mixture was quenched with ice cold distilled water (35 mL) and extracted with anhydrous 
diethyl ether (2 x 35 mL).  The combined organic layer was washed in succession with 1 
N HCl, distilled water, saturated NaHCO3, and then again with distilled water.  The 
organic layer was dried over Na2SO4, and concentrated in vacuo to give 2.934 g (89 %) 
of 51 as pale yellowish oil. 1H-NMR (CDCl3, 400MHz) δ 1.25-1.40 (14H, m), δ 1.53-
1.60 (2H, m), δ 1.68-1.75 (2H, m), δ 2.97 (3H, s), δ 3.22 (2H, t, J = 6.8 Hz), δ 4.19 (2H, t, 
J = 6.8 Hz).  
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1-Azidoundecan-11-thioacetate (52).  Potassium thioacetate (2.02 g, 6.79 mmol) is 
added to a solution of 1-azidoundecan-11-sulfonate 51 (1.00 g, 3.43 mmol) in anhydrous 
THF (10 mL).  The reaction mixture is degassed, refilled with argon and heated under 
reflux for 3 h.  The reaction mixture was quenched with ice cold distilled water (30 mL) 
and extracted with anhydrous diethyl ether (3 x 30 mL).  The combined organic layer was 
dried over Na2SO4 and concentrated in vacuo to give 856 mg (87 %) of 52 as yellowish 
oil. 1H-NMR (CDCl3, 400MHz) δ1.23-1.38 (14H, m), δ 1.50-1.60 (4H, m), δ 2.29 (3H, s), 
δ 2.83 (2H, t, J = 7.6 Hz), δ 3.22 (3H, t, J = 7.6 Hz). 
 
1-Azidoundecane-11-thiol (53).  A solution of 1-azidoundecane-11-thiolacetate 52 (0.1 
g. 0.369 mmol) in anhydrous methanol (7.0 mL) was first degassed and refilled with 
argon.  Concentrated HCl (0.4 mL) was added to the solution and the resulting mixture 
refluxed for 3 h.  The reaction mixture was quenched with distilled water (10 mL) and 
extracted with anhydrous diethyl ether (2 x 10 mL).  The organic layer was dried over 
Na2SO4 and concentrated in vacuo to give 85 mg (100%) of 53 as yellowish oil. 1H-NMR 
(CDCl3, 400MHz) δ 1.25-1.38 (14H, m), δ 1.53-1.62 (4H, m), δ 2.50 (2H, q, J = 15.2 Hz, 
7.2 Hz), δ 3.23 (2H, t, J = 5.6 Hz). 
 
Thiolalkyl-triazole linked NLS peptide (54).  Anhydrous CuI (0.003 g, 0.011 mmol) 
and TBTA (0.007 g, 0.011 mmol) is added to a solution of 1-azidoundecane-11-thiol 53 
(0.02 g, 0.079 mmol) and alkyne-modified NLS peptides PC-37044-PI (0.05 g, 0.039 
mmol) in anhydrous DMF (2 mL). The solution is stirred at room temperature under 
argon for 48 h.  Excess DMF is removed in vacuo, and the residue is quenched with 
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distill water (5 mL).  The resulting mixture is extracted with dichloromethane (2 x 10 
mL) to remove unreacted 1-azidoundecane-11-thiol 53.  The remaining aqueous layer 
was frozen in acetone-dry ice bath and concentrated in vacuo to give 50 mg (43%) of 54 
as brown solid. 1H NMR (DMSO-d6, 400 MHz) δ 0.83 (2H, t, J = 6.0 Hz), δ 1.23-1.36 
(6H, m), δ 1.42-1.54 (3H, m), δ 1.56-1.68 (1H, m), δ 2.13-2.24 (2H, m), δ 2.40-2.50 (5H, 
m), δ 2.66-2.80 (2H, m), δ 2.87 (1H, s), δ 3.29 (1H, t, J = 8.0 Hz), δ 3.34-3.54 (1H, m), δ 
3.62-3.78 (1H, m), δ 4.10-4.30 (1H, m), δ 7.26-7.36 (1H, m), δ 7.64-7.88 (3H, m), δ 7.94 
(1H, s), δ 8.10-8.32 (2H, m); MS (MALDI, CHCA) calc for [C67H123N23O13S + H]+ 
1490.9, found 1491.0.  
 
Synthesis of gold nanorods and peptide conjugation.  The gold nanorods are 
synthesized according to the seed-mediated growth method.66 Briefly, 600 μL 0.01 M ice-
cold sodium borohydride is quickly added into a 10 mL 0.5 mM stirring auric acid, which 
is dissolved in 0.2 M CTAB solution. 2 to 5 nM gold nanoparticles are formed after 2min 
as a seed solution.  In a separate flask, 1 mL of 4 mM silver citrate is added to 50 mL 
growth solution, which contains 0.2 M CTAB, 0.15 M benzyldimethylammonium 
chloride hydrate (BDAC), and 1 mM auric acid.  0.07 mL of 0.0788 M ascorbic acid is 
added to the growth solution to reduce the auric acid to form HAuCl2 solution.  0.08 mL 
seed solution is injected into the growth solution to initiate the rod formation and growth.  
In this procedure, gold nanorods with absorption maximum at 650 nm (aspect ratio of 
2.4) are obtained overnight.  For the conjugation of peptide 5 to gold nanorods, 100 μL 1 
mM peptide 5 is added to 10 mL gold nanorod solution (OD650 = 1.0), and the mixture is 
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left to react for 72 h. The unbound peptide is separated by centrifugation at 5000 rpm for 
10 min. 
 
Cell culture and cellular delivery of peptide conjugated gold nanorod.   One 
nonmalignant epithelial cell line, HaCaT (human keratinocytes) and one malignant 
epithelial cell lines, HSC 3 (human oral squamous cell carcinoma), were cultured on 
coverslips in DMEM (Dulbecco’s Modifictaion of Eagle’s Medicum, Cellgro) plus 10% 
FBS at 37°C under 5% CO2 for 24 h. The DMEM medium is then taken out and rinsed 
with PBS buffer.  Fresh DMEM medium containing 1 nM thioalkyl-triazole peptide/Au 
nanorod conjugates is added, and the cells were put back in incubator for 2 h. After the 
nanorods incubation, the cells are rinsed with PBS buffer, fixed with paraformaldehyde, 
coated with glycerol, and sealed with another cover slip.  
 
Dark field imaging. The dark field images are taken under an inverted Olympus IX70 
microscope. A dark field condenser (U-DCW) with a numerical aperture between 0.9-1.2 
is used to deliver a very narrow beam of white light from a tungsten lamp to the sample. 
A 100x/1.35 oil Iris objective (UPLANAPO) is used to collect only the scattered light 
from samples. In this mode, the samples with highly scattering properties are shown as a 
bright object in a dark background. 
 
Raman measurements. The Raman spectra are obtained with a Holoprobe series 5000 
Micro-spectrometer (Kaiser optical systems, Inc, Ann Arbor, MI) in a 180o reflective 
configuration with a 50x objective. The excitation wavelength is 785 nm from a diode 
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laser. The spectral resolution in Raman experiments was 5 cm-1 and the laser power is 25 
mW. Each spectrum are obtained in 10s collection time with six accumulations.  
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CHAPTER 4 
 
DIRECT DIAZO-TRANSFER REACTION ON BETA-LACTAM:  SYNTHESIS 
AND PRELIMINARY BIOLOGICAL ACTIVITIES OF 6-
TRIAZOLYLPENICILLANIC ACIDS  
 
 
4.1 β-lactam Antibiotics 
 
 β-lactam antibiotics such as penicillin and cephalosporins are the most commonly 
prescribed antibacterial agents.  Their antibacterial efficacy derives from ability to acylate 
a serine residue at the penicillin binding proteins (PBPs) active site.1, 2 Serine acylation 
inhibits the enzymatic activities of PBPs, thus interfering with the essential 
polymerization and cross-linking of the peptidoglycan components of the bacterial cell 
wall.1  However, the emergence of multi-drug resistant bacteria strains such as 
Staphylococcus aureus is threatening the clinical effectiveness of β-lactam antibiotics.3  
The common resistance mechanism in gram-negative bacteria is the cellular expression 
of β-lactamases (or penicillinase), which hydrolyze the β-lactam ring and thus inactivate 
the antibiotics.4-7  Therapeutic agents targeting β-lactamase resistance include 
clavulanate, sulbactam, and tazobactam.  These are generally administered in 
combination with β-lactamase susceptible β-lactams.8, 9  However, the emergence of 
multi-strains β-lactamase has reduced the efficacy of some of these β-lactamase 
inhibitors.10, 11   
  There are also other intracellular factors that attenuate the antibacterial activities 
of β-lactams.  For example, the N-5 amide moiety in penicillins is highly reactive and has 
been proposed to facilitate the hydrolysis of the β-lactam ring in acidic media (Figure 4-
1).12 Incorporation of electron-withdrawing groups at the N-acyl side chain has been 
shown to reduce the acid sensitivity of penicillins.  Another approach to reduction of β-
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lactam acid instability is to introduce steric bulk, commonly tolerated by PBPs, into the 
N-acyl side chains. Examples of such penicillins which can withstand an acidic 
environment similar to human gastric juice include ampicillin, phenethicillin and 
propicillin (Figure 4-2).13    
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Figure 4-1.  Self-induced acid hydrolysis of penicillin. 
 
Similarly, structure activity relationship (SAR) studies have revealed that β-lactamases 
are intolerant of bulky substituents on the N-acyl side chain of β-lactams.  This has led to 
the development of several useful penicillinase resistant β-lactams such as methicillin, 
oxacillin, and cloxacillin (Figure 4-2).14  
Another shortcoming to the effectiveness of β-lactamase antibiotics is the 
bacterial outer membrane, which is a formidable barrier in gram negative organisms.  In 
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addition, the bacterial membrane could acquire efflux pumps that facilitate active 
elimination of drug from the bacterial cytosol.15, 16  All these changes could prevent the 
intracellular accumulation of pharmacologically relevant concentrations of the β-lactam 
antibiotics.  One clever strategy to facilitate β-lactams diffusion across membrane is to 
covalently link them to membrane penetrating groups such as sideophores and peptides.1-
3, 17  However, the synthesis of such β-lactam conjugates often involve long synthetic 
schemes and complicated compound purifications protocols.2b-e   
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Figure 4-2.  The structure of some acid- and β-lactamase-resistant penicillins.     
 
One of the most fruitful β-lactam SAR studies has been the modification of the N-
acyl groups.  These studies have led to the discovery of β-lactam analogs with superior 
antibacterial activity.16, 18-20  Much recent studies have shown that attachment of N-acyl 
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groups incorporating the structural feature of peptidoglycan result in PBP specific β-
lactams and cephalosporins.3, 17, 21 PBPs can also tolerate an assorted variety of non-
amide groups at the C-6 and C-7 positions of penicillins and cephalosporins, 
respectively.20  Some of these non-amide β-lactam analogs, in addition to possessing 
potent antibacterial activity, have differential affinity for PBP isoforms (Figure 4-3).  For 
example, amidocillin, a β-lactam analog with an unusual 6-formylimido moiety, derives 
its antibacterial activity from its specific interaction with PBP-2.22  Very few β-lactams 
with traditional amide bond isosteres have been reported to date.  One such example is 
the sulfonamide derivatives.  A subset of these compounds have been synthesized and 
tested.  However these compounds are still prone to chemical degradation and hydrolysis 
by β-lactamases.23   
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Figure 4-3.  Structure of amide isosteric β-lactams. 
 
We proposed that 1,4-disubstituted-1,2,3-triazoles could serve as an effective 
isostere for the N-acyl group of penicillins and cephalosporins.  Due to bond 
characteristics similar to an amide bond, the triazole group is commonly used as an amide 
bond isostere.24, 25 Unlike amide bond, the triazole moiety is not susceptible to 
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hydrolysis.24  Replacement of the reactive β-lactam acyl bond with a triazole ring could 
lead to β-lactams that are more stable in acidic environment.  Because β-lactamases are 
relatively intolerant of side chain steric hindrance, introduction of the triazole ring could 
lead to β-lactams with improved activity against β-lactamase producing organisms.  In 
addition, the triazole ring will facilitate facile conjugation of β-lactams to assorted cell 
permeable peptides and peptoids for promoted uptake of β-lactams into bacterial cell.  
Here, we report our efforts on the design, synthesis, and preliminary biological activities 
of 6-triazolylpenicillanic acid.   
 
4.2 Molecular design of 6-triazolylpenicillanic acid 
The key intermediate in the synthesis of the proposed 6-triazolylpenicillanic acids 
56 is the 6-azidopenicillanates 57.  It is anticipated that Cu(I)-catalyzed cycloaddition 
between 57 and appropriate alkynes (Sharpless Click Chemistry)26 followed by 
deprotection of the ester protection group will furnish the desired triazolylpenicillanic 
acid 56 (scheme 4-1).  The synthesis of protected 6-azidopenicillanates similar to 57a-c 
has been described in the literature.27-30 These compounds are generally synthesized, in 
moderate yields, using multi-step reactions.  For example, Barrett and Sakadarat 
described the synthesis of benzyl protected 6-azidopecillanate, the final intermediate in 
their total synthesis of 6-aminopenicillanic acid (6-APA), in a six-step reaction scheme 
with a total 
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Scheme 4-1.  Synthetic approach to 6-triazolylpenicillanic acids.   
 
 
 
yield of about 15%.30 For the synthesis of 6-triazolylpenicillanates, we desired a more 
general and mild synthetic strategy to 6-azidopenicillanates.   
As a new general alternative, we envisioned that azidopenicillanic acid could be 
obtained from commercially available 6-aminopenicillanic acids through a diazo-transfer 
reaction using an appropriately carboxyl protected ester.  The diazo-transfer reaction is a 
mild, high yielding reaction that has been used to effect direct conversion of assorted 
amines to azides.31 In addition, a recent observation from our lab has extended the scope 
of this versatile reaction to include azide functionalization of amine-coated solid supports 
under heterogeneous reaction conditions.32 The requisite carboxyl protected 
aminopenicillanates 58a-c  were synthesized adapting literature protocols.21, 33-37 Using 
the PNB protected compound 58a, we initiated diazo-transfer reaction with freshly 
prepared triflyl azide under basic conditions in the classic CH2Cl2/MeOH/H2O solvent 
mixture.31b-e These conditions, however, gave a complex mixture from which we only 
isolated a minute amount of the ring-opened methyl ester azide 59.  This product was 
presumably obtained from Et3N promoted methanolysis of compound 58a in addition to 
the desired diazo-transfer reaction.  The reaction was repeated in anhydrous CH2Cl2 and 
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Et3N.  Gratifyingly, we obtained the desired azide 60a in yields of 50-68% within 2 to 2.5 
h of reaction, though other uncharacterized degradation products persisted.  Because of 
the potential hazard of handling triflyl azide in halogenated solvent, we investigated the 
compatibility of this reaction with non-halogenated solvents.  The reaction worked 
equally well when CH2Cl2 was replaced with toluene, yielding azide 60a in 70% yields.  
Similarly, azides 60b and 60c were obtained from amines 57b and 57c in moderate to 
good yields (scheme 4-2).  The β orientation of the azide group in 60a-c was 
authenticated by 1H NMR (J5,6 coupling constant = 4 Hz),29 thereby confirming that the 
reaction occurred with the characteristic retention of configuration.31b,e     
 
 
 
Scheme 4-2.  Synthesis of protected 6-azidopenicillanic acid.  Conditions:  (a) TfN3, 
Et3N, CH2Cl2/MeOH/H2O, rt, (b) TfN3, Et3N, DMAP, rt, 2-2.5 hrs, (c) TfN3, Et3N, 
toluene, rt, 1.5-2.5 hrs. 
 
 
 
To identify optimum conditions for Cu(I)-catalyzed cycloaddition reaction, we 
investigated the reaction of azides 60b and 60c with 3-phenyl-1-propyne 61 and 2-
ethynyl-1,3-dimethoxybenzene 62.  Our choice of terminal alkynes 61 and 62 is partly 
informed by the possibility that cycloaddition between these alkynes and azides 60 will 
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respectively furnish triazolyl isosteres of penicillin G and methicillin, two historically 
useful penicillin derivatives.  Cu(I)-catalyzed reaction of azide 60b or 60c with alkyne 61 
resulted in triazoles 63a and 63b in excellent yield.  Subsequent TFA deprotection of the 
PMB and the BzD group furnished the desired penicillanic acid 64a in excellent yield.  
Similarly, the reaction of azide 60c with alkyne 62 followed by deprotection of the BzD 
group gave penicillanic acid 64 in 72% overall yield (scheme 4-3).  Because of the 
rapidity of deprotection of the BzD group and the product quality, we focused much of 
our attention on the reactivity of azide 60c.   
 
 
Scheme 4-3.  Cu(I)-catalyzed cycloadditions reaction between 6-azidopenicillanates and 
representative terminal alkynes.  Conditions:  (a) CuI, Hunig’s base, alkynes 61 or 62, 
THF, rt, (b) TFA, anisole, CH2Cl2, -5oC.   
 
 
 
4.3 Structural Activity-Relationship Studies of 6-Triazolylpenicillanic Acids 
We turned to investigate the reactivity of azide 60c with assorted terminal alkynes 
in order to probe the scope of this reaction.  We selected a subset of terminal alkynes 
whose closely related carboxylic acid analogs have been shown to support the 
antimicrobial activities of β-lactams.38-40 Alkynes such as 62, 65h, 65i, and 65k that we 
could not obtain from commercial sources were synthesized from the corresponding  
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Scheme 4-4.  Scope of Cu(I)-catalyzed cycloaddition between 6-azidopenicillanate and 
terminal alkynes.  Conditions:  a) CuI, Hunig’s base, alkynes 65, THF, rt, b) TFA, anisole 
CH2Cl2, -5oC.   
 
 
carboxylic acid, through the intermediacy of aldehyde, using the Bestmann-Ohira 
reagent.41-43 Hydroxyl alkyne 65f and 65l were obtained by a direct Grignard reaction of 
ethynylmagnesium bromide with the appropriate aldehydes.  Detailed protocols for the 
synthesis of these alkynes are reported in the experimental section.   
Cu(I)-catalyzed reaction of alkynes 65a-l with azidopenicillanate 60b or 60c 
proceeded smoothly at ambient temperature, leading to uneventful formation of triazole 
66a-l in good to excellent yields.  Subsequent carbonyl group deprotection furnished the 
desired 6-triazolylpenicillanic acid 67a-l (scheme 4-4).   
 
4.4 Preliminary Antibacterial Activity Studies of 6-Triaozlylpenicillanic Acids 
The synthesized 6-triazolylpenicillanic acids were screened at the National 
Institute of Allergy and Infectious Disease (NIAID) through the In vitro and Animal 
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Models for Emerging Infectious Diseases and Biodefense Screening Program.  
Compounds were screened following the procedures recommended by the Clinical 
Laboratory Standard Institute (CLSI).  Compound 64a, 67e, 67g, and 67l exhibited some 
antibacterial activity against the Gram-positive bacteria strain S. pneumoniae with MIC 
value of 4 to 8 µg/mL.  Similarly, compound 67 showed a moderate activity (MIC ≈ 8 
µg/mL) against B. anthracis.  Other compounds listed in Table 4-1 displayed 
comparatively poor antibacterial activity (MIC > 8µg/mL).   
 
Table 4-1. Minimal Inhibitory Concentration (MIC) of 6-triazolylepenicillanic acids in 
µg/mL:  Each MIC values were obtained from an average of three independent 
experiments. 
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Table 4-1 (continued) 
67d 
S  
 
>8 
 
>8 
 
8 
 
>8 
67e 
 
 
>8 
 
>8 
 
4 
 
>8 
67f OH
 
 
>8 
 
>8 
 
>8 
 
>8 
67g 
 
 
>8 
 
>8 
 
≥8** 
 
>8 
67h 
 
 
>8 
 
>8 
 
>8 
 
>8 
67i 
 
 
>8 
 
>8 
 
>8 
 
>8 
67j O
 
 
>8 
 
>8 
 
>8 
 
>8 
67k 
 
 
N
 
 
>8 
 
>8 
 
>8 
 
>8 
67l* 
N
OH
 
 
>8 
 
>8 
 
≥8** 
 
≥8** 
N
S
O
HN
CO2H
O
 
Penicillin G 
 
 
1 
 
 
>2 
 
 
N. D.*** 
 
 
≤0.125 
N
S
O
HN
CO2H
O
NHO
N
N
O
O
 
Piperacillin 
 
 
 
 
2 
 
 
 
 
4 
 
 
 
 
N. D.*** 
 
 
 
 
1 
*    X = Na 
**  Denotes that one of the 3 replicates had MIC value of 8 µg/mL. 
*** No Data 
 
149 
 
4.5 Conclusion 
 We have reported a convenient route for synthesis of  6-triazolylpenicillanic acid.  
Preliminary biological evaluations have demonstrated that some of these compounds 
possess moderate antibacterial activity.  Currently, we are investigating the SAR of the 
lead compounds in order to identify 6-triazolylpenicillanic acid with improved 
antibacterial activity against drug resistant bacterial strains.  More importantly, we have 
identified a facile, high yielding synthetic scheme of 6-azidopenicllanates enabling of 
conjugation to cell permeable peptides or peptoids for potential bacterial cell-selectivity. 
 
4.6 General Procedure and Experimental 
 
 6-aminopenicillanoic acid (6-APA) was purchased from Sigma Aldrich.  
Anhydrous solvents and other reagents were purchased and used without further 
purification.  Analtech silica gel plates (60 F254) were used for analytical TLC, and uv 
light was used to examine the spots.  200-400 Mesh silica gel was used in column 
chromatography.   NMR spectra were recorded on a Varian-Gemini 400 magnetic 
resonance spectrometer.  1H NMR spectra are recorded in parts per million (ppm) relative 
to the peak of CDCl3, (7.24 ppm), acetone-d6 (2.09 ppm), or DMSO-d6 (2.49 ppm).  13C 
spectra were recorded relative to the central peak of the CDCl3 triplet (77.0 ppm), 
acetone-d6 (205.8 ppm), or the DMSO-d6 septet (39.7 ppm), and were recorded with 
complete hetero-decoupling.  High-resolution mass spectra were recorded at the Georgia 
Institute of Technology mass spectrometry facility in Atlanta.  Triflyl azide was prepared 
as described before and used without storage.32 The Bestmann-Ohira reagent was 
prepared as described by Ghosh et al42 while diphenyldiazomethane was prepared by 
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using the procedure described by Ko et al.37 6-Aminopenicillanates 58a-c were 
synthesized adapting literature procedures.21, 33-37 
 
Representative Procedure for the Alkyne Transformation Reaction.  2-Ethynyl-1,3-
dimethoxybenzene (62).  2,6-dimethoxybenzaldehyde (0.45 g, 2.71 mmol) was first 
dissolved in anhydrous MeOH (25 mL) and stirred under argon at room temperature.  
Anhydrous K2CO3 (1.12 g, 8.12 mmol) and Bestmann-Ohira reagent (1.03 g, 5.42 mmol) 
were added to the reaction mixture and stirring continued for 24 h at room temperature.  
Solvent was evaporated off, and the remaining residue was dissolved in CH2Cl2 (25 mL) 
and washed with saturated NH4Cl (3 x 20 mL).  The organic layer was dried over Na2SO4 
and concentrated in vacuo.  The crude product was purified by flash column 
chromatography (silica gel, 5:1 Hexane/EtOAc) to give 220 mg (50%) of 62 as a white 
solid.  1H-NMR (CDCl3, 400MHz) δ 3.55 (1H, s), 3.88 (6H, s), 6.53 (2H, d, J = 8.4 Hz), 
7.24 (1H, t, 7.4 Hz); 13C-NMR (CDCl3, 100MHz) δ 56.0, 76.2, 85.7, 100.0, 103.5, 130.3, 
162.0. 
 
4-(4-Ethynylphenyl)pyridine (65k).  Reaction of 4-(4-formylphenyl)pyridine (0.3 g, 
1.64 mmol) and Bestmann-Ohira reagent (0.627 g, 3.27 mmol) within 24 h as described 
for the synthesis of compound 7 followed by flash chromatography (silica gel, 2:1 
Hexane/EtOAc) gave 261 mg (89%) of 65k as a white solid.   1H-NMR (CDCl3, 
400MHz) δ 3.16 (1H, s), 7.47 (2H, d, J = 6.4 Hz), 7.59 (4H, s), 8.66 (2H, d, J = 6.4Hz).  
HRMS (EI) calc for [C13H9N] 179.0735, found 179.0746. 
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2-Ethnylbiphenyl (65i).  The required Biphenyl-2-carbaldehyde was synthesized from 
the corresponding carboxylic acid through NaBH4/ BF3:OEt2 reduction to the primary 
alcohol.43 Subsequent PDC oxidation of the primary alcohol furnished Biphenyl-2-
carbaldehyde.  Reaction of biphenyl-2-carbaldehyde (0.66 g, 3.63 mmol) and Bestmann-
Ohira reagent (1.72 g, 7.27 mmol) within 24 h followed by flash chromatography (silica 
gel, 5:1 Hexane/EtOAc) yielded 523 mg (81%) of 65i as a colorless oil.  1H-NMR 
(CDCl3, 400MHz) δ 3.03 (1H, s), 7.28-7.32 (1H, m), 7.36-7.45 (5H, m), 7.57-7.63 (3H, 
m). 
 
3-Ethynylbiphenyl (65h).  The required Biphenyl-3-carbaldehyde was synthesized from 
the corresponding carboxylic acid through NaBH4/ BF3:OEt2 reduction to the primary 
alcohol.43 Subsequent PDC oxidation of the primary alcohol furnished Biphenyl-3-
carbaldehyde. Reaction of biphenyl-3-carbaldehyde (0.87 g, 4.78 mmol) and Bestmann-
Ohira reagent (1.72 g, 9.56 mmol) within 24 h followed by flash chromatography (silica 
gel, 5:1 Hexane/EtOAc) gave 850 mg (100%) of 65h as a reddish oil.   1H-NMR (CDCl3, 
400MHz) δ 3.03 (1H, s), 7.33-7.47 (5H, m), 7.55-7.57 (3H, m), 7.72 (1H, s). HRMS(EI) 
calc for [C14H10] 178.0782, found 178.0797.   
 
Representative Procedure for the Alkyne Transformation via Grignard Reaction.  
1-phenylprop-2-yn-1-ol (65f).  To a solution of benzaldehyde (0.5 g, 4.71 mmol) in 
anhydrous THF (2 mL) was added ethynylmagnesium bromide (14.0 mL, 0.5M in THF) 
at room temperature under argon.  The reaction mixture was stirred for 1 h and quenched 
with distilled water.  The reaction mixture was partitioned between CH2Cl2 (10 mL) and 
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water (15 mL), and the two layers separated.  The organic layer was washed in 
succession with distilled water (2 x 10 mL) and saturated brine (2 x 10 mL), and dried 
over Na2SO4.  Solvent was evaporated off to give 0.626g (100%) of 65f as a brownish 
oil.  1H-NMR (CDCl3, 400MHz) δ 2.66 (1H, d, J = 2.4 Hz), 5.45 (1H, d, J = 4.0 Hz), 
7.30-7.40 (3H, m), 7.54 (2H, d, J = 7.2 Hz); HRMS (FAB, thioglycerol) calc for [C9H8O] 
132.0575, found 132.0566. 
 
1-(4-(pyrdin-4-yl)prop-2-yn-1-ol (65l).  To a solution of benzaldehyde (0.5 g, 2.73 
mmol) in anhydrous THF (2 mL) was added ethynylmagnesium bromide (8.2 mL, 0.5M 
in THF) at room temperature under argon.  The reaction mixture was stirred for 1 h and 
quenched with distilled water.  The reaction mixture was partitioned between CH2Cl2 (10 
mL) and water (15 mL), and the two layers separated.  The organic layer was washed in 
succession with distilled water (2 x 10 mL) and saturated brine (2 x 10 mL), and dried 
over Na2SO4.  Solvent was evaporated off to give 0.491 (86%) of 65l as a brownish solid. 
1H-NMR (CD3OD, 400MHz) δ 3.05 (1H, s), 5.46 (1H, s), 7.66-7.78 (6H, m), 8.56 (2H, d, 
J = 9.2 Hz); HRMS (FAB, thioglycerol) calc for [C14H11NO + H]+ 210.0918, found 
210.0909.  
 
Representative Procedures for Diazo-transfer Reaction.  Method A:  p-Nitrobenzyl 
6-azidopenicillanate (60a). 4-Nitrobenzyl 6-aminopenicillanate salt 58a (5.0 g, 9.5 
mmol) was suspended in EtOAc (40 mL) and washed with saturated NaHCO3 (2 x 30 
mL).  The organic layer was dried over Na2SO4 and concentrated in vacuo to give pure 4-
nitrobenzyl 6-aminopenicillanate. To a solution of 4-nitrobenzyl 6-aminopenicillanate in 
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anhydrous CH2Cl2 (10 mL) was added triflyl azide solution (25 mmol) in CH2Cl2 (25 
mL), and Et3N (2.1 mL, 15.0 mmol).  The reaction mixture was stirred at room 
temperature for 2 h.  Solvent was evaporated off and the residue was directly purified by 
flash chromatography (silica, gradient 4:1; 3:1 Hexane/EtOAc) to give 2.35 g (68%) of 
60a as a colorless gel.  1H-NMR (CDCl3, 400MHz) δ 1.38 (3H, s), 1.61 (3H, s), 4.49 (1H, 
s), 4.92 (1H, d, J = 4.0 Hz), 5.23 (2H, q, J =24.0, 12.0 Hz), 5.43 (1H, d, J = 4.0 Hz), 7.50 
(2H, d, J = 8.8 Hz), 8.17 (2H, d, J = 8.8 Hz); 13C-NMR (CDCl3, 100MHz) δ 26.4, 31.5, 
64.3, 65.7, 66.5, 67.6, 70.0, 123.7, 128.0, 141.5, 147.9, 167.0, 169.8; 
 
Method B:  Benzhydryl 6-azidopenicillanate (60c).  Benzhydryl 6-aminopenicillanate 
salt 58c (3.5 g, 6.32 mmol) was suspended in EtOAc (60 mL) and washed with saturated 
NaHCO3 (3 x 40 mL).  The organic layer was dried over Na2SO4 and concentrated in 
vacuo to give 2.4 g of pure benzhydryl  6-aminopenicillanate.  To a solution of 
benzhydryl 6-aminopenicillanate in anhydrous CH2Cl2 (15 mL) was added triflyl azide 
solution (14 mmol) in CH2Cl2 (35 mL), DMAP (1.15 g, 9.24 mmol), and Et3N (0.1 mL).  
The reaction mixture was stirred at room temperature for 1.5 h and solvent was 
evaporated off.  The residue was directly purified by flash chromatography (silica, 
gradient 1:0; 5:1 Hexane/EtOAc) to give 1.38 g (54%) of 60c as a colorless gel.  1H-
NMR (CDCl3, 400MHz) δ 1.26 (3H, s), 1.64 (3H, s), 4.57 (1H, s), 4.89 (1H, d, J = 4.0 
Hz), 5.47 (1H, d, J = 4.0 Hz), 6.93 (1H, s), 7.28-7.35 (10H, m); 13C-NMR (CDCl3, 
100MHz) δ 26.2, 31.9, 64.7, 66.6, 67.8, 70.2, 78.4, 126.8, 127.5, 128.1, 128.4, 128.5, 
138.8, 166.5, 169.8; HRMS (FAB, mnba) calc for [C21H20N4O3S + H]+ 409.1334, found 
409.1357. 
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Method C:  p-Nitrobenzyl 6-azidopenicillanate (60a). 4-Nitrobenzyl 6-
aminopenicillanate salt 58a (0.75 g, 1.4 mmol) was suspended in EtOAc (30 mL) and 
washed with saturated NaHCO3 (2 x 20 mL).  The organic layer was dried over Na2SO4 
and concentrated in vacuo to give pure 4-nitrobenzyl 6-aminopenicillanate. To a solution 
of pure 4-nitrobenzyl 6-aminopenicillanate in anhydrous toluene (5 mL) was added triflyl 
azide solution (2.97 mmol) in toluene (25 mL), and Et3N (0.3 mL, 2.1 mmol).  The 
reaction mixture was stirred at room temperature for 2 h.  The reaction was diluted with 
EtOAc (10 mL) and washed with 1N HCl (20 mL), distilled water (2 x 20 mL), and 
saturated brine (20 mL).  The organic layer was dried over Na2SO4 and concentrated in 
vacuo to give 361 mg (70%) of 60a as a yellowish solid. 1H-NMR (CDCl3, 400MHz) δ 
1.42 (3H, s), 1.66 (3H, s), 4.52 (1H, s), 4.92 (1H, d, J = 4.0 Hz), 5.26 (2H, q, J = 24.0, 
12.0 Hz), 5.46 (1H, d, J = 4.0 Hz), 7.53 (2H, d, J = 8.8 Hz), 8.24 (2H, d, J = 8.8 Hz). 
 
p-Methoxybenzyl 6-azidopenicillanate (60b). 6-azidopenicillanate 60b was prepared 
from p-Methoxybenzyl 6-aminopenicillanate 58b (4.0 g, 7.9 mmol) and triflyl azide (25 
mmol) in CH2Cl2 (total volume = 25 mL), and Et3N (1.44 mL, 10.3 mmol) using method 
A.  The reaction mixture was stirred at room temperature for 2 h.  Purification of the 
crude product by flash chromatography (silica, gradient 4:1; 3:1 Hexane/EtOAc) afforded 
1.40 g (49%) of 60b as a colorless gel.  1H-NMR (CDCl3, 100MHz) δ 1.36 (3H, s), 1.61 
(3H, s), 3.79 (3H, s), 4.45 (1H, s), 4.88 (1H, d, J = 4.0 Hz), 5.10 (2H, app. q, J = 24.0, 
12.0 Hz), 5.44 (1H, d, J = 4.0 Hz), 6.87 (2H, d, J = 8.8 Hz), 7.27 (2H, d, J = 8.8 Hz); 13C-
NMR (CDCl3, 400MHz) δ 26.6, 31.7, 55.3, 64.6, 66.5, 67.4, 67.7, 70.2, 113.9, 126.5, 
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130.4, 159.7, 167.2, 169,7; HRMS (FAB, mnba) calc for [C16H18N4O4S + H]+ 363.1127, 
found 363.1151. 
 
Representative Procedure for Cu(I)-Catalyzed Cycloaddition Reaction.  p-
Methoxybenzyl benzyl-6-triazolylpenicillanate (63a).  p-Methoxybenzyl 6-
azidopenicillanate 60b (0.27g, 0.635 mmol) and 3-phenyl-1-propyne 61 (0.17 mL, 1.39 
mmol) were dissolved in anhydrous THF (8 mL) and stirred under argon at room 
temperature.  Copper (I) iodide (0.011 g, 0.06 mmol), and Hunig’s base (0.1 mL) were 
then added to the reaction mixture, and stirring was continued for 2 h.  The reaction 
mixture was diluted with CH2Cl2 (40 mL) and washed with 1:4 NH4OH/saturated NH4Cl 
(3 x 30 mL) and again with saturated NH4Cl (30 mL).  The organic layer was dried over 
Na2SO4 and concentrated in vacuo.  The crude product was purified by flash 
chromatography (silica, gradient 3:1; 2:1; 3:2 Hexane/EtOAc) to give 246 mg (71%) of 
63a as a white solid.  1H-NMR (CDCl3, 400MHz) δ 1.35 (3H, s), 1.57 (3H, s), 3.79 (3H, 
s), 4.08 (2H, s), 4.47 (1H, s), 5.12 (2H, app. q, J = 24.0, 12.0 Hz), 5.69 (1H, d, J = 4.0 
Hz), 6.27 (1H, d, J = 4.4 Hz), 6.88 (2H, d, J = 8.8 Hz), 7.20-7.30 (7H, m), 7.42 (1H, s); 
13C-NMR (CDCl3, 100MHz) δ 26.9, 30.9, 32.0, 55.2, 65.3, 66.2, 67.3, 67.5, 70.5, 114.0, 
122.4, 126.5, 128.5, 128.6, 130.6, 138.5, 147.2, 160.0, 167.1, 168.1; HRMS (FAB, 
thioglycerol) calc for [C25H26N4O4S + H]+ 479.1753, found 479.1756. 
 
Benzhydryl benzyl-6-triazolylpenicillanate (63b).  Reaction of benzhydryl 6-
azidopenicillanate 60c (0.270 g, 0.661 mmol) and 3-phenyl-1-propyne 61 (0.17 mL, 1.39 
mmol) within 2.5 h followed by flash chromatography (silica, gradient 3:1; 2:1; 3:2 
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Hexane/EtOAc) gave 246 mg (71%) of  63b as a white solid. 1H-NMR (CDCl3, 400MHz) 
δ 1.61 (3H, s), 1.57 (3H, s), 4.09 (2H, s), 4.59 (1H, s), 5.73 (1H, d, J = 4.0 Hz), 6.29 (1H, 
d, J = 4.4 Hz), 6.94 (1H, s), 7.21-7.35 (15H, m), 7.43 (1H, s); 13C-NMR (CDCl3, 
100MHz) δ 26.7, 31.2, 32.0, 65.4, 66.3, 67.4, 70.6, 78.6, 122.4, 126.5,126.9, 127.6, 
128.3, 128.5, 128.6, 128.7, 138.5, 138.7, 138.8, 147.3, 166.3, 168.1;  HRMS (FAB, 
mnba) calc for [C30H28N4O3S + H]+ 525.1956, found 525.1960. 
 
Benzhydryl 2,6-dimethoxyphenyl-6-triazolylpenicillanate (63c).  Reaction of 
benzhydryl 6-azidopenicillanate 60c (0.227 g, 0.555 mmol) and 2-Ethynyl-1,3-
dimethoxybenzene 62 (0.06 g, 0.37 mmol) within 4 h followed by flash chromatography 
(silica gel, 1:1 Hexane/EtOAc) gave 120 mg (57%) of 63c as a white solid.  1H-NMR 
(CDCl3, 400MHz) δ 1.26 (3H, s), 1.69 (3H, s), 3.78 (6H, s), 4.64 (1H, s), 5.80 (1H, d, J = 
4.8 Hz), 6.42 (1H, d, J = 4.4 Hz), 6.62 (2H, d, J = 8.4 Hz), 6.96 (1H, s), 7.26-7.35 (11H, 
m), 7.95 (1H, s); 13C-NMR (CDCl3, 100MHz) δ 26.7, 31.4, 56.0, 65.2, 66.4, 67.7, 70.6, 
78.6, 104.1, 125.2, 126.9, 127.6, 128.3, 128.5, 128.6, 128.7, 129.9 138.9, 139.9, 158.3, 
166.4, 168.6; HRMS (FAB, thioglycerol) calcd for [C31H30N4O5S + H]+ 571.2015, found 
571.2049. 
 
Benzhydryl 4-pyridyl-6-triazolylpenicillanate (66a).  4-Ethynylpyridyl hydrochloride 
(0.06 g, 0.414 mmol) was suspended in EtOAc (30 mL) and washed with saturated 
NaHCO3 (1 x 30 mL).  The organic layer was dried over Na2SO4 and concentrated in 
vacuo to give 4-ethynylpyridine 65a as white brown solid.  The reaction of benzhydryl 6-
azidopenicillanate 60c (0.15 g, 0.367 mmol) and 65a (0.076 g, 0.734 mmol) within 3 h 
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followed by flash chromatography (silica gel, gradient 1:1; 1:4 Hexane/EtOAc) gave 166 
mg (74%) of 66a as a white solid.  1H-NMR (CDCl3, 400MHz) δ 1.26 (3H, s), 1.69 (3H, 
s), 4.65 (1H, s), 5.80 (1H, d, J = 4.0 Hz), 6.39 (1H, d, J = 4.0 Hz), 6.96 (1H, s), 7.32-7.36 
(10H, m), 7.77 (2H, d, J = 5.20 Hz ), 8.19 (1H, s), 9.03(2H, d, J = 5.20 Hz); 13C-NMR 
(CDCl3, 100MHz) δ 26.8, 31.1, 65.7, 66.2, 67.2, 70.8, 78.8, 120.1, 122.1, 126.7, 127.5, 
128.2, 128.4, 128.5, 138.6, 138.6, 144.5, 149.2, 165.9, 167.5;  HRMS (FAB, 
thioglycerol) calc for [C28H25N5O3S + H]+ 512.1756, found 512.1763. 
 
Benzhydryl 3-pyridyl-6-triazolylpenicillanate (66b).  The reaction of benzhydryl 6-
azidopenicillanate 60c (0.15 g, 0.441 mmol) and 3-ethynylpyridine 65b (0.068 g, 0.661 
mmol) within 3 h followed by flash chromatography (silica gel, gradient 1:1; 1:3 
Hexane/EtOAc) gave 170 mg (76%) of 66b as a white solid.  1H-NMR (CDCl3, 400MHz) 
δ 1.26 (3H, s), 1.70 (3H, s), 4.66 (1H, s), 5.80 (1H, d, J = 4.0 Hz), 6.40 (1H, d, J = 4.0 
Hz), 6.96 (1H, s), 7.32-7.36 (10H, m), 8.13 (1H, s), 8.26 (1H, d, J = 8.24 Hz ), 8.58 (1H, 
br s), 9.03(1H, br s); 13C-NMR (CDCl3, 100MHz) δ 26.9, 31.1, 65.7, 66.3, 67.3, 70.7, 
78.7, 120.8, 126.7, 127.5, 128,2, 128,4, 128,5, 133.8, 138.5, 138.6, 138.6, 144.0, 146.1, 
148.3, 166.0, 167.6; HRMS (FAB, thioglycerol) calc for [C28H25N5O3S + H]+ 512.1756, 
found 512.1773. 
 
Benzhydryl 2-pyridyl-6-triazolylpenicillanate (66c).  The reaction of benzhyldryl 6-
azidopenicillanate 60c (0.15 g, 0.367 mmol) and 2-ethynylpyridine 65c (0.06 mL, 0.55 
mmol) within 6 h followed by flash chromatography (silica gel, gradient 4:1; 2:1; 1:2; 
Hexane/EtOAc) gave 145 mg (64%) of 66c as a white solid.  1H-NMR (CDCl3, 400MHz) 
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δ 1.25 (3H, s), 1.71 (3H, s), 4.64 (1H, s), 5.78 (1H, d, J = 4.0 Hz), 6.39 (1H, d, J = 4.0 
Hz), 6.96 (1H, s), 7.32-7.36 (10H, m), 7.78 (1H, m), 8.18 (1H, d, J = 7.69 Hz), 8.45 (1H, 
s), 8.58 (1H, d, J = 4.39 Hz); 13C-NMR (CDCl3, 100MHz) δ 26.9, 31.3, 65.7, 66.5, 67.4, 
70.8, 78.7, 120.5, 123.0, 126.8, 127.5, 128.2, 128.4, 128.5, 128.6, 138.6, 138.7, 166.1, 
167.8;  HRMS (FAB, thioglycerol) calc for [C28H25N5O3S + H]+ 512.1756, found 
512.1765. 
 
Benzhydryl 2-thiopyl-6-triazolylpenicillanate (66d).  Reaction of benzhydryl 6-
azidopenicillanate 60c (0.15 g, 0.367 mmol) and 3-ethynylthiopene 65d (0.06 g, 0.55 
mmol) within 5 h followed by flash chromatography (silica gel, gradient 1:0; 5:1; 3:1 
Hexane/EtOAc) gave 150 mg (79%) of 66d as a white solid.  1H-NMR (CDCl3, 400MHz) 
δ 1.25 (3H, s), 1.69 (3H, s), 4.64 (1H, s), 5.78 (1H, d, J = 4.4 Hz), 6.36 (1H, d, J = 4.0 
Hz), 6.96 (1H, s), 7.30-7.38 (11H, m), 7.44 (1H, dd, J =4.0, 1.2 Hz), 7.70 (1H, dd, J = 
2.0, 1.2 Hz), 7.90 (1H, s); 13C-NMR (CDCl3, 100MHz) δ 26.7, 30.9, 66.1, 67.3, 70.8, 
78.7, 120.1, 121.6, 125.7, 126.4, 126.9, 127.6, 128.3, 128.6, 128.7, 131.1, 138.7, 138.8, 
143.8, 166.3, 168.2; HRMS (FAB, thioglycerol) calc for [C27H24N4O3S2 + H]+ 517.1368, 
found 517.1374. 
 
p-Methoxybenzyl phenyl-6-triazolylpenicillanate (66e).  Reaction of  p-
methoxybenzyl-6-azidopenicillanate 60b (0.15 g, 0.414 mmol) and phenylacetylene 65e 
(0.14 mL, 1.24 mmol) within 2 h followed by flash chromatography (silica gel, gradient 
3:1; 3:2 Hexane/EtOAc) gave 165 mg (86%) of 66e as a white foam.  1H-NMR (CDCl3, 
400MHz) δ 1.38 (3H, s), 1.66 (3H, s), 3.80 (3H, s), 4.54 (1H, s), 5.14 (2H, app. q, J = 
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24.0, 12.0 Hz), 5.75 (1H, d, J = 4.0 Hz), 6.37 (1H, d, J = 4.0 Hz), 6.89 (2H, d, J = 8.8 
Hz), 7.29-7.35 (3H, m), 7.39-7.42 (2H, m), 7.82 (2H, m), 7.99 (1H, s); 13C-NMR (CDCl3, 
100MHz) δ 27.0, 30.8, 55.2, 65.4, 66.1, 67.2, 67.6, 70.7, 114.0, 120.3, 125.8, 126.5, 
128.4, 128.8, 129.9, 130.6, 147.5, 160.0, 167.1, 168.2; HRMS (FAB, thioglycerol) calc 
for [C24H24N4O4S + H]+ 465.1596, found 465.1571. 
 
Benzhydryl α-hydroxylbenzyl-6-triazolylpenicillanate (66f).  Reaction of benzhydryl 
6-azidopenicillanate 60c (0.2 g, 0.49 mmol) and 1-phenylprop-2-yn-1-ol 65f (0.13 g, 
0.985 mmol) within 2 h followed by flash chromatography (silica gel, 2:1 
Hexane/EtOAc) gave 191 mg (72%) of 66f as a white solid.  1H-NMR (CDCl3, 400MHz) 
δ 1.23 (3H, d, J = 12 Hz), 1.59 (3H, d, J = 8.0 Hz), 4.61 (1H, s), 5.71 (1H, d, J = 4.4 Hz), 
5.99 (1H, d, J = 5.2 Hz), 6.23 (1H, dd, J = 4.0, 1.6 Hz), 6.95 (1H, s), 7.24-7.42 (15H, m), 
7.57 (1H, s). 13C-NMR (CDCl3, 100MHz) δ 26.6, 31.2, 31.3, 65.3, 65.3, 66.3, 66.4, 67.3, 
67.4, 68.7, 68.9, 70.4, 70.5, 78.5, 122.0, 122.1, 126.1, 126.2, 126.3, 126.4, 126.6, 126.7, 
127.1, 127.3, 127.6, 127.7, 128.0, 128.2, 128.3, 128.4, 138.5, 138.6, 141.5, 150.9, 166.0, 
167.4, 167.5; HRMS (FAB, thioglycerol) calc for [C30H28N4O4S + H]+ 541.1909, found 
541.1936. 
 
Benzhydryl 4-biphenyl-6-triazolylpenicillanate (66g).  Reaction of benzhydryl 6-
azidopenicillanate 60c (0.15 g, 0.367 mmol) and 4-ethynylbiphenyl 65g (0.098 g, 0.55 
mmol) within 5 h followed by flash chromatography (silica gel, gradient 1:0; 5:1; 3:1 
Hexane/EtOAc) gave 158 mg (73%) of 66g as a white solid.  1H-NMR (DMSO-d6, 
400MHz) δ 1.26 (3H, s), 1.69 (3H, s), 4.92 (1H, s), 5.88 (1H, d, J = 2.0 Hz), 6.81 (1H, d, 
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J = 2.0 Hz), 6.96 (1H, s), 7.32 (2H, d, J = 8.0 Hz), 7.38 (5H, t, J = 7.2 Hz), 7.47 (5H, t, J 
= 6.8 Hz), 7.52 (2H, d, J = 8.0 Hz), 7.77 (2H, d, J = 8.0 Hz), 7.90 (2H, d, J = 8.0 Hz), 
8.66 (1H, s) 
 
Benzhydryl 3-biphenyl-6-triazolylpenicillanate (66h).  Reaction of benzhydryl 6-
azidopenicillanate 60c (0.15 g, 0.367 mmol) and 3-ethynylbiphenyl 65h (0.098 g, 0.55 
mmol) within 5 h followed by flash chromatography (silica gel, gradient 1:0; 5:1; 3:1 
Hexane/EtOAc) gave 215 mg (100%) of 66h as a white solid.  1H-NMR (CDCl3, 
400MHz) δ 1.14 (3H, s), 1.58 (3H, s), 4.54 (1H, s), 5.68 (1H, d, J = 4.4 Hz), 6.28 (1H, d, 
J = 4.0 Hz), 6.86 (1H, s), 7.12 (1H, s), 7.19-7.24 (10H, m), 7.31-7.39 (3H, m), 7.45 (1H, 
d, J = 8.0 Hz), 7.52 (2H, d, J = 8.0 Hz), 7.69 (2H, d, J = 8.0 Hz), 7.95 (1H, s); 13C-NMR 
(CDCl3, 100MHz) δ 26.7, 30.9, 65.5, 66.2, 67.3, 70.7, 78.7, 120.5, 124.6, 124.7, 126.9, 
127.2, 127.5, 127.6, 128.3, 128.5, 128.6, 128.7, 129.3, 130.4, 138.7, 138.8, 140.6, 141.9, 
147.5, 166.3, 168.2;  HRMS (FAB, thioglycerol) calc for [C35H30N4O3S + H]+ 587.2116, 
found 587.2143. 
 
Benzhydryl 2-biphenyl-6-triazolylpenicillanate (66i).  Reaction of benzhydryl 6-
azidopenicillanate 60c (0.15 g, 0.367 mmol) and 2-ethynylbiphenyl 65i (0.098 g, 0.55 
mmol) within 5 h followed by flash chromatography (silica gel, gradient 1:0; 5:1; 3:1 
Hexane/EtOAc) gave 150 mg (70%) of 66i as a white solid.  1H-NMR (CDCl3, 400MHz) 
δ 1.20 (3H, s), 1.47 (3H, s), 4.47 (1H, s), 5.63 (1H, d, J = 4.0 Hz), 6.26 (1H, d, J = 4.4 
Hz), 6.80 (1H, s), 6.93 (1H, s), 7.22-7.45 (18H, m), 8.15 (1H, d, J = 8.0 Hz); 13C-NMR 
(CDCl3, 100MHz) δ 26.7, 31.3, 65.4, 66.3, 67.4, 70.4, 78.6, 123.0, 126.9, 127.2, 127.5, 
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127.8, 128.1, 128.2, 128.5, 128.6, 128.6, 128.7, 128.8, 129.2, 130.3, 138.8, 140.2, 141.5, 
166.3, 167.0;  HRMS (FAB, thioglycerol) calc for [C35H30N4O3S + H]+ 587.2116, found 
587.2143. 
 
Benzhydryl 6-methoxynapthalyl-6-triazolylpenicillanate (66j).  Reaction of 
benzhydryl 6-azidopenicillanate 60c (0.15 g, 0.367 mmol) and 2-ethynyl-6-
methoxylnapthalene (0.067 g, 0.37 mmol) within 5 h followed by flash chromatography 
(silica gel, gradient 1:0; 5:1; 3:1 Hexane/EtOAc) gave 175 mg (81%) of 66j as a white 
solid.  1H-NMR (CDCl3, 400MHz) δ 1.27 (3H, s), 1.72 (3H, s), 3.91 (3H, s), 4.67 (1H, s), 
5.80 (1H, d, J = 4.4 Hz), 6.41 (1H, d, J = 4.4 Hz), 6.97 (1H, s), 7.13-7.16 (2H, m), 7.31-
7.35 (10H, m), 7.77 (2H, dd, J = 6.4, 2.8 Hz), 7.88 (1H, dd, J = 6.4, 1.6 Hz), 8.08 (1H, s), 
8.26 (1H, s); 13C-NMR (CDCl3, 100MHz) δ 26.7, 31.0, 55.3, 65.5, 66.2, 67.3, 70.8, 78.7, 
119.3, 120.2, 124.3, 124.6, 125.1, 126.9, 127.4, 127.6, 128.3, 128.6, 128.7, 128.9, 129.7, 
134.4, 138.7, 138.8, 147.7, 158.0, 166.3, 168.2; HRMS (FAB, mnba) calc for 
[C34H30N4O4S + H]+ 591.2066, found 591.2061. 
 
Benzhydryl 4-pyridylphenyl-6-triazolylpenicillanate (66k).  Reaction of benzhydryl 6-
azidopenicillanate 60c (0.15 g, 0.367 mmol) and 4-(4-ethynylphenyl)pyridine 65k (0.098 
g, 0.55 mmol) within 5 h followed by flash chromatography (silica gel, gradient 1:1; 1:2; 
1:4 Hexane/EtOAc) gave 202 mg (94%) of 66k as a white solid.  1H-NMR (CDCl3, 
400MHz) δ 1.27 (3H, s), 1.71 (3H, s), 4.66 (1H, s), 5.80 (1H, d, J = 4.0 Hz), 6.40 (1H, d, 
J = 4.0 Hz), 6.97 (1H, s), 7.31-7.35 (12H, m), 7.61 (2H, br s), 7.72 (2H, d, J = 8.0 Hz), 
7.97 (2H, d, J = 8.0 Hz), 8.09 (1H, s); 13C-NMR (CDCl3, 100MHz) δ 26.7, 30.9, 65.6, 
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66.2, 67.3, 70.7, 78.7, 120.8, 126.5, 126.9, 127.5, 127.6, 128.3, 128.6, 128.7, 131.2, 
137.3, 138.7, 138.8, 146.6, 148.8, 148.9166.3, 168.1; HRMS (FAB, thioglycerol) calc for 
[C34H29N5O3S + H]+ 588.2069, found 588.2100.  
 
Benzhydryl 4-pyridylbenzylhydroxyl-6-triazolylpenicillanate (66l).  Reaction of 
benzhydryl 6-azidopenicillanate 60c (0.15 g, 0.367 mmol) and  1-(4-(pyrdin-4-yl)prop-2-
yn-1-ol 65l (0.115 g, 0.55 mmol) within 2 h followed by flash chromatography (silica gel, 
gradient 1:2; 1:3 Hexane/EtOAc) gave 190 mg (84%) of 66l as a white solid.  1H-NMR 
(CDCl3, 400MHz) δ 1.22 (3H, d, J = 12 Hz), 1.60 (3H, d, J = 5.6 Hz), 4.58 (1H, s), 5.72 
(1H, d, J = 4.4 Hz), 6.08 (1H, s), 6.28 (1H, d, J = 4.4 Hz), 6.92 (1H, s), 7.24-7.32 (10H, 
m), 7.44 (2H, dd, J = 6.0, 1.6 Hz ) 7.52-7.58 (4H, m), 7.67 (1H, s), 8.53 (2H, dd, J = 6.4, 
1.6 Hz). 13C-NMR (CDCl3, 100MHz) δ 26.7, 30.6, 31.1, 31.2, 64.3, 65.4, 66.2, 66.3, 
67.3, 68.4, 68.5, 70.5, 78.6, 121.4, 122.0, 126.6, 126.9, 127.1, 127.4, 128.1, 128.3, 128.4, 
128.5, 137.1, 137.2, 138.5, 142.9, 147.8, 149.6, 150.8, 150.9, 166.0, 167.5, 167.6; HRMS 
(FAB, thioglycerol) calc for [C35H31N5O4S + H]+ 618.2175, found 618.2180 
 
Representative Procedure for Deprotection of Carboxyl Protecting Group.  Benzyl-
6-triazolylpenicillanic acid (64a).  p-Methoxybenzyl benzyl-6-triazolylpenicillanate 63a 
(0.13 g, 0.26 mmol) was dissolved and stirred in anhydrous CH2Cl2 (1 mL) at -5oC.  
Anhydrous anisole (0.2 mL, 1.83 mmol) and trifluoroacetic acid (0.5 mL, 6.49 mmol) 
were added, and the reaction mixture stirred for 2 h.  The reaction mixture was diluted 
with cold Et2O (10 mL), and the solvent was evaporated off in an ice bath.  The residue 
was concentrated in vacuo on an ice bath for 15 minutes, and redissolved in THF (5 mL) 
163 
 
and ½ saturated NaHCO3 (15 mL) at 0oC.  The resulting mixture was stirred at 0oC for 15 
minutes and partitioned between deionized water (5 mL) and EtOAc (20 mL).  The two 
layers were separated and the aqueous layer was extracted with EtOAc (2 x 20 mL).  The 
aqueous layer was acidified to pH 3 in an ice bath with 1N HCl and extracted with 
EtOAc (3 x 20 mL).  The combined organic layer was dried over Na2SO4 and 
concentrated in vacuo to give 89 mg (100%) of 64a as a white solid.  1H-NMR (acetone-
d6, 400MHz) δ 1.55 (3H, s), 1.70 (3H, s), 4.07 (2H, s), 4.55 (1H, s), 5.85 (1H, d, J = 4.4 
Hz), 6.58 (1H, d, J = 4.4 Hz), 7.26-7.28 (5H, m), 7.79 (1H, s); 13C-NMR (acetone-d6, 
100MHz) δ 26.8, 31.0, 31.8, 65.1, 67.0, 67.8, 70.7, 123.2, 126.7, 128.8, 128.9, 129.0, 
139.9, 168.4, 168.5;  HRMS (FAB, mnba) calc for [C17H18N4O3S + H]+ 359.1177, found 
359.1177.  
 
2,6-Dimethoxyphenyl-6-triazolylpenicillanic acid (64b).  The reaction of a CH2Cl2 
solution of 63c with anisole and TFA within 2 h, as described for the synthesis of 64a 
from 63a, afforded 85 mg (100%) of 64b as a white solid.  1H-NMR (acetone-d6, 
400MHz) δ 1.59 (3H, s), 1.77 (3H, s), 3.77 (6H, s), 4.62 (1H, s), 5.93 (1H, d, J = 4.4 Hz), 
6.73 (1H, d, J = 4.4 Hz), 6.74 (2H, d, J = 8.4 Hz), 7.35 (1H, t, J = 8.4 Hz), 8.15 (1H, s); 
13C-NMR (acetone-d6, 400MHz) δ 26.9, 31.2, 55.9, 65.2, 67.2, 68.0, 70.7, 104.6, 126.2, 
131.0, 158.7, 168.6; HRMS (FAB, mnba) calc for [C18H20N4O5S + H]+ 405.1232, found 
405.1214. 
4-pyridyl-6-triazolylpenicillanic acid (67a).  The reaction of a CH2Cl2 solution of 66a 
with anisole and TFA within 0.5 h, as described for the synthesis of 64a from 63a, 
afforded 80 mg (100%) of 67a as a white solid. 1H-NMR (acetone-d6, 400MHz) δ 1.56 
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(3H, s), 1.73 (3H, s), 4.60 (1H, s), 5.95 (1H, d, J = 4.0 Hz), 6.78 (1H, d, J = 4.0 Hz), 8.57 
(2H, br s), 9.01 (2H, br s), 9.07 (1H, s); 13C-NMR (acetone-d6, 100MHz) δ 27.1, 31.6, 
65.7, 67.7, 68.0, 71.4, 122.8, 126.8, 142.8, 143.6, 146.6, 167.5, 170.7; HRMS (FAB, 
mnba) calc for C15H15N5O3S + H]+ 346.0973, found 346.0972.  
 
3-pyridyl-6-triazolylpenicillanic acid (67b).  The reaction of a CH2Cl2 solution of 66b 
with anisole and TFA within 0.5 h, as described for the synthesis of 64a from 63a, 
afforded 80 mg (100%) of 67b as a reddish white solid.  1H-NMR (acetone-d6, 400MHz) 
δ 1.57 (3H, s), 1.74 (3H, s), 4.60 (1H, s), 5.95 (1H, d, J = 4.0 Hz), 6.76 (1H, d, J = 4.0 
Hz), 8.15 (1H, br s), 8.84 (1H, s), 8.92 (2H, m), 9.41 (1H, br s); HRMS (FAB, mnba) calc 
for [C15H15N5O3S + H]+ 346.0973, found 346.0972. 
 
2-pyridyl-6-triazolylpenicillanic acid (67c).  The reaction of a CH2Cl2 solution of 66c 
with anisole and TFA within 0.5 h, as described for the synthesis of 64a from 63a, 
afforded 80 mg (100%) of 67c as a white solid. 1H-NMR (acetone-d6, 400MHz) δ 1.57 
(3H, s), 1.76 (3H, s), 4.63 (1H, s), 5.95 (1H, d, J = 4.0 Hz), 6.79 (1H, d, J = 4.0 Hz), 7.79 
(1H, m), 8.39 (1H, m), 8.48 (1H, m), 8.90 (1H, d, J = 5.1 Hz), 8.95 (1H, s); 13C-NMR 
(acetone-d6, 100MHz) δ 27.1, 31.5, 65.7, 67.6, 68.0, 71.2, 122.8, 125.3, 125.7, 143.2, 
145.9, 146.7, 160.2, 167.8, 168.6; HRMS (FAB, mnba) calc for [C15H15N5O3S + H]+ 
346.0973, found 346.0974. 
 
2-Thiopyl-6-triazolylpenicillanic acid (67d).  The reaction of a CH2Cl2 solution of 66d 
with anisole and TFA within 1 h, as described for the synthesis of 64a from 63a, afforded 
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81 mg (100%) of 67d as a yellowish solid. 1H-NMR (acetone-d6, 400MHz) δ 1.57 (3H, 
s), 1.74 (3H, s), 4.59 (1H, s), 5.90 (1H, d, J = 4.0 Hz), 6.65 (1H, d, J = 4.0 Hz), 7.54 (1H, 
m), 7.57 (1H, dd, J = 3.0, 1.5 Hz), 7.87 (1H, dd, J = 3.0, 1.5 Hz), 8.34 (1H, s); 13C-NMR 
(acetone-d6, 100MHz) δ 27.1, 31.3, 65.4, 67.3, 68.0, 71.2, 121.4, 121.6, 126.3, 127.1, 
132.4, 143.7, 168.3, 168.9; HRMS (FAB, mnba) calc for [C14H14N4O3S2 +H]+ 351.0585, 
found 351.0577. 
 
Phenyl-6-triazolylpenicillanic acid (67e).   The reaction of a CH2Cl2 solution of 66e 
with anisole and TFA within 2 h, as described for the synthesis of 64a from 63a, afforded 
68.5 mg (93%) of 67e as a white solid. 1H-NMR (acetone-d6, 400MHz) δ 1.47 (3H, s), 
1.67 (3H, s), 4.54 (1H, s), 5.80 (1H, d, J = 4.0 Hz), 6.76 (1H, d, J = 4.4 Hz), 7.34 (1H, 
m), 7.44 (2H, m), 7.89 (2H, m), 8.60 (1H, s); 13C-NMR (acetone-d6, 100MHz) δ 27.2, 
31.2, 65.4, 67.3, 68.0, 71.2, 121.6, 126.1, 126.1, 128.6, 129.4, 131.3, 147.3, 168.4; 
HRMS (FAB, mnba) calc for [C16H16N4O3S + H]+ 345.1021, found 345.1015.  
 
α-Hydroxylbenzyyl-6-triazolylpenicillanic acid (67f). The reaction of a CH2Cl2 
solution of 66f with thioanisole and TFA within 0.5 h, as described for the synthesis of 
64a from 63a, afforded 76 mg (100%) of 67f as a pale yellowish solid. 1H-NMR 
(acetone-d6, 400MHz) δ 1.53 (3H, s), 1.67 (3H, s), 3.37 (1H, s), 4.55 (1H, s), 5.84 (1H, 
bs), 5.97 (1H, s), 6.55 (1H, bs), 7.22-7.43 (4H, m), 7.80 (1H, s); HRMS (FAB, 
thioglycerol) calc for [C17H18N4O4S + H]+ 375.1127, found 375.1192.  
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4-Biphenyl-6-triazolylpenicillanic acid (67g).  The reaction of a CH2Cl2 solution of 66g 
with anisole and TFA within 2 h, as described for the synthesis of 64a from 63a, afforded 
65 mg (100%) of 67g as a yellowish solid. 1H-NMR (DMSO-d6, 400MHz) δ 1.48 (3H, s), 
1.65 (3H, s), 4.38 (1H, s), 5.79 (1H, d, J = 4.0 Hz), 6.72 (1H, d, J = 4.0 Hz), 7.35-7.40 
(1H, m), 7.47 (2H, t, J = 8.0 Hz), 7.74 (4H, dd, J = 11.2, 8.0 Hz), 7.99 (2H, d, J = 8.0 
Hz), 8.63 (1H, s); HRMS (FAB, mnba) calc for [C22H20N4O3S + H]+ 421.1334, found 
421.1333. 
 
3-Biphenyl-6-triazolylpenicillanic acid (67h).  The reaction of a CH2Cl2 solution of 66h 
with anisole and TFA within 2 h, as described for the synthesis of 64a from 63a, afforded 
54 mg (83%) of 67h as a white solid.  1H-NMR (acetone-d6, 400MHz) δ 1.59 (3H, s), 
1.77 (3H, s), 4.61 (1H, s), 5.93 (1H, d, J = 4.0 Hz), 6.71 (1H, d, J = 4.0 Hz), 7.38 (1H, 
m), δ 7.48 (2H, m), 7.54 (1H, t, J = 8.0 Hz), 7.64 (1H, m), 7.72 (2H, m), 7.96 (1H, dt, J = 
8.0, 1.5 Hz), 8.23 (1H, t, 1.5 Hz), 8.58 (1H, s); 13C-NMR (acetone-d6, 100MHz) δ 27.2, 
31.2, 65.5, 67.3, 68.0, 71.3, 122.0, 124.6, 125.1, 127.2, 127.5, 128.1, 129.4, 130.0, 131.9, 
141.1, 142.2, 147.2, 168.4, 168.9; HRMS (ESI, mnba) calc for [C22H20N4O3S + H]+ 
421.1329, found 421.1312. 
 
2-Biphenyl-6-triazolylpenicillanic acid (67i).  The reaction of a CH2Cl2 solution of 66i 
with anisole and TFA within 1 h, as described for the synthesis of 64a from 63a, afforded 
65 mg (100%) of 67i as a white solid. H-NMR (acetone-d6, 400MHz) δ 1.53 (3H, s), 1.59 
(3H, s), 4.41 (1H, s), 5.78 (1H, d, J = 4.0 Hz), 6.55 (1H, d, J = 4.0 Hz), 7.00 (1H, s), 
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7.22-7.25 (2H, m), 7.32-7.52 (6H, m), 8.07 (1H, dd, J = 5.8, 1.5 Hz); HRMS (ESI, mnba) 
calc for [C22H20N4O3S + H}+ 421.1329, found 421.1359. 
 
6-Methoxynaphthalyl-6-triazolylpenicillanic acid (67j).  The reaction of a CH2Cl2 
solution of 66j with anisole and TFA within 1 h, as described for the synthesis of 64a 
from 63a, afforded 56 mg (89%) of 67j as a white foam. 1H-NMR (DMSO-d6, 400MHz) 
δ 1.58 (3H, s), 1.78 (3H, s), 3.91 (3H, s), 4.17 (1H, s), 5.80 (1H, d, J = 4.0 Hz), 6.62 (1H, 
d, J = 4.0 Hz), 7.16 (1H, dd, J = 6.5, 2.2 Hz), 7.30 (1H, m), 7.85 (2H, dd, J = 3.0, 5.0 
Hz), 7.98 (1H, m), 8.39 (1H, m), 8.55 (1H, s); 13C-NMR (acetone-d6, 100MHz) δ 26.7, 
30.7, 55.1, 65.0, 67.0, 67.6, 70.8, 106.1, 119.5, 121.3, 124.4, 124.5, 126.2, 127.7, 129.3, 
129.9, 134.9, 147.4, 158.4, 168.3, 168.4; HRMS (FAB, thioglycerol) calc for 
[C21H20N4O4S + H]+ 425.1283, found 425.1264. 
 
4-Pyridylphenyl-6-triazolylpenicillanic acid (67k).  The reaction of a CH2Cl2 solution 
of 66k with anisole and TFA within 1 h, as described for the synthesis of 64a from 63a, 
afforded 37 mg (65%) of 67k as a white foam.  1H-NMR (acetone-d6, 400MHz) δ 1.58 
(3H, s), 1.77 (3H, s), 4.61 (1H, s), 5.94 (1H, d, J = 4.0 Hz), 6.74 (1H, d, J = 4.0 Hz), 8.17 
(4H, m), 8.47 (2H, br s), 8.64 (1H, s), 9.04 (2H, br s); HRMS (FAB, mnba) calc for 
[C21H19N5O3S + H]+ 422.1287, found 422.1301. 
 
4-Pyridylbenzylhydroxyl-6-triazolylpenicillanic acid salt (67l).  Benzhydryl 4-
pyridylphenyl-6-triazolylpenicillanate 66l (0.09 g, 0.14 mmol) was dissolved and stirred 
in anhydrous CH2Cl2 (1 mL) at -5oC.  Anhydrous thioanisole (0.2 mL, 1.83 mmol) and 
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TFA (0.5 mL, 6.49 mmol) were added, and the reaction mixture stirred for 0.5 h.  The 
reaction mixture was diluted with cold Et2O (10 mL), and the solvent was evaporated off 
in an ice bath.  The residue was concentrated in vacuo on an ice bath for 15 minutes, and 
redissolved in aqueous NaHCO3 (0.018 g, 0.21 mmol) at 0oC.  The resulting mixture was 
stirred at 0oC for 15 minutes and partitioned between deionized water (5 mL) and EtOAc 
(20 mL).  The two layers were separated and the aqueous layer was extracted with EtOAc 
(2 x 20 mL).  The aqueous layer was frozen in acetone-dry ice bath and concentrated in 
vacuo to give 35 mg (52%) of 67l as a white solid. 1H-NMR (DMSO-d6, 400MHz) δ 1.46 
(3H, s), 1.61 (3H, m), 4.51 (1H, s), 5.75 (1H, d, J = 4.4 Hz), 5.94 (1H, s), 6.67 (1H, d, J = 
4.0 Hz), 7.57 (2H, d, J = 8.0 Hz), 7.86 (4H, m), 8.75 (2H, m); HRMS (FAB, mnba) calc 
for [C22H20N5NaO4S + H]+ 474.1212, found 474.1234. 
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ketophosphonates and a-diazophoshonoacetates. Synth. Commun. 1984, 14, 155-
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CHAPTER 5 
 
HETEROGENEOUS DIAZO-TRANSFER REACTION:  A FACILE 
UNMASKING OF AZIDE GROUP ON AMINE-FUNCTIONALIZED 
INSOLUBLE SUPPORTS FOR SOLID PHASE SYNTHESIS 
 
 
 
5.1 Solid Phase Synthesis 
 
Solid-phase synthesis (SPS) has become a routine and unmatched method for the 
synthesis of biomacromolecules such as peptide, DNA and RNA.1 Vital to the success of 
SPS is an optimal covalent attachment of the leader monomer onto insoluble supports. 
Majority of the protocols for the immobilization of leader monomer onto solid supports 
are based on alkylation and acylation reactions. However, these protocols usually require 
special procedures, which in untrained hands, are often difficult and time consuming. For 
example, attachment of a substrate nucleoside onto a commercially available insoluble 
solid support such as 3-aminopropylated-CPG could take days to accomplish, under 
rigorous exclusion of moisture.2 Also, partial support-loading could result in unwanted 
side-reactions which could compromise product quality. To address these problems and 
expand the scope of functionalities which can serve as handle for SPS, a large collection 
of linkers have been investigated and developed.3-6 However, the vast majority of these 
linkers still rely on the traditional coupling protocols for the monomer support 
attachment. It is therefore of prime interest to have flexible synthetic methodologies for 
rapid loading of leader monomers onto the supports.  This realization has continued to 
spawn immense efforts in the literature.7-12    
The utility of organic azides in bioconjugations and synthetic organic chemistry 
applications is enjoying a renaissance. They are extensively used in photoaffinity labeling 
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of biomacromolecules,13 the Staudinger ligation reaction,14 and protection strategy for 
amines.15  Moreover, with the recent discovery of  Cu(I) catalysis, termed click chemistry 
by Sharpless and co-workers,16 Huigsen cycloaddition reaction between azides and 
terminal alkynes has become the premier conjugation technique in chemistry, biology and 
material science applications. Click chemistry has allowed rapid construction of complex 
macromolecules, whole cell and organism modification, and small molecules with 
diverse biological properties.17
There are several methods for the synthesis of organic azides.18, 19 Among these 
are substitution reactions between various electrophiles and azide nucleophiles to 
generate aliphatic azides. Aromatic azides can be easily prepared by diazotization of the 
corresponding amines;18, 20 and reaction of aryl Grignard or lithium reagents and aryl 
amide salts with para-tosylazide.21, 22  Solid-supported azides have been principally 
generated by direct nucleophilic displacement of appropriately activated supports.23-25 
This reaction usually proceeds rather sluggishly under harsh conditions.  More 
conveniently, a direct conversion of organic amines to azides (diazo-transfer) is 
commonly achieved by the reaction of the corresponding amine with triflyl azide 
[Caution! Triflyl azide may be explosive and it should be handled with care. However, 
we have not experienced any difficulties in handling triflyl azide].15, 26 Diazo-transfer is a 
high-yielding reaction that proceeds under mild conditions, and it is especially useful for 
the synthesis of tertiary azides where steric hindrance precludes the traditional synthesis 
through a direct nucleophilic displacement of leaving groups such as halides and sulfates. 
Commercially available are numerous amine-attached insoluble solid supports, whose 
surfaces offer a challenging steric maze that may be well-suited for diazo-transfer 
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reaction. Inspired by this possibility, we investigated the feasibility of heterogeneous 
diazo-transfer reaction. We report that triflyl azide rapidly reacts with a series of amine 
functionalized solid-supports to generate azide-coated supports. The “azide-coat” was 
further shown to allow a facile loading of alkyne-functionalized leader nucleoside-
monomers and subsequent assembly of oligonucleotides by conventional SPS methods.  
These results extend the scope of amine-azide conversion reaction and also demonstrate 
the suitability of click-chemistry in the support-attachment of leader nucleoside-
monomers for solid phase oligonucleotide synthetic applications.   
 
5.2 Heterogeneous Diazo-transfer Reaction  
 Firstly, we investigated the possibility of reaction of triflyl azide with ArgoPore-
NH2 resin.  Diazo-transfer reaction was initiated with seven-mole excess of freshly 
prepared triflyl azide (Figure 5-1a).26e, h The reaction progress was monitored by 
quantitative ninhydrin analysis and FTIR. We noticed a clear distinction between 
solution-phase and heterogeneous diazo-transfer reaction; namely, the heterogeneous 
reaction proceeded rapidly in the presence of Cu (II) catalyst.26e The reaction reached its 
maxima within 4h as judged by quantitative ninhydrin analysis27 (Table 5-1) and the 
presence of azide moiety was confirmed by FTIR (2097 cm-1)28 (Figure 5-1b). In the 
absence of Cu (II) catalyst, the reaction proceeded at a much slower rate, reaching 
maximal conversion at 21h (Table 5-1).   
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(a) 
 
(b) 
 
Figure 5-1: Analysis of heterogeneous diazo-transfer Reactions.  (a) Conditions for 
heterogeneous diazo-transfer reaction (the blue circle represents the part of the resin 
unaffected by the reaction). (b) FTIR spectra (KBr) of Cu (II) catalyzed reaction: (i) 
unmodified resin, (ii) 20 min reaction time, and (iii) 21 h reaction time. 
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Table 5-1: Quantification of the extent of heterogeneous diazo-transfer reaction of 
ArgoPore-NH2 resin in the presence (a) and absence (b) of Cu (II) catalyst (Quantitative 
ninhydrin analysis). 
(a)     (b)    
Reaction 
Time (min) 
mmol/g 
NH2
mmol/g 
N3 a
% NH2 
Conversion 
 Reaction 
Time (min) 
mmol/g 
NH2
mmol/g 
N3 a
% NH2 
Conversion 
0 1.174 b - -  0 1.174 - - 
20 0.126 1.048 89.3  20 0.683 0.491 41.8 
60 0.084 1.090 92.8  60 0.260 0.914 77.9 
240 0.048 1.126 95.9  240 0.142 1.032 87.9 
1260 0.057 1.117 95.1 c  1260 0.039 1.135 96.7 
a mmol/g N3 was calculated from the difference between mmol/g NH2 of unmodified 
resin and mmol/g NH2 at a given time during the course of the reaction, b standard 
loading ArgoPore-NH2 resin, recommended manufacturer loading capacity is 
0.90mmol/g, c. within the limit of assay error obtained from standard deviation from two 
experiments. 
 
 
Based on this interesting result, we sought to probe the generality of this reaction.  
We turned to investigate the reactivity of four additional commercial amine-terminated 
resins, namely: aminopropylated-CPG, Tentagel S-NH2, polystyrene A-NH2 and 
(aminomethyl) polystyrene. These resins each offer different arrays of polymeric 
backbones and conceivably varied steric environments. Tentagel S-NH2, polystyrene A-
NH2 and (aminomethyl) polystyrene reacted with triflyl azide in similar fashion to the 
ArgoPore resin yielding azide-coated resins in excellent yields (Table 2). However, 
aminopropylated-CPG failed to react with triflyl azide under identical conditions used for 
ArgoPore resin. We then tested various solvents and temperature conditions and found 
that the reaction occurred at slightly elevated temperature, between 37oC to 40oC, to give 
azide-coated aminopropylated-CPG in 50% yield within 24h (Table 5-2). The 
179 
 
introduction of azide onto solid supports by the conventional nucleophilic displacement 
reactions required the synthesis of activated supports or the use of limited commercial 
activated supports such as Merrifield resin.23-25 These reactions proceed slowly under 
extreme conditions. Operationally however, the current heterogenous diazo-transfer 
reaction proceeds rapidly and smoothly in conventional reaction flask at ambient 
conditions without any need for an elaborate technical handling. 
 
Table 5-2. Heterogeneous diazo-transfer reaction explored on amine-terminated resins. 
Type of 
Resins 
Reaction 
Temperature
(oC) 
Azide 
Conversion*
(%) 
Reaction 
Time 
(h) 
ArgoPore 25 90 4  
Polystyrene 
A 
25 90 4  
(Aminoethyl)
Polystyrene 
 
25 90 4  
Tentagel 25 90 4 
CPG 37 50 24  
    *Calculated from quantitative ninhydrin analysis. 
 
5.3 Synthesis of Alkyne Functionalized Nucleosides   
 Among the bioconjugations protocols utilizing organic azides, Cu (I) catalyzed 
alkyne-azide cycloaddition reaction (Sharpless click chemistry)16 has attracted the most 
attention in macromolecular fabrication.  The application of click chemistry in the 
immobilization of oligonucleotides probes on self-assembled monolayers on thiol-coated 
silicon wafers has recently appeared in the literature.29 Similarly, click-chemistry has 
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been used to directly functionalize resins for the solid phase synthesis of a library of 
dopaminergic arylcarbamides,24 tertiary amines,25 and peptidotriazole.16b, 30 As an 
extension of the application of this versatile chemistry, we explored the suitability of two 
of the synthesized azido-resins in the loading of nucleoside leader monomers for solid 
phase oligonucleotide synthesis. Toward this end we have prepared new alkyne 
functionalized nucleosides 70a, 70b and 72a. Acylation of 5’-O-
dimethoxytritylthymidine 68 with acid fluorides 69a-b adapting the procedure described 
by Oliver and Oyelere furnished 3’-alkyne esters 70a and 70b in good yields.31 Similarly, 
2’-deoxyadenosine-3’-alkyne ester 72a was obtained from acylation of commercially 
available protected 2’-deoxyadenosine 71 and acid fluoride 69b (Scheme 5-1). These 
alkyne functionalized nucleosides were evaluated as substrates for attachment to azide-
coated supports by click chemistry. 
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Scheme 5-1. Synthesis of Alkyne Functionalized Nucleosides 
 
5.4 Attachment of Leader Alkyne-monomers to Solid Supports and Solid Shase 
Oligonucleotide Synthesis.  
 
 The azide-coated resins were first treated with acetic anhydride to cap any traces 
of unreacted amines using standard protocol. To identify the optimum reaction conditions 
for the attachment of the alkyne nucleosides onto azide-coated supports, we tested resin 
derivatization of alkynes 70a and 70b by copper catalyzed Huigsen reaction on 
ArgoPore-N3 resin (Scheme 5-2).   
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 Scheme 5-2. Azido-Resin Derivatization with Alkyne Monomer by Cu(I) Catalyzed 
Huigsen Reaction  
 
 
 In a typical reaction, 70a or 70b was incubated with ArgoPore-N3 resin and CuI 
in THF and Hunig’s base mixture in the presence of tris-(benzyltriazolylmethyl)-amine 
(TBTA).32 The reaction proceeded smoothly at ambient conditions resulting in an 
uneventful resin loading. Quantitative trityl group33 analysis revealed that as little as 0.5 
equivalents of the alkyne 70a or 70b is sufficient for a near quantitative nucleoside resin 
loading within 2h. Because such a maximal resin loading may not be ideal for an SPS 
application, a series of loading reactions were then investigated to obtain nucleoside resin 
loadings at typical concentrations for solid phase oligonucleotide synthesis. We found 
that the reaction of about 0.1 equivalents of 70a or 70b resulted in ArgoPore-N3 resin 
loading of about 7-10 μmol/g within 30 min while a prolonged reaction time resulted in 
increase nucleoside attachment. For example, within 2h, a loading of about 30-46 μmol/g 
was obtained. We saw no significant difference in the loading capacity of compounds 70a 
and 70b. Interestingly, about ten times as much of compound 71a is necessary to obtain 
nucleoside loadings comparable to that of 70a or 70b; we could however not ascertain the 
source of this coupling disparity. Due to the wide application of aminopropylated-CPG 
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resin in solid phase oligonucleotide synthesis, we turned our attention to study the 
coupling behavior of CPG-N3 resin. We found that using 2 mole equivalents of 
compound 70b under similar conditions described for ArgoPore-N3 resin resulted in 
coupling yields of 40 ± 5 μmol/g within 2h (Scheme 5-2).   
Encouraged by these results, we then decided to investigate the suitability of this 
solid-support coupling protocol in solid phase oligonucleotide synthesis. Thymidine- and 
deoxyadenosine-linked ArgoPore resins 73 (a or b) and 74 respectively and thymidine-
linked CPG resin 75 prepared above were employed in automated oligonucleotide 
synthesis in Expedite34 and Applied Biosystems DNA synthesizers using 
phosphoramidite chemistry.1c, 35 In these experiments, we synthesized on 1 μmol scale a 
15mer (AGC CAG ATT TGA GCT) and a 30mer (AGC CAG ATT TGA GCT TGG 
GGC TCT CTG GCT) on thymidine immobilized supports; and a 30mer (TGC CAG 
ATT TGA GCT TGG GGC TCT CTG GCA) on 2’-deoxyadenosine immobilized 
support. Oligonucleotide syntheses, and the subsequent deprotection and cleavage of the 
support-bound products followed standard procedures.35 Figure 5-2 shows the reverse-
phase HPLC elution pattern of a representative crude product. This HPLC profile 
compared favorably well with that of similar oligo made from commercial resins. The 
identities of the HPLC-purified oligos were further confirmed by UV-vis absorption and 
MALDI-TOF MS analysis (see Chapter 6. Experimental and Spectra Data for details). 
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Figure 5-2. Reverse-phase HPLC elution pattern of a crude oligonucleotide. Deprotected 
crude 15mer (AGC CAG ATT TGA GCT), HPLC conditions: Phenomenex RP C-18 
column; solvent A 0.1 M NH4OAc; solvent B, acetonitrile, gradient 6-28 % of solvent B 
in 45 min; flow rate 1 mL/min. 
   
5.5 Conclusion 
In summary, we have demonstrated the feasibility of heterogeneous diazo-transfer 
reaction on commercial, amine-terminated resins. We also showed that the so-formed 
azide-coat can be used to load leader nucleoside-monomers on solid supports using click 
chemistry under benign experimental conditions. This approach avoids expensive, toxic 
and moisture sensitive additives, that are required for traditional monomer support-
attachment by esterification reactions. Furthermore, we demonstrated the potential utility 
of the support coupling protocol, herein described, in oligonucleotide solid phase 
synthetic applications. Part of our ongoing work is the syntheses of nuclear targeting 
oligopeptides and second generation-linkers that will allow facile cleavage of SPS 
assembled macromolecules from various insoluble supports.  
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5.6 General Procedure and Experimental 
 
 Tentagel S-NH2, polystyrene A-NH2 and (aminomethyl) polystyrene resins were 
procured from Fluka. ArgoPore-NH2 resin was obtained from Argonaut Technologies Inc 
(www.biotage.com) while aminopropylated-CPG was purchased from Proligo Reagents. 
Cyanuric fluoride was from Alfa and was used without further purification.  Anhydrous 
solvents and other reagents were purchased from Aldrich and used without purification. 
Analtech silica gel plates (60 F254) were used for analytical TLC, and the spots were 
examined with UV light. Column chromatography was carried out on 200-400 mesh 
silica gel.  Triflyl azide was prepared as described by Titz et al, and Liu and Tor.26h-i Acid 
fluorides were made according to Oliver and Oyelere31 while 5’-O-
Dimethoxytritylthymidine 68 was prepared following the procedure of Meier et al.36 
Oligonucleotides HPLC purification was performed using Phenomenex RP C-18 column, 
eluting with a gradient of 6-28 % acetonitrile in 0.1 M triethylammonium acetate (pH = 
7.1).  
 
5’-O-(4,4’-Dimethoxytrityl)-3’-O-pent-4-ynoate)thymidine (70a). 5’-O-Dimethoxy-
tritylthymidine 68 (0.750 g, 1.38 mmol) was added to an oven-dried round bottom flask 
(10 mL) under argon and coevaporated with anhydrous pyridine (2 x 5 mL). Dry 
dichloromethane (4 mL), dry pyridine (0.4 mL) and dry triethylamine (0.5 mL) were 
added under argon. A solution of pent-4-ynoyl fluoride 69a (0.200 g, 2.00 mmol) in dry 
dichloromethane (1 mL) was added to the solution and the mixture stirred at room 
temperature under argon for 24 h. The reaction was partitioned between dichloromethane 
(40 mL) and saturated sodium bicarbonate (30 mL). The two layers were separated and 
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the organic layer was washed with saturated sodium bicarbonate (30 mL), saturated brine 
(30 mL) and dried over Na2SO4. Solvent was concentrated and the crude material purified 
by flash chromatography (silica gel, step gradient 8:1; 6:1 CH2Cl2/acetone) to give 0.560 
g (64%) of 70a. 1H NMR (CDCl3, 400 MHz) δ 1.35 (3H, s), 2.01 (1H, t, J = 2.4 Hz), 2.51 
(6H, m), 3.46 (2H, m), 3.77 (6H, s), 4.13 (1H, br s), 5.47 (1H, d, J = 5.6 Hz), 6.44 (1H, 
m), 6.82 (4H, d, J = 8.8 Hz), 7.22-7.38 (9H, m), 7.59 (1H, s), 9.10 (1H, s); 13C NMR 
(CDCl3, 100 MHz). δ 11.6,14.3, 33.1, 37.9, 55.2, 63.6, 69.6, 75.8, 81.9, 83.9, 84.2, 87.1, 
111.7, 113.2, 127.2, 128.0, 128.1, 130.0, 130.3, 135.0, 135.1, 135.3, 144.1, 150.6, 158.7, 
158.7, 163.8, 171.3. HRMS (FAB, thioglycerol) calcd for [C36H36N2O8 + H]+ 625.2550, 
found 625.2544. 
 
5’-O-(4,4’-Dimethoxytrityl)-3’-O-hex-5-ynoate)thymidine (70b). Reaction of 
5’-O-Dimethoxytritylthymidine 68 (0.750 g, 1.38 mmol) and hex-5-ynoyl fluoride 69b 
(0.229 g, 2.00 mmol) for 24 h as described for compound 70a followed by flash 
chromatography (silica gel, step gradient 8:1; 6:1 CH2Cl2/acetone) gave 0.571 g (65%) of 
chromatographically pure 70b. 1H NMR (CDCl3, 400 MHz) δ 1.35 (3H, s), 1.82 (2H, m), 
1.97 (1H, t, J = 2.6 Hz), 2.25 (2H, m), 2.46 (4H, m), 3.45 (2H, m), 3.77 (6H, s), 4.11 (1H, 
br. s), 5.44 (1H, d, J = 4.8 Hz), 6.43 (1H, app. t), 6.82 (4H, d, J = 8.8 Hz), 7.22-7.38 (9H, 
m), 7.59 (1H, s), 9.20 (1H, s); 13C NMR (CDCl3, 100 MHz). δ 11.6,17.7, 23.2, 32.7, 37.9, 
55.2, 63.6, 69.5, 75.3, 82.9, 83.9, 84.2, 87.1, 111.7, 113.2, 127.1, 128.0, 128.0, 130.0, 
130.0, 135.0, 135.1, 135.3, 144.1, 150.6, 158.7, 158.7, 163.8, 172.5. HRMS (FAB, 
thioglycerol) calcd for [C37H38N2O8 + H]+ 638.2628, found 638.2606. 
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5’-O-(4,4’-Dimethoxytrityl)-6-N-(benzoyl)-2’-deoxy-3’-O-hex-5-ynoate)adenosine 
(72a). Reaction of protected nucleoside 67 (0.200 g, 0.30 mmol), hex-5-ynoyl fluoride 
69b (0.114 g, 1.00 mmol) and catalytic amount of DMAP in dichloromethane (4 mL), dry 
pyridine (0.4 mL) and dry triethylamine (0.5 mL) for 2 h followed by flash 
chromatography (silica gel, step gradient 12:1; 10:1 CH2Cl2/acetone) gave 0.184 g (82%) 
of chromatographically pure 72a. 1H NMR (CDCl3, 400 MHz) δ 1.82 (2H, m), 1.99 (1H, 
t, J = 2.6 Hz), 2.25 (2H, m), 2.50 (2H, app. t), 2.66 (1H, m), 2.98 (1H, m), 3.43 (2H, d, J 
= 4.0 Hz), 3.74 (6H, s), 4.28 (1H, m), 5.53 (1H, d, J = 6.0 Hz), 6.50 (1H, m), 6.77 (4H, d, 
J = 8.8 Hz), 7.17-7.29 (9H, m), 7.36 (2H, d, J = 7.2 Hz), 7.47 (2H, app. t), 7.56 (1H, app. 
t), 8.00 (2H, d, J = 8.4 Hz ), 8.17 (1H, s), 8.69 (1H, s), 9.14 (1H, br. s); 13C NMR (CDCl3, 
100 MHz). δ 17.7, 23.3, 32.7, 38.2, 55.2, 63.5, 69.5, 75.2, 82.9, 84.4, 84.5, 86.7, 113.1, 
127.0, 127.8, 127.9, 128.0, 128.8, 129.9, 130.0, 132.7, 133.5, 135.4,144.1, 144.3, 149.3, 
151.6, 152.6, 158.5, 164.7, 172.3. HRMS (FAB, thioglycerol) calcd for [C44H41N5O7 + 
H]+ 752.3084, found 752.3110. 
 
Representative Procedure for Heterogeneous Diazo-transfer Reaction.  ArgoPore-N3 
Resin.  ArgoPore-NH2 (1.0 g, 0.90 mmol/g) was swelled in a homogeneous mixture of 
CH2Cl2 (5.6 mL), MeOH (5.2 mL), distilled H2O (4.9 mL), and Et3N (0.21 mL) for 2 
hours.  After 2 hours, the swelling solution was decanted. Triflyl azide (7.0 mmol) in 
CH2Cl2 (12 mL), and CuSO4 (0.011 g, 0.04 mmol) in distilled H2O (0.13 mL) were added 
to the swelled resin and gently stirred (or gently rocked) at 25oC.  Small portions of the 
resin were taken out at 10 min, 20 min, 40 min, 1 h, 2 h, 4 h, and 21 h for quantitative 
ninhydrin analysis.  The resin was washed in succession with swelling solvent, conc. 
188 
 
NH4OH (2 x 10 mL), swelling solvent; and dried in vacuo to give brownish solid. IR 
2097 cm-1. [Note: the reaction worked equally well when CH2Cl2 is replaced with 
toluene. Because of its better safety profile,26i we recommend toluene as a solvent of 
choice]  
 
Polystyrene A-N3 Resin.  This resin was synthesized from polystyrene A-NH2 as 
described for the synthesis of ArgoPore-N3 from ArgoPore-NH2 to give brown-greenish 
solid. IR 2090 cm-1.   
 
(Aminomethyl) Polystyrene-N3 Resin.  This resin was synthesized from (aminomethyl) 
polystyrene as described for the synthesis of ArgoPore-N3 from ArgoPore-NH2 to give 
light yellow solid. IR 2092 cm-1.    
 
Tentagel-N3 Resin.  This resin was synthesized from Tentagel S-NH2 as described for 
the synthesis of ArgoPore-N3 from ArgoPore-NH2 to give greenish solid. IR 2106 cm-1.    
 
CPG-N3 Resin.  This resin was synthesized from CPG-NH2 as described for the 
synthesis of ArgoPore-N3 from ArgoPore-NH2 except that the reaction was stirred at 
37oC for 24 h to give white-blue solid. IR 2359, 2341 cm-1. 
  
Representative protocol for nucleoside loading. In a typical reaction, a mixture of 66a 
(0.019g, 0.03 mmol), ArgoPore-N3 resin (0.065g, approx 0.06 mmol), CuI (0.003g, 0.02 
mmol) and TBTA (0.009g, 0.02 mmol) in THF (1.2 mL) and Hunig’s base (12 μL) was 
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shaken at rt for 2h. The resin was filtered off, washed with THF, CH2Cl2 and dried in 
vacuo. Quantitative DMT group33 analysis gave a nucleoside loading of approximately 
0.5 mmol/g. 
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 APPENDIX A 
 
1H and 13C NMR characterization for both SAHA-like Triazole-linked HDACi, 
Nonpeptide Macrocyclic HDACi, NLS-HDACi, Fluorescent Tagged NLS and HDACi 
and their intermediates 
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1H NMR characterization for thiolalkyl-triazole-linked NLS peptide and its intermediates 
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1H and 13C NMR characterization for 6-triazolylpenicillanic acids and their intermediates 
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Additional Spectra for Chapter 5 
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Figure D1. (a) and (b) are UV absorbance spectra, after quantitative ninhydrin assay, in 
the presence and absence of CuSO4 respectively, of 5mg portion of ArgoPore-NH2 resin 
at specified time. Note that the dilution factors of unmodified resin and reactions without 
Cu (II) at 20min are six times that of the reaction with Cu (II) in order to bring the 
absorbance value to the linear range of the Beer-Lambert law. 
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Figure D2.  MALDI-TOF MS analysis and HLPC profile of purified 15mer (AGC CAG 
ATT TGA GCT). 
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Figure D3.  MALDI-TOF MS analysis and HLPC profile of purified 30mer (AGC CAG 
ATT TGA GCT TGG GGC TCT CTG GCT). 
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1H NMR of 70a: 
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ArgoPore-NH2 Resin: 
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Figure D4.  IR spectra of ArgoPore-NH2 and ArgoPore-N3 resins.  
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CPG-NH2 Resin: 
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Figure D5.  IR spectra of CPG-NH2 resin and CPG-N3 resins. 
 
 
 
 
 
 
 
 
 
433 
 
(Aminomethyl) Polystyrene-NH2 Resin: 
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Figure D6.  IR spectra of (Aminomethyl) Polystyrene-NH2 and (Aminomethyl) 
Polystyrene-N3 resins. 
 
 
 
 
 
 
 
 
 
434 
 
Polystyrene A-NH2 Resin: 
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Figure D7.  IR spectra of Polystyrene A-NH2 and Polystyrene A-N3 resins.  
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Tentagel-NH2 Resin: 
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Figure D8. IR spectra of Tentagel-NH2 and Tentagel-N3 resins. 
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ArgoPore-N3 Resin prepared with triflyl-azide dissolved in toluene: 
 
 
 
Figure D9.  IR spectra of ArgoPore-N3 resins prepared in toluene solution of triflyl azide. 
 
437 
 
VITA 
 
 
 Po Chen was born in Taipei, Taiwan on October 10, 1980 to Frank and Ann Chen.  
He has a younger brother named Wei.  Po obtained his nickname, Bob, from his English 
teacher in Taiwan.  Bob spent his first eleven years in Taipei, Taiwan.  Bob came over to 
the United State when he was twelve years old.  He grew up in Florence, South Carolina 
and graduated from South Florence High School in May 1999.  In May of 2003, Bob 
graduated with B. S. in Chemistry from Vanderbilt University, where he also worked as 
an undergraduate research for Dr. Piotr Kaszynski.  After graduation, he attended 
graduate school at Georgia Institute of Technology.  Throughout his graduate career, he 
published six papers in respected chemistry journals such as Journal of Medicinal 
Chemistry, Journal of Organic Chemistry, Bioorganic & Medicinal Chemistry, and 
Bioconjugate Chemistry.  In 2006 and 2008, he was a recipient of the GAANN 
predoctoral fellowship from Georgia Tech Center for Drug Design, Development, and 
Delivery.  He received his Ph.D. in organic chemistry in May 2009 from Georgia 
Institute of Technology under the guidance of Dr. Adegboyega (Yomi) Oyelere. 
